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Abstract: Cannabis is one of the earliest cultivated plants. Cannabis of industrial utility and culinary value is generally 
termed as hemp. Conversely, cannabis that is bred for medical, spiritual and recreational purposes is called marijuana. The 
female marijuana plant produces a significant quantity of bio- and psychoactive phytocannabinoids, which regained the 
spotlight with the discovery of the endocannabinoid system of the animals in the early 90's. Nevertheless, marijuana is 
surrounded by controversies, debates and misconceptions related to its taxonomic classification, forensic identification, 
medical potential, legalization and its long-term health consequences. In the first part, we provide an in-depth review of 
the botany and taxonomy of Cannabis. We then overview the biosynthesis of phytocannabinoids within the glandular 
trichomes with emphasis on the role of peculiar plastids in the production of the secreted material. We also compile the 
analytical methods used to determine the phytocannabinoid composition of glandular trichomes. In the second part, we 
revisit the psychobiology and molecular medicine of marijuana. We summarize our current knowledge on the recreational 
use of cannabis with respect to the modes of consumption, short-term effects, chronic health consequences and cannabis 
use disorder. Next, we overview the molecular targets of a dozen major and minor bioactive cannabinoids in the body. 
This helps us introduce the endocannabinoid system in an unprecedented detail: its up-to-date molecular biology, 
pharmacology, physiology and medical significance, and beyond. In conclusion, we offer an unbiased survey about 
cannabis to help better weigh its medical value versus the associated risks. 
Keywords: Addiction, Cannabis sativa/indica, cannabis use disorder, endocannabinoid system, phytocannabinoid synthesis, 
psychosis, synaptic plasticity, tetrahydrocannabinol. 
1. INTRODUCTION 
Cannabis is a genus of plants indigenous to Asia. 
Archaeological findings evidence that cannabis was among 
the first plants cultivated and bred by humans in Asia and 
later, worldwide. Cannabis was cultivated for its achene 
fruits (often wrongly referred to as seeds, which are rich in 
oils and other phytonutrients [1,2], and were used as human 
food or animal feedstuff) as well as for its fibers, for 
traditional medicine and spiritual purposes [2–4]. The word 
cannabis most likely originates from ancient Akkadian 
(qunnabtu), Neo-Assyrian and Neo-Babylonian (qunnabu), 
with the meaning of 'way to produce smoke', which was then 
transformed into kan(n)ab(is) (for instance in Greek) and 
hanaba, then hennep and hemp in English. 
The angiosperm plant belongs to the order Urticales 
and the family Cannabaceae. However, further taxonomic 
classification of the Cannabis genus into species, subspecies,  
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varieties or morphotypes has been a matter of debate for well 
over two centuries due to (1) its worldwide cultivation and 
(2) extensive breeding for different purposes by different 
cultures over several millennia, (3) the presence of escaped 
and hybridized forms of the different cultivars, as well as (4) 
several so-called chemovariants (chemotypes) and wild 
forms, (5) which are, in addition, interfertile [2,5–9]. In 
general, three Cannabis species are distinguished, namely 
Cannabis sativa L., C. indica Lam. and C. ruderalis Janisch., 
corresponding to useful, Indian and wild cannabis plants, 
respectively. However, others consider only useful cannabis 
(C. sativa) and the narcotic plant (C. indica) as the only two 
real species [6], while the most recent and most 
comprehensive taxonomic work defines Cannabis as one 
highly variable, highly hybridized and introgressed, 
panmictic species divided into 6 groups [2]. 
Genome and transcriptome sequence analyses (e.g., 
[10–14]) and/or chemotaxonomic analyses (e.g., [6,7,10]) 
would further contribute to the better understanding of the 
biological properties (including sex determination), 
phenotypic variation, evolutionary history of the genus and 
the molecular impact of domestication and breeding on the 
different Cannabis taxa including wild germplasm, 
landraces, cultivars, chemotypes, strains, biotypes and 
accessions. 
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This dioecious annual flowering plant has taproot 
system and erect 1-5 m high shoots [2,15]. Female plants are 
in general more robust but shorter than male plants. The 
leaves are palmately compound consisting typically of 3-9 
(up to 13) linear-lanceolate leaflets with serrate leaf margins 
[2]. Leaves are arranged in opposite way (decussate) on the 
basis of the shoots and alternately (spirally) near the shoot 
tip. The leaflet margins are serrate, and their venation pattern 
is a peculiar character for morphological identification of 
cannabis leaves (the veins run out obliquely from the midrib 
to the tips of the teeth). The abaxial leaf surfaces are pale 
green and contain white to yellowish brown resinous glands 
[16]. The male flowers are arranged into loose cymose 
panicles on male plants, while female flowers are borne on 
racemes on female plants. However, rarely monoecious 
individuals bearing both female and male flowers at different 
shoot parts can be also observed as an intriguing result of 
human domestification [2]. The flowers are surrounded by 
greenish tepals often erronously called calyxes. Female 
flowers, in addition, are encircled by cup-shaped perigonal 
bracts rich in resin-containing glandular hairs. The female 
flowers of Cannabis ruderalis and C. sativa are small, while 
those of drug-type hybrids are larger and abundantly covered 
by secreted material (often termed as resin). The plant is 
wind-pollinated and produces achene fruits after fertilization. 
Interestingly, in the absence of pollen grains and pollination, 
the style and stigma parts of 'virgin' pistils of female 
cannabis plants bred for their psychoactive compounds are 
morphologically expanded [17]. Most cannabis varieties are 
short day plants with the exception of C. ruderalis that may 
be day-neutral and auto-flowering, and grows as weed 
especially on recently disturbed sites with high soil nitrogen 
content. 
The leaves and floral buds (termed as inflorescences 
including bracts and tepals rich in resin-producing glandular 
hairs) of drug-type female cannabis plants are used to 
produce the recreational drugs (or folk medicine products) 
called marijuana (also called pot, dagga, ganja, ganza, grass, 
padinha, and the fruitless flowers referred to as sinsemilla) 
and additional preparations (e.g., bhang) among others. The 
scrapped off glandular hairs and their secretory product 
(resin) itself is called hashish (also known as charas) (see 
also Section 3.1.2.1). Other extracts including hash oil and 
wax (known also as shatter, budder or butane hash oil) are 
also produced from the plants. Its medical use is not only 
proved by archaeological evidence (including a footed 
ceramic bowl with carbonized cannabis 'seeds' found in a 
Bronze Age grave at Gurbaneşti in Romania dated back to 
3500 B.C. and similar findings from the Caucasus [18]) but 
is also extensively documented in written records of several 
cultures. These include China (in the book "Pen Ts'ao", aka 
"The Herbal", written by the then Chinese emperor Shen 
Nung in 2737 B.C.), Egypt (Ebers Papyrus, 1550 B.C.), 
India (Atharvaveda, 1200-800 B.C.), Greece (Herodotus 
described in 440 B.C the use by Scythians of the smoke of 
cannabis 'seeds' for ritual purposes after burial), and the 
Greek physicians of the Roman Empire (Dioskurides, 100 
A.D., Galen, 170 A.D.) [3,8]. The psychotropic properties of 
Cannabis have also been well documented since long, from 
around 100 B.C. in China and by Galen in 170 A.D. 
After having been used in medicine in the Western 
world (e.g., in the US since 1840, or even by Queen Victoria 
of England in 1890), it was listed as dangerous and illicit 
drug by the Geneva Convention in 1925 and by the Federal 
Law since 1937. In the last 50 years, an increasingly intense 
political and scientific debate surrounds the legalization and 
the safety issues of cannabis-based medical treatments. 
Vaporized or smoked dried buds, capsules, different extracts 
applied for instance as oral (oromucosal) sprays (such as 
Sativex® - known as Nabiximols® in the US), and even 
prescription drugs including synthetic cannabinoids 
(synthetic Δ9-tetrahydrocannabinol [Δ9-THC] called 
dronabinol and marketed as Marinol®, as well as a Δ9-THC-
analog, nabilone - marketed as Cesamet®) are available in 
some countries as 'medical cannabis' [19–21] (see also 
Sections 3.3.3 and 3.3.11). 
In spite of ongoing clinical trials with various 
cannabinoid compounds [21], the medical use of marijuana 
(e.g., for treating neuropathic pain associated with multiple 
sclerosis, muscle spasticity, eating disorders, reducing 
nausea and vomiting in chemotherapy, and alleviating the 
anorexia associated with AIDS-related weight-loss) is still 
illegal in most countries with few exceptions (Australia - 
underway, Canada, Cyprus, Chile, Croatia, Czech Republic, 
Germany, Israel, Italy, Puerto Rico, US). This is mainly due 
to political and legislative reasons and the fact that the 
concentrations of the active compounds cannot be controlled 
within the smoke of cannabis plant. To circumvent this, 
medical cannabis oils with controlled Δ9-THC:cannabidiol 
(CBD) (Fig. 1) content are progressively substituting 
smokable medical marijuana [22,23]. The long-term health 
consequences of marijuana use (especially under the age of 
30) are not clear either: safety concerns also include risk for 
dependence, psychosis and cognitive problems (see Sections 
3.1.2.3-4; 3.3.6-9). For more details about the medical, legal 
and ethical perspectives as well as future research about 
medical marijuana or purified cannabinoids the authors are 
kindly directed towards [8,19,20,24–26], as well as to 
Section 3.3.3. 
Marijuana is estimated to be consumed by up to 227 
million people and, thus, represents the most used illicit drug 
substance in the world [27] (see Section 3.1.1) besides being 
a highly valuable (although illegal) crop [2]. Consequently, 
its major psychoactive compound (Δ9-THC) (Fig. 1) is the 
fourth most popular and addictive recreational chemical 
(following caffeine, ethyl alcohol and nicotine) [2]. In this 
review, we aim at following the long journey of 
phytocannabinoids from their biosynthesis in the plants 
towards the receptors in humans where they exert their 
potential effects. 
2. THE CANNABIS PLANT: ACTIVE COMPOUNDS, 
IDENTIFICATION AND BIOSYNTHESIS OF 
PHYTOCANNABINOIDS 
2.1. Active Compounds of Cannabis Plants with 
Emphasis on Phytocannabinoids 
Cannabis plants contain more than 545 known 
compounds [28,29]. In addition to phytocannabinoids, they 
include alkanes, sugars, nitrogenous compounds (such as 
spermidine alkaloids or muscarine), flavonoids, non-
cannabinoid phenols, phenylpropanoids, steroids, fatty acids, 
approximately 140 different terpenes that are predominantly 
monoterpenes such as β-myrcene, α- and β-pinene, α-
terpinolene, but also sesquiterpenes including β-
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caryophyllene, di- and triterpenes, as well as various 
common compounds [30–37]. 
The strong and very characteristic odor of cannabis 
plants (and drugs, including hashish) is caused 
predominantly by terpenes. β-caryophyllene and its 
oxidation product, caryophyllene oxide are used as leading 
substances to train dogs to detect hashish and marijuana [38–
40] (see also Section 3.2.3.3). It has to be noted, however, 
that many of these terpenes (especially monoterpenes such as 
α-pinene and limonene) are volatile and, therefore, present in 
higher amounts only in fresh material [41]. In spite of the 
scarceness of available data on cannabis terpenes and their 
medicinal effects [37,42–46], two stereospecific 
monoterpene synthases (limonene synthase and α-pinene 
synthase) were cloned and characterized from cannabis 
trichome cells [47]. 
Yet, the most conspicuous and noteworthy compounds 
of cannabis are called phytocannabinoids. Natural 
cannabinoids are often termed as phytocannabinoids in order 
to distinguish them from the chemically different 
endogenous cannabinoid receptor ligands 
(endocannabinoids) and from synthetic cannabinoids such as 
nabilone, dexanabinol and ajulemic acid (Fig. 1). Although 
in general, phytocannabinoids are considered unique to this 
genus, substances with phytocannabinoid activity have been 
found in liverworts (Radula marginata and R. perrotteti) 
[48,49], in the composite Helichrysum umbraculigerum [50] 
and in several additional plants (see Section 3.2). 
Phytocannabinoids of the cannabis plant (hereafter referred 
to as phytocannabinoids for the sake of simplicity) are C21 
terpenophenolic compounds with physiological and often 
psychotogenic effects. They possess monoterpene and 
alkylresorcinol (i.e., olivetol or olivetolic acid) moieties in 
their molecules. 
More than 109 phytocannabinoids are present in 
cannabis [28]. These can be classified into several major 
classes each having a representative molecule such as 
cannabigerol (CBG), cannabichromene (CBC), CBD (Fig. 
1), cannabinol (CBN) and tetrahydrocannabinol (6a,10a-
trans-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-
dibenzo[b,d]pyran-1-ol, later abbreviated as Δ9-THC) (Fig. 
1) [30,32]. These classes contain the different isomers, 
biogenic precursors (such as Δ9-THC acids A and B for Δ9-
THC, abbreviated hereafter as Δ9-THCA), degradation 
products and/or artifacts of the representative compounds. 
For instance Δ9-THC(A) isomers may be present both as cis 
or trans isomers. In addition, they occur both in 9,10 and 8,9 
double-bond configurations referred to as Δ9-THC(A) and 
Δ8-THC(A), respectively. Δ8-THC is thermodynamically 
more stable, but at least 20% less active than Δ9-THC and 
probably represents an analytical artifact [30]. Alkyl (propyl) 
homologs of the C-3 n-pentyl side chain of the different 
phytocannabinoids including Δ9-THC, CBC, CBD and CBG 
are termed as Δ9-tetrahydrocannabivarin (Δ9-THCV), 
cannabichromevarin (CBCV), cannabidivarin (CBDV) and 
cannabigerovarin (CBGV), respectively. Studies elucidating 
structure-activity relationships of Δ9-THC and its synthetic 
analogs identified the C-3 side chain as the key 
pharmacophore for pharmacological potency and for ligand 
affinity and selectivity at the cannabinoid receptors [51]. 
Some of the identified phytocannabinoids such as CBN and 
cannabicyclol are probably the respective degradation 
products of Δ9-THC and CBC, formed as a result of 
enzymatic activity [30,32]. Δ9-THC is oxidized to CBN in 
the presence of air (oxygen) and UV light [16]. 
Phytocannabinoids are thought to be synthesized and 
accumulated primarily in the form of phytocannabinoid acids 
(e.g., cannabidiolic acid, CBDA; and the above mentioned 
Δ9-THCA forms) in planta [52–54]. Therefore, the 
concentrations of phytocannabinoid acids are much higher in 
fresh plants than those of the respective neutral 
phytocannabinoids. The latter are formed by non-enzymatic 
decarboxylation (and thus neutralization) of the 
phytocannabinoid acids, which occurs predominantly during 
the processing of the herbal product (drying, storage, 
heating) and provides the most active compounds (e.g., 
CBD, Δ9-THC) [55]. Δ9-THC has been first isolated in 1942 
[56] but its correct structure assignment was done by Yechiel 
Gaoni and Raphael Mechoulam in 1964 using nuclear 
magnetic resonance spectroscopy (NMR) [57]. In addition to 
its euphoriant psychotropic property, acute or chronice Δ9-
THC administration also produces a wide variety of 
therapeutically relevant peripheral and central effects, both 
in animal models and man [2,37,58], while Δ9-THCA has 
mostly antibacterial and antibiotic potential [16]. For the full 
spectra of the molecular targets and the effects of 
phytocannabinoids, see Section 3. 
Several other phytocannabinoids have been also shown 
to have medicinal value. For instance, CBD, a non-
psychoactive phytocannabinoid, may account up to 40% of 
the cannabis extracts, and was shown to relieve convulsion, 
inflammation, cough, congestion and nausea, and have 
anxyolytic, antipsychotic, analgesic, sedative, anti-epileptic, 
sleep-inducing, neuroprotective, antirheumatic, sebostatic, 
antibiotic and anticancer (antioxidant) effects, either in 
animal models or in man or both [2,37,59–62]. CBN exerts 
sedative, antibiotic, anticonvulsant, anti-inflammatory and 
mild psychotropic effects [30]. Other phytocannabinoids 
may also possess therapeutic potential, including 
antibacterial (CBC, CBG, CBDA), antifungal (CBC, CBG), 
anti-inflammatory (CBC, CBG), analgesic or sedative (CBC, 
CBG, cannabidiolic acid), or even antileishmanial (a recently 
isolated CBG derivative, 4-acetoxy-2-geranyl-5-hydroxy-3-
n-pentylphenol) effects [16,30,32,37,63,64] (see also 
Sections 3.3.3-6). 
Several data support that CBD interactively and 
positively modifies the effects of Δ9-THC: the combined use 
of Δ9-THC and CBD reduces the adverse (e.g., 
psychotogenic) effects of Δ9-THC while increasing its 
clinical efficacy and prolonging its duration [2,65]. 
Furthermore, the effects of extracted phytocannabinoids 
(applied as single-molecule pharmaceuticals) often differ 
from that of the crude drugs (marijuana, hashish), which 
outlines the importance of the highly complex interactions of 
the natural constituents present in the plant [2]. The above-
mentioned mouth spray (Sativex® – nabiximols, by GW 
Pharmaceuticals, London) is the only available licensed 
medication based on natural phytocannabinoid extracts to 
treat spasticity in patiens with multiple sclerosis [21,66]. 
Sativex contains approximately equal amounts of Δ9-THC 
and CBD, which is achieved using identical cannabis clones 
grown under strictly controlled conditions for extraction, and 
followed by refining. Sativex has been in three phase III 
clinical trials as adjunctive treatment to optimized chronic 
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opioid therapy in cancer patients who experience inadequate 
analgesia. In 2015, GW Pharmaceuticals and Otsuka 
announced that Sativex failed to produce superiority over 
placebo in the overall cohort involving patients from 
Mexico, Europe and the US [67]; albeit in the last two trials 
it did show significant reduction in sleep disruption, as well 
as superior analgesia in the US cohort [68]. Sativex also 
scored significant results on a number of secondary 
endpoints including subject global impression of change and 
physician global impression of change [68]. Other 
preparations containing CBD or Δ9-THCV, or CBD and Δ9-
THC as the main active ingredient(s) are also in phase II and 
III trials to treat different diseases [21–23]. 
The phytocannabinoid content and composition is 
different in female and male plants, and varies during plant 
development and among the different organs [2,69–71]. For 
instance, the Δ9-THC content of drug-type cannabis leaves is 
more or less constant during development, while that of the 
bracts increases considerably during flowering [72]. Several 
phytohormones have been shown to influence the 
biosynthesis of terpenoids and Δ9-THC in cannabis plants 
[43–46]. In addition, the phytocannabinoid production is 
influenced by the cultivation protocol used and by 
environmental factors (stressors) such as humidity (drought), 
temperature, soil nutrient content [2,15,70,73,74] and 
illumination conditions (including light quality and quantity, 
and photoperiod) [2,69,75]. Phytoannabinoid content seems 
to increase under stress conditions, however, as noted by 
Small [2], it is difficult to estimate this value on whole plant 
basis as the lowermost leaves with low Δ9-THC content are 
in general dropped by the plant under such conditions. Stress 
also causes the plant to grow smaller, but in this case the net 
change in the overall phytocannabinoid production is not 
fully understood. The relative ratio of phytocannabinoids 
vary among the different cannabis species, strains and 
hybrids, which is most relevant in the case of the Δ9-
THC/CBD ratio [2,36,42,72] (see Sections 3.1.1, 3.2.3.3, 
3.3.3.1. and 3.3.8 as well). Although not typically, but the 
phytocannabinoid composition and/or content among 
different individuals of the populations of the same cultivar 
may also show considerable variation [76]. 
Chemotaxonomic evaluation has led to the 
establishment of three major chemotypes: fiber-type 
chemovariants contain predominantly CBD, intermediate 
chemovariants have equal amounts of CBD and Δ9-THC, 
while the latter is the major compound in drug-type plants 
[2,71,72,77–79]. In spite of quantitative variations observed 
in phytocannabinoid contents (e.g., [75]), it has been 
demonstrated that the chemotype is not influenced by sex or 
developmental age [70]. Due to their different 
phytocannabinoid composition, the distinct species and/or 
strains (chemotypes) have different medical and 
psychotropic potential. Therefore, the genetic background of 
the different chemotypes [69,77,80,81] as well as their 
chemotaxonomy especially in terms of molecular/metabolic 
fingerprinting [6,7,10,42,82] have been extensively studied. 
Metabolic fingerprinting may be also used in forensic 
identification of the different chemotypes or during quality 
control and breeding/selection of the different drug-type 
cannabis lines [42,70]. In addition, in countries where 
industrial cultivation of fiber-type hemp is allowed, the Δ9-
THC content of cultivars should not exceed the allowed level 
which normally varies between 0.2-0.35% Δ9-THC in the 
inflorescence or young infructescence of plants on a dry 
mass basis in Europe, Canada and New Zealand [2,83–86]. 
Considering that 1% Δ9-THC content is generally accepted 
as the treshold for the intoxicating potential of marijuana, 
cultivars with Δ9-THC content (slightly) higher than 0.35% 
are also allowed for cultivation in Switzerland and in some 
parts of Australia [2]. However, the permitted Δ9-THC 
content of seeds and seed oils of gastronomic purposes is 
even much lower [2]. On the other hand, several 
pharmacological firms as well as clandestine breeders breed 
different drug-type strains with specific phytocannabinoid 
composition, including strains that selectively overproduce 
one phytocannabinoid (e.g., Δ9-THC without CBD – aka 
skunk, CBD, CBC or CBG) at levels over 10% [2]. 
The insect-repellent (anti-herbivorous), antimicrobial 
and antifungal properties of Δ9-THC and other 
phytocannabinoids and terpenes produced by cannabis are 
extensively reviewed elsewhere [15,87], and suggest that 
these compounds may serve for self-defense purposes 
[2,15,88]. However, some data with phytocannabinoid-free 
Cannabis breeding lines do not confirm this hypothesis [81], 
while other works have clearly demonstrated that THCA and 
cannabichromenic acid (CBCA) induce necrotic cell death in 
leaf cells, and may be, thus, involved in self-defense and 
senescence [89]. These compounds may be involved in the 
minor allelopathic properties of Cannabis plants [2,88]. 
It has been also suggested that - similarly to several 
phenolic compounds of plants - Δ9-THC may have a role in 
protecting the plants from high UV-B radiation. This was 
concluded on the basis of increased Δ9-THC content found in 
(1) Cannabis plants originating from locations with intense 
ambient UV-B irradiation [90], (2) in drug-type Cannabis 
plants exposed to high UV-B light under greenhouse 
conditions [91], and from the fact that the Δ9-THC of the 
resin of fiber-type Cannabis did not show photochemical 
decomposition upon UV and visible light exposure [92]. 
However, it is important to mention that the Δ9-THC content 
of fiber-type plants did not vary with increased UV 
irradiation under the same greenhouse conditions [91], and 
that the CBD content of the resin of fiber-type plants 
decreased upon exposure to the same UV and visible light 
regime [92]. In addition, the phytocannabinoid containing 
and producing glands are concentrated on the lower (abaxial) 
side of the leaves and the perigonal bracts in the 
inflorescence (see Section 2.4), further questioning their 
speculated protective effect against UV radiation [2]. These 
data show that a better understanding of the effect of UV 
light on Δ9-THC biosynthesis and accumulation in different 
varieties is necessary. 
2.2. Identification of Cannabis and Its Products 
The identification of cannabis plants and products may 
be done on the basis of observation of general plant 
morphology, that is, the typical shape and venation of leaves 
and the structure of the inflorescence. However, this is not 
always possible in case of forensic samples and different 
cannabis products. With the exception of hashish oil and 
other extracts, micromorphological features such as 
characteristic trichomes on the surface of the fruiting and 
flowering top may be microscopically identified (see [16,30] 
and below in Section 2.4). 
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Furthermore, phytocannabinoids provide a unique 
chemical fingerprint for cannabis identification and can be 
unequivocally identified by several analytical methods 
[16,93]. These include high performance liquid 
chromatography (HPLC) [10,75,89,94–96], gas-liquid 
chromatography (GLC) [72,75,97–100] or gas 
chromatography (GC) [5,6,28,30,71,72,84] coupled with 
flame ionization or mass spectrometric (MS) detection. In 
addition to discrimination between the different cannabis 
species, cultivars, chemovariants and samples collected by 
forensic scientists on the basis of their phytocannabinoid 
composition, these data may even provide information about 
plant cultivation (indoor or outdoor) and about the country of 
origin [30]. Promising quantification and separation of 
phytocannabinoids can also be achieved using liquid 
chromatography coupled with ion trap mass spectrometry 
[101]. 
For chromatographic analyses, dried plant material 
(sometimes prepared previously as dry powder - [84,94,99]) 
is usually incubated for approx. 1-4 h with solvent (e.g., 
petroleum ether - [72], chloroform [5,6,44–46,99], hexane - 
[84,89], methanol - [96], chloroform/methanol - 
[16,28,94,101–103], ethanol - [77], methanol:ethanol (1:1) 
mixed with equal amount of CHCl3 - [95], or sequentially by 
various solvents - [64]). The extract is then filtered, 
sonicated and/or centrifuged, and in some cases, directly 
injected to the chromatograph [28] or dried under nitrogen 
stream and then dissolved in another solvent (e.g., in 
cyclohexane - [72], methanol - [44–46,89], chloroform plus 
internal standard in methanol - [5], acetone with internal 
standard - [6], internal standard in ethanol - [99]) before 
injection. Internal standards such as 4-androstene-3,17-dione 
(e.g., [5,28,99,102]), anthracene (e.g., [96]), phenantrene 
(e.g., [77]), n-eicosane [6], chrysene-d12 [84] or α-colestane 
(e.g., [72,104]) are used. Sometimes derivatization 
(silylation or methylation) is necessary to obtain information 
about phytocannabinoid acids, the dominating 
phytocannabinoids, but the total phytocannabinoid content 
can be determined from samples without derivatization 
[16,30,64]. Solid phase-micro extraction methods of 
Cannabis samples are also available [16]. 
HPLC (e.g., [75,89,94–96]) or ultra-performance liquid 
chromatographic (UPLC) [44,45] analyses using carefully 
optimized gradient elution programs, sometimes reversed 
phase columns and/or diode-array detection also enable the 
quantification of the major phytocannabinoids for 
chemotyping, the evaluation of psychoactive potency, and 
finally, the quality control of medicinal marijuana. 
There are different protocols suitable for rapid 
screening and on-site field testing, including thin-layer 
chromatography, color reactions (such as Fast Corinth V salt 
test, Fast Blue B salt test, Duquenois-Levine test – all 
described in detail in [16]), macro- and micromorphological 
(microscopic) observations and a combination of these latter 
may be also applied [16,30]. Some chemotaxonomic studies 
used the different phytocannabinoid (Δ9-THC and CBD) 
banding patterns on starch gele electrophoresis to 
discriminate between the different accessions [6,7]. The pros 
and cons of the use of planar chromatographic methods 
(such as classical thin layer chromatography, overpressured-
layer chromatography, automated optimal performance 
laminar chromatography – OPLC, or automated multiple 
development – AMD) for evaluation of cannabis samples are 
carefully compared and discussed elsewhere 
[16,93,103,105]. 
DNA-based profiling techniques used for cannabis 
identification are reviewed by others [16,106] and the DNA 
sequence of some cultivars is already publicly available 
[11,12]. Based on the polymorphisms of the enzyme 
responsible for Δ9-THCA synthesis [14], fluorescent duplex-
PCR test [82] and single nucleotide polymorphism assay 
[83] were developed and successfully applied to discriminate 
between drug-type and fiber-type cannabis. Recently, a 
candidate gene involved in phytocannabinoid biosynthesis 
has been identified that clearly distinguishes these two 
chemotypes [14] (see later in Section 2.3). 
Similarly, 1H-nuclear magnetic resonance spectroscopy 
was recently proved to be a promising non-destructive, fast 
and sensitive method to identify chemotypes during the 
entire cultivation period [96]. The extraction methods used 
for metabolic fingerprinting are discussed elsewhere [42], 
while data about trichome isolation are discussed in Section 
2.4. 
2.3. Biosynthesis of Phytoannabinoids in the Cannabis 
Plant 
Phytoannabinoids of the cannabis plant are prenylated 
polyketides (terpenophenolic compounds) which derive from 
isoprenoid and fatty acid precursors. However, some 
molecular details of their biosynthetic pathway still need to 
be elucidated. 
The first committed step of phytocannabinoid 
biosynthesis is the prenylation of the phenolic moiety (the 
polyketide-derivative, 5-pentenyl resorcinolic acid, also 
termed as olivetolic acid, OA) with the terpenoid 
(isoprenoid) moiety, geranyl pyrophosphate (GPP) (Fig. 2). 
This condensation of OA and GPP is driven by the soluble 
geranylpyrophosphate:olivetolate geranyltransferase (GOT) 
[107], and yields CBG acid (CBGA) which is the direct 
precursor of CBDA, CBCA and Δ9-THCA. CBGA is 
converted directly to Δ9-THCA by Δ9-THCA synthase 
enzyme in all cannabis strains [6,55,80,104,108,109]. The 
conversion of CBGA to CBDA or to CBCA is driven by 
CBDA synthase or CBCA synthase, respectively [55,110–
113]. Both Δ9-THCA synthase [114] and CBDA synthase 
[113] are FAD-dependent oxidases responsible for the 
stereospecific oxidative cyclization of the monoterpene 
moiety of CBGA in the presence of molecular oxygen 
required for catalysis. The enzymes converting CBGA to 
different phytocannabinoid acids are thought to be localized 
in monomeric form in the cytosol [109,114]. Additionally, 
CBGA and Δ9-THCA synthase activity was also 
demonstrated in the secretory cavity of the glandular 
trichomes (see Section 2.5) [108]. 
In addition, the above-mentioned enzymes can also 
convert CBGV (the propyl homolog of CBG) to the 
respective propyl homologs (Δ9-THCV, CBCV and CBDV) 
of the major phytocannabinoids [115,116]. CBGV is thought 
to be formed by the condensation of GPP with divarinic acid 
(5-propyl resorcinolic acid, a C10 compound) instead of OA 
(a C12 compound) [107,116]. 
Using deep sequencing technology, the draft genome 
and transcriptome sequences of a drug-type cannabis strain 
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were determined and compared with that of fiber-type hemp 
cultivars [12]. These data showed that Δ9-THCA synthase 
excusively occurred in the transcriptome of the drug-type 
cultivars, and was replaced by CBDA synthase in fiber-type 
hemp cultivars, explaining the different phytocannabinoid 
composition of the studied varieties [12]. Recent studies 
have shown that the presence of a nonfunctional CBDA 
synthase (positively selected during breeding) distinguishes 
the drug-type cultivars from fiber-type hemp [14]. This is the 
first work that provides a tool to clearly dissociate these two 
chemotypes for the benefit of both agriculture and drug 
policy [14]. Phylogenetic and genetic analyses suggest that 
gene duplication and divergence events as well as other 
genetic factors (quantitative trait loci) have influenced the 
drug content and potency of the different chemotypes [14]. 
As discussed in detail elsewhere [2,73,77,117], qualitative 
and quantitative aspects of phytocannabinoid production 
(and its inheritance) have to be considered, the former being 
influenced by the genes involved in phytocannabinoid 
production, their genetic control and inheritance. The 
absolute quantity of phytocannabinoids produced by an 
individual plant is influenced by the growth and 
development of phytocannabinoid producing structures (i.e., 
secretory glands and organs containing many of these glands 
– see Section 2.4). These quantitative aspects are strongly 
influenced by environmental factors (see Section 2.1), but 
are independent from biosynthetic pathways and are very 
probably determined by several – yet mostly unknown – 
genes (quantitative trait loci) [2]. Therefore, Δ9-THC-less 
cannabis may be bred by disruption of phytocannabinoid 
biosynthesis or gland development [81]. However, detailed 
discussion about these genetic factors is beyond the scope of 
this paper and is discussed elsewhere [2,69,73,77,80,81]. 
It should be mentioned that the GOT-catalyzed 
prenylation of OA may also occur with neryl-diphosphate 
besides with GPP, resulting in the formation of 
cannabinerolic acid (the trans-isomer of CBGA - [109]), 
which is subsequently converted into cannabinolic acid 
[107]. Transcriptomic analyses of glandular hairs identified 
an expressed sequence tag encoding a predicted 
prenyltransferase probably corresponding to GOT [11]. 
Interestingly, the encoded protein related more to members 
of the membrane-bound chloroplast-localized family of 
prenyltransferases than to soluble prenyltransferases [11], 
which may indicate the role of plastids in this reaction. 
Recently, the gene encoding this aromatic prenyltransferase 
responsible for the condensation of OA and GPP has been 
identified [118]. 
The phenolic moiety (OA) of phytocannabinoids is 
thought to be formed by the condensation of three molecules 
of malonyl-CoA and one molecule of n-hexanoyl-CoA into a 
C12 polyketide, followed by the cyclization of the latter. The 
first reaction is driven by a putative type III polyketide 
synthase (termed as tetraketide synthase, TKS - [119], or 
olivetol synthase - [120]), the presence and activity of which 
needs further elucidation [11,107,119–124]. The C2-C7 
intramolecular aldol condensation with carboxylate retention 
(the cyclization) is catalyzed by a recently identified 
polyketide cyclase, OA cyclase (OAC) [119], which enzyme 
functions in concert with the TKS to generate carbon 
scaffolds and OA. In case of the synthesis of the propyl 
homologs, instead of three molecules of malonyl-CoA, only 
two are condensed with n-hexanoyl-CoA, resulting in a C10 
polyketide, which is subsequently cyclisized to DA. A 
cytoplasm-located acyl-activating enzyme (hexanoyl-CoA 
synthase) involved in the activation of medium- and long-
chain fatty acids (including hexanoate) has been identified 
by transcriptome analysis of the trichomes of female flowers 
[125]. On the basis of the high transcript abundance of 
desaturases and lipoxygenases found in these analyses, it has 
been suggested that hexanoate may be formed through 
oxygenation and breakdown of unsaturated fatty acids [125]. 
However, other transcriptomic analyses of RNA isolated 
from Cannabis glands suggested that hexanoyl-CoA was 
produced via de novo fatty acid biosynthesis in the plastids 
[11]. Therefore, the pathway leading to hexanoate formation 
may need further investigations. Malonyl-CoA is derived 
from the carboxylation of acetyl-CoA by acetyl-CoA 
carboxylase [11]. 
The precursors of GPP are isopentenyl pyrophosphate 
and dimethylallyl pyrophosphate. These molecules can 
originate from the cytoplasmic mevalonate pathway or from 
the plastid-located non-mevalonate pathway (2-C-methyl-D-
erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate 
pathway). Studies using 13C-labeled glucose [126] and 
analyzing the transcriptome of glandular trichomes [11,12] 
have proven that the latter is active during phytocannabinoid 
biosynthesis. The same plastidial biosynthetic pathway is 
needed for the production of monoterpenes and diterpenes, 
outlining the active contribution of plastids to the 
biosynthesis of terpenes and phytocannabinoids, which is 
also bolstered by the presence of plastids with peculiar 
ultrastructural features in the secretory cells of the glands 
(see Section 2.5). 
Pure Δ9-THC has an extremely high market price, 
probably reflecting that both the organic synthesis and the 
isolation and purification of the different phytocannabinoids 
from Cannabis plants by different chromatographic methods 
[89,127–131] are not simple procedures. Therefore, there 
were several attempts to produce Δ9-THC 
biotechnologically. Δ9-THCA synthase [108,114] and CBDA 
synthase [132] have been already cloned and heterologously 
expressed in transgenic tobacco hairy root cultures 
[108,114], Spodoptera frugiperda insect cell cultures [114] 
and transgenic methylotrophic yeast (Pichia pastoris) [132]. 
These systems produce recombinant enzymes and yielded 
Δ9-THCA or CBDA when fed with CBGA. Upon heating, 
smoking or under alkaline conditions, Δ9-THCA and CBDA 
are non-enzymatically decarboxylated to their respective 
neutral forms (Δ9-THC and CBD) [53,130]. Transgenic yeast 
expressing OAC-TKS was also able to efficiently produce 
OA in the presence of its precursors [119]. Works with 
recombinant proteins may contribute to the understanding of 
the structure-function of the different enzymes (e.g., Δ9-
THCA synthase [108,114,133]) involved in 
phytocannabinoid biosynthesis. After the necessary 
optimization of metabolic engineering, the invested effort 
may result one day in the establishment of an enzyme-based, 
high purity, scalable fermentation production system for Δ9-
THC or other cannabinoids in microorganisms or other 
systems. Using combinatorial biosynthesis approaches, these 
systems may alternatively be also used for the production of 
novel phytocannabinoid derivatives. Knowledge about the 
enzymes of the biosynthetic pathway and about the pathways 
producing its precursors is essential also for molecular 
breeding of cannabis plants with specific phytocannabinoid 
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content (i.e., low-Δ9-THCA and low-CBDA hemp) through 
targeted mutagenesis. 
2.4. Glandular Trichomes of Cannabis 
The different glandular and non-glandular epidermal 
structures of cannabis have been extensively studied since 
their first description by Briosi and Tognini in 1894 and 
1897 [134–138]. Numerous unicellular, rigid and curved 
non-glandular trichomes with a slender, pointed apex can be 
observed on cannabis [16]. In addition, bear claw-shaped 
cystolithic trichomes may have calcium carbonate crystals 
(cystoliths) at their bases. The presence of silica (deposited 
in the cell walls) and calcium carbonate crystals (formed in 
the vacuole of the non-glandular, cystolithic trichomes) may 
be useful to identify marijuana or even its ash residues by 
light or scanning electron microscopy, the latter occasionally 
coupled with X-ray microanalyses [137]. The simultaneous 
presence of bear claw-shaped cystolithic trichomes on the 
adaxial leaf surface, and slender, non-cystolithic trichomes 
on the abaxial leaf surface are features used for forensic 
identification of cannabis [16]. Bear claw-shaped cystolithic 
trichomes also occur on younger stems, but can be only 
occasionally observed on perigonal bracts, especially on 
drug-type plants (Fig. 3A) [139]. Identification can be 
further assisted by the presence of the specific glandular 
trichomes discussed below. The number, size and 
distribution of different trichomes on the central leaflets of 
the compound leaves may be used to distinguish the major 
Cannabis taxa (i.e., C. indica, C. ruderalis, C. sativa) even 
before flowering stage. 
Three types of glandular trichomes can be distinguished 
on cannabis plants [135]: the normal green leaf and stem 
surfaces (except the hypocotyl and the cotyledons) of the 
whole plant contain small bulbous and large capitate-sessile 
glandular hairs, while large capitate-stalked trichomes (Fig. 
3A-B) with very high phytocannabinoid content 
(approximately 20 times higher content than those of 
capitate-sessile glands) develop predominantly on the floral 
bracts and bracteoles only after flower initiation 
[100,137,138]. The glands have a flattened-disc like head 
composed of few to many cells and covered by the secretory 
product accumulated beneath a cuticular sheath [135] (Fig. 
3B). 
The full-sized bulbous glands are 25-30 µm high and 
have a short stalk (stipe) and a head with 20 µm diameter 
[135–137]. These heads contain 1, 2 or 4 secretory cells in a 
single layer, their stalk is composed of 1 or 2 cells, bearing a 
1- or 2-celled base layer [136]. 
The mature capitate-sessile glands have very short axes 
consisting of one base and one stalk cell layer, and therefore, 
appear to be attached directly to the bract surface [135,136]. 
They have a larger, circular to slightly oblong head 
containing 8-13 secretory cells arranged in a single layer of 
40-70 µm diameter. Some authors distinguished two types of 
capitate-sessile trichomes based on their size: big ones 
present only in the flowers and smaller ones present also on 
other plant parts (leaves and stems) [134,137]. The CBCA 
present in the resin of the capitate-sessile glands shows light 
bluish autofluorescence under UV excitation in fluorescence 
microscopes [89]. 
The development of bulbous and capitate-sessile glands 
starts early after the initialization of bract development, 
while capitate-stalked trichomes are the last to mature 
[135,136]. Capitate-sessile glands or capitate-stalked glands 
are the most conspicuous in young or old bracts, respectively 
[135]. The latter have a multicellular, 150-200 µm high stalk 
bearing a globular head (diameter: with 50-100 µm) attached 
to a 4-celled stalk and a base, and having so-called 
abscission zones both at the base and upper stalk cell layers 
[135,136]. The heads of both capitate glands have similar 
structure, but the diameter of capitate-stalked glands is 
frequently larger than that of capitate-sessile glands [136]. 
Recently, it has been shown that the average diameter of 
capitate-stalked glands of a high-Δ9-THC containing medical 
cannabis strain is 129 µm while that of fiber-type, low-Δ9-
THC industrial hemp is 80 µm, and the mean resin volume 
of the former was more than four times larger than that of the 
latter [139]. 
Bulbous and capitate-sessile glands derive from a 
single epidermal initial [136,140]. The head cells, primary 
stalk and base layers of the capitate-stalked glands also have 
epidermal origin, but one part of their multicellular stalks 
derives secondarily from surrounding sub-epidermal and 
epidermal cells of the bract and is continuous with the bract 
mesophyll [136,140] (Fig. 3B). The three types of glandular 
hairs are hardly distinguishable at their early developmental 
stages [136]. The development of capitate-stalked hairs is 
first restricted to the vein ridges, but later they also appear on 
intervein regions but are rarely observed on bract margins. 
Their development is discussed in more detail by [136]. 
Interestingly, glands are restricted to the abaxial side of 
young leaves, to twigs and most prominently to the outer 
(abaxial) side of the perigonal bracts, while the inner 
(adaxial) surface of bracts is devoid of glands and contains 
only occasionally non-glandular trichomes [2,135]. This 
specific distribution of glands may suggest their protective 
role of the young flowers and developing fruits similarly to 
Humulus [139]. The reproductive shoots of male plants also 
contain relatively high concentrations of phytocannabinoids 
[141], and also have lower densities of glandular trichomes 
[97,137]. These include stalked glands covering the tepal, 
massively stalked glands present on the filament, and 
special, very large sessile (or short-stalked) glands observed 
on the inner surface (grooves) of anthers [2,97,137]. Due to 
the presence of these glands, phytocannabinoids can be also 
detected on the pollen grains [142], however, as male plants 
are no drug source, these are less studied and will not be 
discussed here in detail. The various terpenes, 
phytocannabinoids and other secreted secondary metabolites 
(flavonoids and aromatic compounds) accumulate mainly in 
the capitate-sessile (stalkless) and capitate-stalked glandular 
trichomes of cannabis [97,98,100,134–136,138,143]. 
Nevertheless, there is no simple quantitative relationship 
between gland density and phytocannabinoid concentration 
of various plant organs of the different chemotypes, and the 
phytocannabinoid content of individual gland types also 
showed variation depending on the position and maturity of 
the gland, and on the developmental stage of the plant and 
the organ [99,100,144]. Still, the human selection of narcotic 
cannabis strains apparently favored greater gland density 
and/or size [2,135]. This latter has been confirmed by the 
presence of extremely large gland heads in recently selected 
strains with extremely high Δ9-THC level [139]. To 
influence gland density by preventing seed/fruit development 
is now a standard practice during the production of 
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marijuana [139]. This practice is based on the observation 
that the perigonal bracts grow considerably after fertilization 
to cover and protect the (developing) seeds/fruits, but their 
expansion results in a strong decrease in gland density [139]. 
The capitate-stalked glandular trichomes have large, 
round, yellow-orange to brown heads in the high CBD and 
Δ9-THC accumulating breeding lines, and sparkle under the 
stereomicroscope [81]. Not surprisingly, the ethanol extracts, 
smoke and vapor of cannabis are composed of a complex 
mixture of phytocannabinoids and other terpenoids [145]. 
Phloroglucinol glucoside (a phenolic compound) has been 
also detected in stem-exudates originating from non-
articulated laticifers and in glandular trichomes [138,146]. 
The floral leaf surface of cannabis plants is resinous and 
sticky as a result of the presence of the above-mentioned 
major secretory products (terpenes and phytocannabinoids). 
In the absence of the latter compounds (for instance in case 
of phytocannabinoid-poor breeding lines), the surface of the 
mature female inflorescence is dry and the trichome heads 
are small, grey and dull, but contain terpenes (except 
limonene) [81]. Most pure phytocannabinoid constituents are 
yellow-orange to brown oils (e.g., [64]). 
2.5. Production and Analysis of the Active Compounds in 
the Glandular Trichomes 
Phytocannabinoids are deposited in the secretory 
cavity. This intrawall cavity of the glands is limited by the 
outer wall of the secretory (disc) cells and covered by cuticle 
and a portion of the middle layer of the cell wall 
[138,140,147]. Cytochemical studies have shown that 
cellulases are involved in the formation of the cavity [148]. 
Ultrastructural analyses of the disc cells revealed the 
presence of dense cytoplasm, transitory lipid bodies and 
fibrillar material, few dictyosomes and secretory vesicles 
derived from them, well-developed endoplasmic reticulum 
and proplastid-like leucoplast sections with few inner 
membranes and some electron-dense inclusions at the pre-
secretory stage [140,149]. During the secretory stage, 
vacuolization of the cells occurs, and mitochondria as well as 
elongated leucoplasts (also termed as lipoplasts, 
corresponding in fact to secretory plastids) become 
abundant. A symplast – i.e., large intercellular cytoplasmic 
connections, plasmodesmata – develop between the secretory 
cells of the head [140]. 
The production of the secretory product is associated 
with the increased number and structural complexity of 
mature leucoplasts measuring 1.4-1.6 µm in diameter [140]. 
Leucoplasts have a dense stroma and develop a 
paracrystalline body (also called a tubular complex or a 
reticulate body of a diameter of 0.8 µm) [140,149] 
resembling the prolamellar body of etioplasts of dark-
germinated angiospersms (Fig. 4A-C) [150]. Such special 
membrane arrangement is often observed in secretory tissues 
of different plants [151–157] or in suspensor cells 
synthesizing plant hormones including gibberellin [158–
160]. All these tissues – similarly to cannabis disc cells – 
have active plastidial isoprenoid biosynthesis, necessitating 
the accumulation of geranyl pyrophosphate and isopentenyl 
diphosphate intermediates. However, in contrast with 
etioplasts, the tubular complex of cannabis gradually fills the 
whole stroma area of the mature plastids of the disc cells 
[140]. These plastids have a huge internal membrane surface 
and appear only in the secretory cells of actively 
synthesizing glands and may be, thus, involved in the 
production of the secreted material. Although their function 
in Δ9-THC synthesis is less clear, plastids are probably 
involved in monoterpene biosynthesis and in providing 
precursors (GPP or lipids or both) for Δ9-THC synthesis. 
Electron transparent material – interpreted as a 
secretion of probably terpenoid nature – appears in the 
plastids, and is associated with the tubular complex 
membranes, the envelope, and seems to be secreted through 
pores of the envelope to the plastid surface, where it appears 
as a narrow zone of electron transparent material (Fig. 4B-C) 
[149]. This material then migrates and accumulates along the 
cell surface close to the secretory cavity [140,149]. It is then 
directly extruded through modified regions of the plasma 
membrane into the cell wall next to the cavity and into the 
cavity where it forms spherical lipophilic bodies 
accumulating in vesicle-like bodies in parallel with the 
enlargement of the secretory cavity (Fig. 4D) 
[138,140,147,161–163]. These vesicles (and their contents 
synthesized by the disc cells) are perhaps also engaged in the 
formation and growth of the cuticular sheath surrounding the 
secretory cavity [147,162–164]. Microchannels that are 
presumably associated to the release of volatile secretory 
compounds are formed in the cuticle after vesicle fusion 
[161]. It is important to note that stalk (stipe) and base cells 
of the glands as well as surrounding epidermal cells contain 
chloroplasts, with starch accumulation observed only in the 
latter [140]. This phenomenon further outlines the role of 
secretory plastids in the production of the secondary 
metabolites of the glands. 
Interestingly, Δ9-THCA synthase enzyme activity has 
been found in the non-cellular secretory cavity of glandular 
trichomes, indicating that this enzyme may also be secreted 
out along with other compounds to the cavity, and that 
maybe the biosynthesis of Δ9-THCA also terminates 
extracellularly [108]. This statement is further confirmed by 
(1) RT-PCR analyses showing that Δ9-THCA synthase is 
expressed predominantly in the disc/secretory cells of the 
glandular trichomes, (2) data from transgenic tobacco plants 
expressing Δ9-THCA synthase fused to green fluorescent 
protein showing fluorescence in the secretory cavity of 
glandular hairs [108], and (3) studies in insect cultures in 
which the recombinant Δ9-THCA synthase was also secreted 
to the medium [114]. In addition, a monoclonal antibody-
colloidal gold probe for Δ9-THC localized this 
phytocannabinoid to the cell wall, the fibrillar matrix and the 
surface of the vesicles in the secretory cavity, the 
subcuticular wall and the cuticle of the trichomes 
[138,165,166]. At the same time, only minor amounts of Δ9-
THC were occasionally localized to the cytoplasm (and 
organelles such as plastids) of the disc cells or to epidermal 
cells in the high pressure cryofixed-cryosubstituted [165] or 
chemically fixed [166] samples analyzed by TEM. In line 
with these results, other analytical data showed that nearly 
all of the phytocannabinoid content of capitate-stalked 
glands was present in the secretory cavity [98]. The 
intracellular formation and massive accumulation of Δ9-THC 
would probably lead to death of the plants as both Δ9-THCA 
and CBCA are cytotoxic and induce apoptosis in cannabis 
leaf cell suspension cultures [89]. Therefore, the secretion 
(and transport) of the synthesized phytocannabinoids (or 
their precursors), or the enzymes responsible for their 
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synthesis into the secretory cavity may be needed to prevent 
cellular damage [134]. In addition, the extracellular Δ9-
THCA synthesis (the reaction generated by Δ9-THCA 
synthase) results in hydrogen peroxide production [108], 
which has general antimicrobial properties, similarly to Δ9-
THCA itself [87], and may explain the role of Δ9-THCA in 
plant defense [15,55]. Δ9-THCA also induced apoptosis in 
insect cells supporting the hypothesis of Δ9-THCA being 
also involved in plant defense against predators [108]. 
Extracellularly synthesized Δ9-THC seems to be bound to a 
cell wall component and transported to the secretory cavity 
with wall materials released from the disc cell wall during 
gland maturation [166]. 
In vitro cell suspension cultures and somatic embryos 
contain practically negligible amounts of phytocannabinoids 
[167] and no Δ9-THC synthase, and the biosynthesis of these 
compounds cannot be induced by either biotic or abiotic 
elicitors in these systems containing undifferentiated cells 
[168]. Similarly, phytocannabinoids and olivetol synthase 
activity were reported to be absent [95] or present at trace 
levels [125] in roots, leaves, fruits and young plants [95], 
and in concert with this, phytocannabinoids were absent 
from calli [70]. For instance, the CBDA content of leaves, 
stems and roots was 4.8-, 48- and 600-times lower, 
respectively, than that of the female flowers of a fiber-type 
hemp cultivar [125]. However, they were also detected in 
very low amounts in seed oil [1], although in this case, they 
probably reflect contamination with glands from leaf or bract 
surfaces during improper processing [2]. In addition to 
glandular trichomes, laticifers and latex of cannabis plants 
also showed positive histochemical response to 
phytocannabinoid indicators (Fast Blue B salt, Duquenois-
Negm and Beam tests, and Gibb reaction – see below) [169]. 
These data – along with other works - indicate that 
phytocannabinoid synthesis is strongly associated with 
glandular trichomes and their development, and is thus 
regulated at developmental and tissue-specific levels [168]. 
However, while the qualitative phytocannabinoid profile of a 
strain or clone may be characteristic, the phytocannabinoid 
contents of the different glands can vary in different organs, 
in different areas of an organ, but also show seasonal 
variation, and variation with gland maturation [100]. 
The above discussed destructive analytic methods used 
for identification and quantification of phytocannabinoids 
(GC, GC-MS, HPLC, etc.) do not provide spatial resolution 
of the different compounds at the (sub)cellular level. 
Therefore, immuno-localization [138,165,166], submicron 
confocal microscopy based on label-free coherent anti-
Stokes Raman scattering [170] and fluorescence microscopy 
(using the bluish autofluorescence of CBCA under UV 
excitation) [89] can be used for in planta visualization of the 
phytocannabinoids. In addition, several tests and stains are 
available for histochemical localization and identification of 
phytocannabinoids. These include Fast Blue B (FBB) salts 
(Δ9-THC and CBD show up in red while CBN presents 
purple coloration) [143,169], Duquenois-Negm test (Δ9-THC 
and CBN both stain purple) [169], Beam test (red-brown 
color is observed for Δ9-THC and CBN, purple for CBD) 
[169], and Gibb reaction (for Δ9-THC, CBD and CBN: 
yellow color develops upon addition of 2,6-dibromo-
quinone-4-chlorimide, and blue-black color is observed upon 
isopropyl-amine addition) [169]. However, the Duquenois 
test (more exactly the Duquenois-Levine test) used quite 
often in (field) tests has been shown to give many false 
positives, and thus its use for phytocannabinoid 
identification was questioned [171]. 
There are several methods to isolate and further analyze 
the glandular trichomes and their metabolites. The heads of 
the different capitate glandular trichomes may be removed 
one by one from the plants using a tungsten needle under the 
stereomicroscope [99,100]. The heads can be then placed 
directly to a solvent (for instance chloroform) for further 
analyses [100]. Similarly, the resin contents of the secretory 
cavity of individual glands may be collected and transferred 
to solvent, which can be either petroleum ether [97] or 
chloroform - [98], using a fine needle under 
stereomicroscope [97] or a siliconized glass micropipette in a 
micromanipulator under inverted microscope [98], as well as 
a stretched glass pipette head [108], respectively. Other 
methods are less laborious and meticulous and may yield 
higher amounts of the glands. For instance, the gland-
containing plant parts may be shaked with powdered dry ice 
and sieved [172]. Alternatively, the glandular hairs can be 
removed from the frozen female inflorescences or flowers by 
shaking this material through a tea leaf sieve and collecting it 
in a mortar containing liquid nitrogen [121] or by the Bead 
Beater method adapted from [173] to cannabis [119,125]. 
During this process, the trichome-rich surfaces were 
immersed in ice-cold water, then abraded with teflon rotor in 
the presence of glass beads and isolation buffer, then filtered 
and washed twice with different buffers [119]. Alternatively, 
the trichome-rich surfaces that are immersed in sterile water 
may be sonicated to remove the glands [89]. Other works 
added phosphate buffered saline solution to the cannabis 
bract tissue, then vortexed, sieved and centrifuged the 
material [11]. Glandular trichomes may also be isolated by 
blending the plant material in cold sodium acetate buffer and 
through different filtrations [146]. By choice, trichomes may 
be isolated by laser microdissection and their 
phytocannabinoid content may be analyzed by liquid 
chromatography-mass spectroscopy or cryogenic NMR 
[134]. Interestingly, these studies detected 
phytocannabinoids not only in the heads of the capitate-
sessile and capitate-stalked trichomes, but also in the stalks 
of the latter, indicating the possibility of a more complex 
biosynthesis and localization of the metabolites within the 
glands [134]. 
3. THE PSYCHOBIOLOGY AND MOLECULAR 
MEDICINE OF CANNABIS 
3.1. Recreational Cannabis 
3.1.1. Need for Weed – Cannabis Abuse in Numbers 
A cross-national analysis of cumulative (lifetime) 
substance use revealed that cannabis is the third most 
popular substance after alcohol and tobacco [174]. The 
United States (US) and New-Zealand registered the highest 
rates of lifetime use, which amounted to 42% for both 
countries. These numbers qualify cannabis as the most 
widely used illicit substance worldwide [27,174-177], and 
cannabis use is constantly escalating among adolescents 
[177,178]. In the city of Porto, Portugal, 14.6% (356 
teenagers) of the surveyed 17-year-old adolescents born in 
1990 admitted lifetime use of illicit drugs, and 251 referred 
to hashish whereas 51 mentioned marijuana as the first 
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experimented drug [179]. Among the whole surveyed 2465 
teenagers, the most popular drug of abuse was cannabis with 
the lifetime prevalence of 12.6%, followed by cannabis 
combined with alcohol (5.5% lifetime prevalence). The past-
year prevalence for cannabis use was 12.3% while the past-
month prevalence was almost the same (12.2%), indicating 
that almost all who tried cannabis once (12.6%) became a 
habitual user [179]. In the US, the past-year prevalence of 
marijuana use increased from 4.1% to 9.5%, comparing the 
years 2002-2003 with the years 2012-2013 [180]. In the 
general population, the prevalence of marijuana/cannabis use 
disorder (CUD; [181,182]) significantly increased – 
practically doubled – from 1.5% to 2.9%, although among 
cannabis users, this value slightly decreased from 35.6% to 
30.6% by 2012-2013 [180]. The authors speculate that 
beyond certain strength (as gauged by the Δ9-THC vs. CBD 
content), cannabis cannot push the prevalence of CUD above 
31-36%. In other words, virtually every third user may 
become habitual abuser or dependent of cannabis. The 
particular significance of CBD will be discussed extensively 
below (see e.g., Sections 3.1.2.2, 3.2.3.3, 3.3.3.1. and 3.3.8). 
3.1.2. Cannabis Effects 
3.1.2.1. The "Ins and Outs" of Cannabis Getting In and Out 
of the Body 
Cannabis evokes a plethora of biophysical responses, 
but all depend on its mode of consumption: what, when and 
how [183]. The dried leaves and flowering buds of the 
female cannabis plant are used for the preparation of 
marijuana. Hashish is a concentrated resin obtained from the 
female Cannabis plant. Evidently stronger than marijuana, 
hashish can be ingested via smoking and chewing. Kief is a 
mass of trichomes collected from the leaves and the flowers, 
and often serves to make hashish from it. Hashish oil is a 
concentrated mixture of phytocannabinoids, monoterpenes 
and sesquiterpenes [184], and its baking in oven increases 
the transformation of the abundant Δ9-THCA into Δ9-THC, 
the major psychoactive ingredient. Finally, cannabis "wax" is 
the most concentrated form of Δ9-THC, containing up to 
90% of this substance along with remaining solvents and 
pesticides [185]. 
The modes of consumption also strongly affect the 
psychobiological responses. Inhalation is the most typical 
mode of consumption [177], which can be achieved by 
smoking or "dabbing" the smoldering marijuana. If not 
submitted to burning, the psychoactive content of the 
product may be different. Oral ingestion delays the onset of 
effects by 0.5-2 hours, and the circulating levels of Δ9-THC 
will be smaller but longer-lasting than when cannabis is 
smoked or intravenously administered [186,187]. There is a 
delay in the appearance of subjective "high" after plasma 
peak Δ9-THC levels [187]. This discrepancy prompts the 
hypothesis that the delay time is required for the generation 
of some phytocannabinoid metabolites that have major 
psychobiological effects at cannabinoid receptors [188,189], 
or that some phytocannabinoid ligands interfere with 
endocannabinoid inactivation and in turn, increase 
endocannabinoid bioavailability [190,191], or simply that the 
partial agonist Δ9-THC needs time to reach sufficient levels 
around its central receptors in the highly lipophilic 
environment. Addressing the pharmacokinetics of Δ9-THC, 
an early study measured a few ng/mL plasma Δ9-THC levels 
after cannabis consumption [192], which would be 
equivalent with a plasma concentration of a few nmol/L. 
Since this was published more than 3 decades ago, we can 
assume that the Δ9-THC content of the tested cannabis 
preparations was not as high as nowadays. In a recent study, 
blood samples from Swiss drivers suspected to operate motor 
vehicles under influence were analyzed by liquid 
chromatography-tandem mass spectrometry [193]. One of 
the many interesting findings was that the plasma:blood 
partition coefficient was 1.7 for phytocannabinoids. The 
authors measured blood levels of Δ9-THC between 0.7-51 
ng/mL, which corresponds to the concentration range of ~2-
~160 nM. This Δ9-THC concentration range is definitely 
active at cannabinoid receptors in vitro (see Section 3.3.6). 
Furthermore, the brain likely passively sequesters Δ9-THC 
from the blood due to its high lipophilicity, thus central Δ9-
THC levels can surpass the circulating levels for a prolonged 
time. 
After a single administration of ~10 mg Δ9-THC in a 
cigarette or 5 mg Δ9-THC intravenously to young adult male 
subjects, it was found that Δ9-THC levels rapidly drop below 
1% of the original (which was around ¼ of the smoken dose) 
within half a day [194]. However, this study could not 
establish the half-life of Δ9-THC in the plasma because of its 
constant re-release from the body tissues into the circulation, 
thus they supposed that the complete elimination of Δ9-THC 
from the body requires certainly more than 20 hours, but it 
may take even a week more [194]. After a cumulative 
administration of 4 cannabis cigarettes each containing 15 
mg Δ9-THC during two days in chronic marijuana users, the 
half-life of THC in the circulation increased to at least 4 days 
[195]. This methodological approach probably more 
adequately reflects phytocannabinoid excretion in regular 
chronic marijuana users. The excretion of Δ9-THC 
metabolites can last for several weeks in frequent heavy 
users [196,197]. The lasting excretion is due to the 
absorption of Δ9-THC in the adipose tissue which slowly re-
releases the substance in the following days [198]. Δ9-THC 
together with the rest of the phytocannabinoids is 
metabolized primarily in the liver, via microsomal 
cytochrome P450 metabolism [199-201]. THC-COOH (11-
nor-9-COOH-THC) is the secondary metabolite of Δ9-THC, 
and its presence in body fluids is considered an incontestable 
proof of Δ9-THC abuse in forensic sciences [201,202]. 
Nevertheless, it has been recently discovered that a hair test 
can produce false positive THC-COOH readouts as 
reflecting external contamination (e.g., from smoke or 
cannabis handling), stressing that urine and blood tests 
should be regarded as reliable proofs of cannabis 
consumption that occurred in the period of past hours to 
recent weeks [202]. Very recent cannabis consumption that 
occurred within one day can be solely determined from the 
saliva [203,204]. 
3.1.2.2. Short-term Cannabis Effects 
Many factors can influence the acute effect of cannabis 
in humans, including the Δ9-THC/CBD contents, mode of 
consumption, consumer's life style, frequency of the use of 
cannabis and other drugs, and gene polymorphisms. Acute 
cannabis effects can be subgrouped roughly in two 
categories: physiological effects (many of which exhibit 
therapeutic potential) and recreational (psychotomimetic) 
effects. Acute physiological effects encompass anesthesia, 
airway relaxation, hypothermia, postural hypotension (albeit 
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hypertension if not in standing position), hypolocomotion, 
increased blood flux in frontal, limbic and paralimbic brain 
areas, catalepsy, tachycardia of 1.2-1.5-times the resting 
heart rate, decreased intraocular pressure in glaucoma, 
antiemesis, and increased insulin release, increase in 
appetite, thirst, food palatability and in caloric intake 
[198,205-210]. 
The acute mental and psychotomimetic outcomes of 
cannabis intoxication cover the sought effects including 
euphoria, relaxation, richer sensory experiences and 
increased sociability, as well as the mostly benign and self-
limited side effects and misadventures, such as 
hallucinations, paranoid and grandiose delusions, conceptual 
disorganization, feelings of unreality, blunted affect, lack of 
spontaneity, psychomotor retardation, increased reaction 
time (contributing to driving incapability), social and 
emotional withdrawal, altered external and internal 
perceptions including binocular depth inversion, time-
dilatation, deficits in attention, verbal fluency and working 
memory and sometimes increased anxiety, dysphoria, 
paranoia, and panic attacks [177,183,211-218]. Most of these 
effects coincide with schizophrenia-like positive and 
negative symptoms [215-218]. 
Four out of the acute effects, namely hypothermia, 
hypolocomotion, catalepsy and analgesia (altogether: "the 
tetrade effects") are the cardinal signatures of 
cannabimimetics (cannabinoid receptor activators) 
[219,220]. To be more precise, only those cannabimimetics 
produce tetrade effects which activate the cannabinoid CB1 
receptor (see Sections 3.2.2-3). However, most acute effects 
observed in drug-naïve subjects are blunted in regular 
cannabis users except subjective effects of 'high', tachycardia 
and increased serum cortisol in both groups [216]. The 
consequences of chronic cannabis abuse are discussed in the 
following paragraphs as well as at the end of this review 
(Sections 3.3.6-8). 
3.1.2.3. Cannabis Tolerance and Withdrawal 
Tolerance to cannabis effects can be achieved within 
days in animal experiments [221-224]. In a pioneering study 
[221], mice were fed daily with 8 mg Δ9-THC dissolved in 
milk, for 15 days. On the 16th day, the drug-naïve milk-fed 
control mice responded with hypothermia – a 1.3 °C-
decrease in their body temperature – to a single injection of a 
low dose (2 mg/kg) of Δ9-THC, while the tolerant mice 
showed a 1.0 °C increase on average in their rectal 
temperature. During 15 days of treatment, body weight and 
milk intake were not different between groups. No tolerance 
developed to acute Δ9-THC-induced immobility on day 16 in 
the chronic Δ9-THC-group, and bodily metabolism of Δ9-
THC also remained unchanged in these animals [221]. 
Apparently, there are subtle differences between species, 
because rats chronically injected intraperitoneally with 2×5 
mg/kg Δ9-THC daily for 14 days showed tolerance both to 
immobility and catalepsy, albeit reproduced the 
hyperthermic effect of Δ9-THC [224]. In these tolerant rats, 
in vivo electrophysiology revealed that Δ9-THC 
administration no longer affected nigrostriatal dopaminergic 
activity, while it still stimulated dopaminergic activity in the 
"reward area", that is, in the ventral tegmentum after 14 days 
of treatment [224]. 
These data bolster the observations that in humans, 
tolerance is developed to most cognitive, physiological and 
endocrine effects of cannabis except cannabis-induced 
"high", which underlies the abuse liability of Δ9-THC 
[216,225,226]. For instance, in frequent chronic marijuana 
consumers, resting-state time overestimation and 
underproduction can be detected, but intravenous Δ9-THC 
(15-50 µg/kg) does not significantly affect time perception 
beyond the already existing impairments [218,227]. Mild 
tolerance also develops toward the somnolent effects of 
higher doses of Δ9-THC [228]. 
In animal models, CB1R maximum binding sites (Bmax) 
decrease throughout the brain upon 2-week-administration of 
Δ9-THC and the more potent synthetic cannabimimetic, 
CP55940 (see Section 3.2.3.1; Fig. 1) while CBD produces 
no such effect [222]. A recent elegant superresolution 
microscopy study revealed that CB1R density dropped by 
74% in the nerve terminals of perisomatic interneurons of 
the hippocampus of mice treated twice daily with 10 mg/kg 
Δ9-THC for 6.5 days [229]. Full recovery took 
approximately 6 weeks [229]. During the development of 
tolerance, systemic and cellular energy metabolism show 
adaptive responses to constant cannabinoid receptor 
activation, and synaptic plasticity becomes strongly impaired 
in the autonomic and the limbic nervous systems. These are 
congruent with the wide variety of physical and psychical 
discomforts caused by cannabis withdrawal. Early 
withdrawal studies in rats were enabled by the availability of 
the first CB1R-preferring inverse agonist, SR141716A 
(rimonabant) ([230]; see Section 3.2.3.1). As we will see 
later, SR141716A not only abruptly prevents central Δ9-THC 
effects but also impairs basal (constitutive) CB1R activity 
[231,232], worsening the symptoms beyond those caused by 
a neutral antagonist (see Section 3.2.3.1). In one of the early 
studies, 4-day regimens with increasing doses of Δ9-THC 
were abrupted, or in other cases, were substituted with 
SR141716A [233]. Although the high dose regimens were 
way beyond those humans could ever be exposed to, even 
the lower-dose regimens (0.5-4 mg/kg) caused physical 
dependence within just a few days. SR141716A precipitated 
the following withdrawal symptoms (depending on the Δ9-
THC doses used): scratching, rubbing face with paws, 
licking, wet-dog shakes, arched back and ptosis [223,233]. 
Rats that received the highest Δ9-THC doses showed 
additional signs: biting, tongue rolling, retropulsion, head 
shakes, extended limbs or high stepping, ataxia, myoclonic 
spasms and front paw treading [233]. Abrupt withdrawal did 
not cause abstinence signs robust enough to be statistically 
significant [223,233], and this was probably because the 
lipophilic Δ9-THC and its metabolites are excreted slowly 
[199,201], and to some extent, may be retained for longer 
periods in lipid-rich tissues such as the adipose tissue and the 
brain. The time-course of Δ9-THC (metabolite) excretion 
probably allows room for gradual recovery with moderate 
withdrawal symptoms in those behavioral studies in rodents. 
Although the above studies were all carried out in 
young animals, apparently aging strongly influences CB1R 
functioning and its sensibility to chronic agonist exposure. 
Presynaptic CB1R density is already 10% smaller by 6 
months of age in the rat hippocampus, which decreases by 
the end of the 2nd year to 70% of the original value measured 
at 2 months of age [234]. In mouse hippocampal membranes, 
even greater decrease was observed both in terms of basal 
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and CP55940-stimulated [35S]-guanosine 5'-O-[gamma-
thio]triphosphate ([35S]-GTPγS) binding in the middle-aged 
(12-month-old) mice (for the explanation of the technique, 
see Section 3.2.3.1) [235]. Importantly, 8 injections of Δ9-
THC during 5 days caused desensitization in CB1R-coupling, 
and also reduced hypomotility in response to acute Δ9-THC 
injection in behavioral assays only in the young (6-8-week-
old) mice, rather than in their middle-aged counterparts 
[235]. 
There is an increasing demand from CUD patients for 
the treatment of cannabis dependence [236], but this meets a 
paucity of available therapeutic tools that could provide 
some degree of relief [237,238]. In Δ9-THC-tolerant rats, 
classical approaches such as dopamine D1 or D2 receptor 
(D1R, D2R) blockade failed to affect SR141716A-
precipitated withdrawal, although vertical activity and 
grooming were reduced. In contrast, D1R or D2R agonists 
worsened the withdrawal symptoms and triggered seizures 
[239]. N-acetylcysteine therapy proved so far one of the 
most useful approaches in a limited number of human 
patients, and the outcomes of a recently completed clinical 
trial on the efficacy of 1200 mg N-acetylcysteine on the 
recovery from cannabis dependence in about 300 CUD 
patients will be soon published [240]. 
3.1.2.4. Long-term Consequences of Cannabis Abuse 
Long-term marijuana consumption is clearly associated 
with a risk of addiction [177]. The level of risk is dependent 
on genetic predisposition, lifestyle, frequency of use and 
more importantly, the age when frequent marijuana 
consumption starts. For instance, in the general population, 
the overall risk of becoming addicted to marijuana is 9%, but 
the risk almost doubles in adolescents who try marijuana, 
and is 25-50% in daily users [177]. 
There are important gender-dependent differences in 
CUD: males have higher prevalence for CUD and more 
frequently seek CUD treatment, while females easier and 
faster develop cannabis-dependence after initial use [241-
244]. This predicts that the subjective effects of Δ9-THC are 
different in the two sexes, and indeed, this is what has been 
observed: female participants of a recent study were more 
sensitive than males to the subjective effects of an orally 
administered low-dose of Δ9-THC [245]. 
Besides dependence, tolerance and withdrawal 
symptoms which collectively fall under the term of CUD, 
long-term cannabis abuse can provoke several alterations in 
the human body, and only a few of them are benign. Once 
again, it is difficult to draw a clear picture because of several 
influencing factors including e.g., individual differences in 
frequency of use, dosage, life-style and genetic background. 
Due to the high density and significance of CB1Rs in both 
the developing and the adult nervous tissues, long-term 
exposure to Δ9-THC and synthetic cannabinoids either pre- 
or post-natally has deleterious effects on the fetal, adolescent 
and adult brain, with permanent neurodevelopmental 
alterations and serious risks to neuropsychiatric disorders 
including schizophrenia (see Sections 3.3.7-8). 
Chronic marijuana consumption has long-term 
peripheral effects as well. To start with the toxicity of the 
smoke, a study ordered by the Canadian government in 2007 
revealed that marijuana smoke contains 20-times more 
ammonia, 3-5-times more hydrogen cyanide, nitrous oxides 
and some aromatic amines, and 50-70% more carcinogenic 
hydrocarbons than the smoke of filter tobacco cigarettes 
[246]. Consequently, some studies find association between 
cannabis use and the narrowing and extensive injury of the 
airways as well as cancers in the respiratory tract and 
reproductive organs. However, there is no change in the 
frequency of head-neck cancers in lifetime users when 
compared to non-users [247-250]. 
Due to the profound effects of cannabis constituents on 
the blood vessels and the heart, prolonged use of cannabis 
alone can provoke serious and sometimes fatal 
cardiovascular complications in some individuals, even in 
the absence of comorbid cadiovascular diseases. There are 
several reports on cannabis-induced multifocal intracranial 
vasoconstriction, (recurrent) ischemic strokes, cerebellar 
infarction [251-254], and multiple cardiovascular fatalities 
[255]. A case of cannabis-provoked recurrent pancreatitis 
[256], as well as synthetic cannabis- (K2) induced 
myocardial ischemia in a series of pediatric patients [257] 
have been also reported. 
Chronic cannabis consumption also can have positive 
outcomes on certain metabolic parameters. Albeit heavy and 
long-term (15-year) marijuana abuse is associated with 
~23% higher caloric intake and 3-times greater alcohol 
intake as well as increased tobacco use in 3617 young adults 
in 4 major metropolitan areas of the US [210], some 
metabolic parameters improve against all odds: A recent 
study found that current cannabis use in the past 30 days was 
associated with 16% lower fasting insulin and 3.7 % lower 
plasma glucose levels, 1.63 mg/dL higher high-density 
lipoprotein-C levels, better insulin sensitivity and smaller 
waist circumferences compared to those who never used 
cannabis, among the enrolled 4657 US adults [258]. These 
positive associations appeared to be short-lived as they were 
already blunted in those who ingested cannabis more than a 
month before the survey [258]. Another similar study in the 
US population (n=10896) found that current and past 
cannabis users were less prone to diabetes mellitus and had 
higher HDL levels [259]. This study also reported reduced 
low-density lipoprotein (LDL, bad cholesterol) and lower 
triglyceride, glucose and C reactive protein levels in the 
serum of past and current users [259]. However, cross-
correlative analysis of the reports also reveals a few 
discrepancies: increase [210], no change [258] or even a 
decrease [259] in circulating triglyceride levels were all 
reported. Also, systolic blood pressure was found to be 
unaffected among cannabis users in one study [258] while it 
was found increased by another survey [210]. Nevertheless, 
multivariate analysis revealed that increased alcohol 
consumption among cannabis users was the confounding 
factor contributing to the greater triglyceride and systolic 
blood pressure values in the above study [210]. 
In conclusion, past and present cannabis use is 
associated with a decreased prevalence for metabolic 
disorders if alcohol use remains low. However, it remains to 
be elucidated whether chronic cannabis consumption acts as 
an activator or rather, as a deactivator of cannabinoid 
receptors in the human body. This question has been 
prompted by several lines of observations discussed later in 
this review. One of these observations is truly amazing, 
because similarly to long-term cannabis use, the CB1R 
blocker SR141716A (rimonabant) also confers beneficial 
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effects on the cardiometabolic risk factors, including waist 
circumference, lipid levels, glycemia and insulin sensitivity 
[260-263]. 
3.2. The Pharmacology and Molecular Biology of the 
Endocannabinoid System Sensu Lato 
The history of scientific research on cannabis stretches 
back over 150 years, which has been reviewed elsewhere 
[264]. The curiosity about the cellular targets of Δ9-THC and 
related phytocannabinoids has led to the discovery of a great 
number of proteins and lipid molecules that can be abridged 
as the "endocannabinoid system sensu lato" (Fig. 5). The 
term "endocannabinoid" [265,266] was coined to distinguish 
cannabinoid molecules endogenously produced by the body 
from those of exogenous origin such as Δ9-THC. 
Strictly speaking, the term "endocannabinoid system" 
refers to the endocannabinoid molecules – among them the 
most studied ones are N-arachidonoylethanolamine 
(anandamide) and sn-2-arachidonoylglycerol (2-AG); their 
synthesizing and metabolizing enzymes; the cannabinoid 
CB1 and CB2 receptors (CB1Rs and CB2Rs); furthermore, an 
elusive endocannabinoid membrane transporter (EMT); and 
finally, the CB1R interacting protein 1a (CRIP1a) which is 
emerging as a regulator of CB1R signaling. However, to tell 
the endocannabinoid signalosome apart from other signaling 
families is as difficult as to define the contours of the green 
color in a rainbow. To fully appreciate the acute and long-
term physiological consequences of cannabis intake as well 
as the therapeutic potential of marijuana-based medicines, it 
is necessary to overview additional targets which subserve 
the physiological actions of marijuana. Many 
phytocannabinoids of the cannabis and other plants [37,267-
270] serve as ligands for receptors beyond the CB1R and the 
CB2R. Such additional receptors are the serotonin 5-HT1A 
receptor (5-HT1AR) and the deorphanized GPR55. 
Phytocannabinoids also interact with ionotropic receptors of 
the transient receptor potential (TRP) family including the 
TRPV1 receptor, which is in fact a bona fide ionotropic 
endocannabinoid receptor (besides being much more). Last 
but not least, cannabinoids can go nuclear. The psychoactive 
nature of cannabis ingredients prompts us to focus on the 
central nervous system, but the role of the endocannabinoid 
system in some other selected peripheral mechanisms will be 
also reviewed. 
3.2.1. Endocannabinoids 
Shortly after the discovery and cloning of the CB1R 
[271-273], their first endocannabinoid ligand, N-
arachidonoylethanolamine (anandamide) was reported 
[274,275], and its calcium-dependent formation, release and 
inactivation were characterized in cultured neurons [265]. 
Following the discovery of the second cannabinoid receptor, 
the CB2R [276], another endocannabinoid, sn-2-
arachidonoylglycerol (2-AG) was identified [277,278]. 
Anandamide is at least two orders of magnitude less 
abundant in the brain than 2-AG [279]. Moreover, 
anandamide in many assays appeared less efficacious at the 
CB1R and CB2R than 2-AG, and is also less potent than Δ9-
THC [219,280-284]. Consequently, the CB1R and the CB2R 
were recognized as 2-AG receptors [283-284], while 
anandamide together with Δ9-THC fall in the category of 
partial agonists. Additional endogenous fatty acid-derivative 
ligands of the CB1R and the CB2R were also reported (see 
Section 3.2.3.4), but more research is needed to better 
understand their physiological significance. Finally, the 
endogenous ligands of the "unofficial" cannabinoid receptors 
GPR18 and GPR55 will be discussed together with their 
cognate receptors. 
3.2.1.1. Endocannabinoid Synthesis 
Precursors for both anandamide and 2-AG are believed 
to be stored in the cell membranes where the synthesis and 
the release of the two endocannabinoids occur [285,286]. 
Multiple synthetic routes have been identified for 
anandamide [286,287]. Its principal precursor is N-
arachidonoyl-phosphatidylethanolamine (NAPE) [286-288]. 
Different enzymatic steps can lead to "on demand" 
anandamide cleavage from NAPE, which can involve the 
Ca2+-dependent activation of specific phospholipases A2, C, 
D and α,β domain serine hydrolase 4 (ABDH4) [286-288]. 
There is evidence that NAPE-hydrolyzing phospholipase D 
(NAPE-PLD) is predominantly presynaptic in the 
hippocampus in excitatory afferents, with highest density in 
the CB1R-negative mossy fiber terminals [289]. In the 
ventral pallidum, NAPE-PLD is also predominantly 
presynaptic in both inhibitory and excitatory terminals which 
are often CB1R-negative, apposing to CB1R-positive nerve 
terminals [290]. As only 12% of NAPE-PLD 
immunoreactivity appeared dendritic, it is to conclude that 
NAPE-PLD-mediated anandamide signaling follows the 
classical pattern as being anterograde, unlike 2-AG 
signaling, which is principally retrograde at central synapses 
(see Section 3.3.2). 
The chief biosynthetic pathway for 2-AG (when 
participating in endocannabinoid signaling) starts with the 
phospholipase-Cβ (PLCβ)-mediated hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) [291] resulting 
in the intermediate sn-2-diacylglycerol (DAG), from which 
2-AG is cleaved by the enzyme sn-2-DAG lipase α 
(DAGLα) [292-294]. Additionally, at least two other routes 
of 2-AG synthesis have been identified [295,296] with 
elusive physiological importance. 
In the nervous tissue, 2-AG – when participating in 
endocannabinoid signaling – is also thought to be released 
"on-demand" [297]. This means that typically in dendrites, a 
depolarization-induced Ca2+ entry or the stimulation of Gq/11 
protein-coupled metabotropic receptors or both activate 
DAGLα to produce 2-AG in a millisecond to second scale 
[286,298,299] (Fig. 6). As a footnote, this mechanism is not 
restricted to neurons: Gq/11-coupled receptor activation can 
trigger DAGL-mediated 2-AG release and consequent CB1R 
activation in transfected Chinese hamster ovary (CHO) cells, 
too [300]. Some hypothesized that in special cases 2-AG 
could be pre-synthesized and stored until stimulus [301,302], 
but till now the theory of "on demand" endocannabinoid 
release remains the leading concept [303]. 
3.2.1.2. Endocannabinoid Degradation and Transport 
Several enzymes can degrade endocannabinoids, but 
only a few of them are responsible for the bulk metabolism. 
Anandamide is hydrolyzed into arachidonic acid and 
ethanolamine by intracellular enzymes among which the 
fatty acid aminohydrolase-1 (FAAH-1) bears major 
importance [304]. FAAH-2 is another enzyme sharing 20% 
similarity in its amino acid sequence with FAAH-1, and is 
expressed in humans but not in laboratory rodents [305], 
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which makes difficult to dissect its physiological importance. 
FAAH-1 is recognized as a therapeutic target in a number of 
health conditions [306-310], because its blockade increases 
anandamide tone that can indirectly activate cannabinoid 
receptors without psychoactive side effects. A third enzyme, 
a splice variant product of the FAAH-1 gene, the so-called 
FAAH-like anandamide transporter (FLAT) was described 
as a protein involved in the transport of anandamide through 
the cell membranes [311], but it has been "downgraded" later 
as just one more cytosolic anandamide degrading enzyme 
[312]. 
Figure 6 summarizes the major components and steps 
of 2-AG signaling in a glutamatergic synapse. As for the 
termination of 2-AG signaling, the presynaptic intracellular 
monoacylglycerol lipase (MAGL) [313,314] provides the 
predominant 2-AG hydrolytic activity in the mammalian 
brain, producing arachidonic acid and glycerol from 2-AG. 
Acute MAGL inhibition increases 2-AG half-life in the 
synapse [315-317]. As a consequence of 2-AG being 
abundant and a full CB1R agonist, chronic MAGL inhibition 
or the genetic deletion of MAGL causes prolonged elevation 
in 2-AG levels, causing the desensitization of CB1R 
signaling [318-320]. Later, a microglial MAGL-like activity 
was also reported, but to our knowledge, this MAGL-2 has 
not been fully characterized [321]. 
Two additional classes of metabolizing enzymes, α,β 
serine hydrolase domain 6 and 12 (ABDH6/12) are mainly 
responsible for the remaining 2-AG metabolizing activity 
[322-324]. In the synapse, these two enzymes are found in 
the post-synaptic membranes. While ABDH12 faces the 
lumen or the extracellular space, ABDH6 is rather located in 
the membrane facing the cytoplasm, thus they can mitigate 
2-AG levels at both sides of the membrane [322-324]. Other 
enzymes including cyclooxygenase-2 (COX-2) [325-328], 
12-lipoxygenase [329], 15-lipoxygenase [325] and 
neuropathy target esterase [330] were also shown to readily 
metabolize endocannabinoids into bioactive non-
endocannabinoid molecules, but these pathways probably 
gain more importance either in peripheral tissues or under 
pathological conditions. 
The most elusive member of the endocannabinoid 
signalosome is the purported EMT, which has not yet been 
identified despite huge efforts, and perhaps it does not even 
exist – as predicted by models of passive endocannabinoid 
diffusion driven by hydrolysis [312,331,332] (Fig. 6). 
Finally, the oddball of intercellular anandamide signaling 
indeed involves "odd balls": microvesicles. Microglia – 
which can be regarded as the fourth component of the 
quadripartite synapse [333] – can release membrane 
segments containing anandamide in the form of 
microvesicles onto GABAergic synapses with functional 
implications [334]. This form of endocannabinoid signaling 
presumably does not require the direct release of anandamide 
from the membrane into the extracellular space. 
3.2.2. CB1 and CB2 Cannabinoid Receptors 
The cloning and initial characterization of the central 
cannabinoid receptor, the CB1R were reported in the 
beginning of the nineties [271-273,335]. Only a few years 
later, another cannabinoid receptor type, the human and the 
rat CB2R was discovered [276,336,337], with almost 
exclusive expression in the immune tissues [338]. Both of 
these two receptors belong to the rhodopsin-like G protein-
coupled receptor (GPCR) superfamily, and contain 7 α 
helical transmembrane domains. 
The high similarity in amino acid sequence of the 473 
amino acid-long rat CB1R [273] and the 472 amino acid-long 
human CB1R (hCB1R) [272] represents evolutionary 
conservation [339]. One shorter splice variant of the rat and 
two of the human CB1R have also been identified [340,341]. 
The "normal length" CB1R and its expressed splice variants, 
CB1RA and CB1RB proteins all significantly differ in their 
pharmacological profile both in terms of the affinity and the 
efficacy of ligands [282,341]. For instance at the CB1RA and 
CB1RB, 2-AG behaves as an inverse agonist (i.e., it inhibits 
GTPγS binding – see Section 3.2.3.1) while anandamide 
loses efficacy [341]. The CB1R in its homomeric form 
preferentially couples to Gi/o proteins [342,343]. 
The first cloned hCB2R has only 360 amino acids, 
sharing only 44% overall homology with the hCB1R, and 
68% identical amino acid identity considering only the 7 
transmembrane domains [276]. Mice have 2 (CB2RA,B) while 
rats have 4 CB2R splice variant products (CB2RA-D) 
[344,345], with possibly differing pharmacological profile. 
The CB2R also couples predominantly to Gi/o proteins 
[346,347] to inhibit adenylyl cyclase activity, which is 
thought to be the underlying mechanism of CB2R-mediated 
downregulation of immune functions [280,336,348,349]. 
Both the CB1 (Fig. 7) and the CB2 receptors couple to 
multiple intracellular effectors, including adenylyl cyclase, 
extracellular regulated kinase 1/2 (ERK1/2), p38 mitogen-
activated protein kinase (MAPK), c-Jun N-terminal kinase 
(JNK), and phosphoinositide 3-kinase (PI3K)/protein kinase 
B (Akt) [350-359]. Common CB1R signaling routes through 
Gi/o proteins are displayed in Fig. 7. For additional signaling 
pathways, see Guzmán et al. [360] and Harkany et al. [361]. 
Nevertheless, cannabinoid receptor mediated signaling 
cannot be viewed mechanistically, as context-dependent 
decisions are made at signaling crossroads. For example, 
CB1R activation converging onto PI3K and ERK activation 
promotes survival against ceramide-induced apoptosis [355], 
but chronic CB1R and CB2R activation itself stimulates the 
generation of ceramide, which causes sustained ERK 
activation via RAF proto-oncogene serine/threonine-protein 
kinase (Raf-1), leading to apoptosis [360,362,363]. 
CB1Rs and CB2Rs can modulate intracellular cation 
levels. CB1Rs are negatively coupled to N-, L-, P- and Q-
types of voltage-gated Ca2+ channels (VGCCs) via the βγ 
subunit of the G protein, and positively associated with 
inwardly rectifying K+ channels (GIRKs), probably via 
direct physical complexing [364-369]. As discussed above, 
under special circumstances, CB1Rs can trigger intracellular 
Ca2+ transients, too [370,371]. The stimulation of CB2Rs 
may also produce transient increases in intracellular Ca2+ 
concentration ([Ca2+]i) via PLCβ [284,372], at least in 
transfected cells. Although initially it was found that the 
CB2R was unable to modulate VGCCs [365,373], later it 
turned out that those negative data were the consequence of 
functional selectivity of the ligands (see Section 3.2.3.1) and 
strain differences [374,375]. Namely, the Δ9-THC analog 
CP55940 (Fig. 1) inhibited VGCCs in human embryonic 
kidney cell line 293 (HEK293) transfected with either the 
mouse or the rat CB2R of the long isoform, while the 
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aminoalkylindole WIN55212-2 inhibited VGCCs currents 
only in cells transfected with the rCB2R [376]. 
3.2.3. Pharmacology of the CB1R and the CB2R 
Cannabinoids can be divided into major groups based 
on their chemical structure. The phenylterpenoid Δ9-THC 
and all its derivatives which have a pyran ring belong to the 
first group understandably termed as classical cannabinoids. 
Δ9-THC-derivatives without a pyran ring are called non-
classical cannabinoids. Some distant phytocannabinoid-
derivatives are termed as atypical cannabinoids. Other 
synthetic cannabinoids fall in the category of 
aminoalkylindoles: anecdotally, the pharmaceutical company 
Sterling-Winthrop back in the eighties aimed at developing a 
novel class of COX inhibitors based on the aminoalkylindole 
backbone, and the first such promising molecule, 
pravadoline indeed exerted a very strong analgesic and anti-
inflammatory activity. Soon, these effects were attributed to 
an off-target cannabimimetic action, and pravadoline 
research took a new course. 
The agonist profile of CB1 and CB2 receptors is 
considerably overlapping: the ultrapotent classical 
cannabimimetic HU210 as well as the above mentioned 
CP55940 (synthesized by Pfizer in 1974) (Fig. 1), Δ9-THC 
[57] (Fig. 1), WIN55212-2 [377-379] (Fig. 1), anandamide 
and 2-AG (Fig. 1) are the cannabimimetics most typically 
used for studying the role of the CB1R and the CB2R, and 
these ligands do not show significant preference toward one 
or the other receptor [380,381]. However, many additional 
endocannabinoids, non-psychoactive phytocannabinoids and 
novel synthetic ligands differentiate between the two 
receptors (see Sections 3.2.3.3-4). Based on their context-
dependent action, they can be classified as orthosteric 
ligands such as biased agonists, inverse agonists and neutral 
antagonists as well as allosteric ligands. 
3.2.3.1. Multifaceted Interaction of Ligands and G Proteins 
with the CB1R and the CB2R 
As discussed earlier, most GPCR ligands have their 
own intrinsic efficacy in a given system [382], because when 
structurally different ligands bind to their cognate receptor 
they are prone to trigger dissimilar conformational changes. 
Hence the term "biased agonism" was coined [383]. In other 
sources, biased agonism is substituted with "agonist-directed 
trafficking of response" (ADTR) [384,385]. However, we 
here prefer the term "functional selectivity of the ligands" 
because biased antagonism is also an existing phenomenon, 
and curiously, agonists can also act as antagonists at the 
same receptor under special circumstances. The existence of 
splice variants for the CB1R and the CB2R can also greatly 
increase the odds of odd cannabinoid pharmacology in ex 
vivo models or cell culture. 
The first example for functional selectivity was seen at 
the level of G proteins in N18TG2 neuroblastoma 
membranes [386]: WIN55212-2 (up to 100 nM) was capable 
of fully dissociating Gαi1, Gαi2 and Gαi3 from the CB1R, while 
the cannabimimetic desacetyllevonantradol (1 µM) [387] 
fully dissociated the CB1R-Gαi2 and partially disrupted the 
CB1R-Gαi1 complex, and finally, the anandamide analog, R-
methanandamide (100 nM) triggered the dissociation of only 
Gαi3 [386]. This also explains why WIN55212-2 has such a 
high intrinsic efficacy throughout different assays (e.g., 
[388]), therefore this aminoalkylindole agonist is a popular 
cannabimimetic tool for research, because it guarantees the 
success of most functional assays with CB1 and CB2 
receptors. An important note for the field is that above 1 µM, 
WIN55212-2 stimulates [35S]-GTPγS binding in brain 
membranes of the CB1R -/- mice [389], and consequently, it 
can inhibit glutamate release independently from CB1Rs 
[390,391]. 
Many GPCRs exhibit a so-called constitutive activity, 
meaning that they dissociate from GDP-bound G proteins at 
a low rate either because of the presence of residual levels of 
endogenous ligands or by a thermodynamically allowed low-
probability reversal of association, in the absence of agonists 
[383,386]. Theoretically, antagonists are not supposed to 
affect the constitutive auto-uncoupling. An antagonist is 
called silent or neutral when it only prevents an agonist from 
activating the receptor, but in itself does not disturb 
significantly the conformational state of the receptor, hence 
producing no effect per se [392]. The classical cannabinoid 
O-2050 [393] and the diarylpyrazole NESS0327 [394] fall 
under this category as both prevent CB1R activation when 
agonists are present, but per se they do not produce any 
effect [395]. Notwithstanding, a recent characterization of O-
2050 revealed some unexpected in vitro partial agonist 
activity in cyclic AMP assay, and a lack of antagonism on in 
vivo effects of Δ9-THC and WIN55212-2 [393]. In our 
hands, O-2050 (1 µM) had no effect on the depolarization-
induced release of GABA, glutamate and serotonin in the 
frontal cortex [396,397], and prevented the inhibitory action 
of WIN55212-2. In that sense, it mimicked the effect of the 
genetic deletion of the CB1R and we concluded that O-2050 
is a useful in vitro CB1R antagonist up to the concentration 
of 1 µM. 
In special cases, a GPCR can assume an inactive 
structure which would sequester surrounding G proteins 
rather than allowing their spontaneous dissociation. The 
probability of this phenomenon is facilitated by certain 
ligands which are called inverse agonists. The first 
prototypic CB1R antagonist, 1,5-diarylpyrazole SR141716 
[230] is in fact an CB1R inverse agonist [351,386,392], 
which means that it triggers responses on its own via the 
blockade of constitutive (also known as basal) CB1R 
signaling, and the consequent disruption of active 
intracellular coupling. As a result, the direction of those 
responses will be perceived as reversed compared to the 
responses triggered by a true agonist, hence the name inverse 
agonist. Strikingly, under GTPγS treatment, R-
methanandamide inhibited the forced dissociation of Gαi1-
GTPγS and Gαi2-GTPγS while desacetyllevonantradol 
precluded the dissociation of Gαi3-GTPγS and attenuated that 
of Gαi1-GTPγS from the CB1R [386]. This paradoxical 
observation means that not only an antagonist but also an 
agonist can behave as an inverse agonist at the same time, 
i.e., activating a pathway for which it has high intrinsic 
efficacy while antagonizing other pathways; thus adding to 
the complexity of biased agonism. Although WIN55212-2 
inhibits cyclic adenosine monophosphate (cAMP) 
accumulation both in vivo in the striatum and in vitro [398], 
it exhibits a very peculiar case of biased agonism in the 
presence of Gq/11 proteins, as this aminoalkylindole – unlike 
classical, non-classical or eicosanoid agonists – stimulated 
Ca2+ outflow from intracellular stores in cell cultures, via the 
CB1R and Gq/11 proteins [371]. In another study, CP55940 at 
very low concentrations stimulated cAMP accumulation in 
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CB1R-expressing CHO cells via pertussis toxin-insensitive G 
proteins; however, CP55940 at much higher concentration 
counteracted the forskolin-induced stimulation of cAMP 
accumulation [370]. Additional studies in CHO cells 
unveiled that the blockade of Gi/o by pertussis toxin triggers 
the association of CB1Rs to stimulatory G proteins (as 
witnessed by the facilitation by HU210, CP55940, Δ9-THC, 
WIN55212-2 and anandamide of the forskolin-stimulated 
rather than the basal cAMP accumulation) [384,399]. These 
agonist- and concentration-dependent phenomena are termed 
as promiscuous G protein coupling [400]. There is a 
surprising twist to the promiscuous G protein coupling, too, 
because the intrinsic efficacy of ligands changes dramatically 
when the CB1R couples to Gs [384]. In the present example, 
WIN55212-2 was the most efficacious either to stimulate 
basal cAMP accumulation or to inhibit forskolin-stimulated 
cAMP accumulation, while the efficacy of Δ9-THC to 
stimulate basal cAMP accumulation dropped 30%, and that 
of CP55940 was halved and finally, the efficacy of 
anandamide fell to 1/3 [384]. 
3.2.3.2. Allosteric Modulation of the CB1R 
An additional case of receptor-ligand interaction does 
not directly involve the principal (orthosteric) binding site of 
the CB1R. Allosteric modulators can either negatively 
(negative allosteric modulator, NAM) or positively (positive 
allosteric modulator, PAM) affect the conformation of the 
receptor so that orthosteric cannabimimetics display smaller 
or greater affinity and efficacy at the receptor [401]. The 
characterization of the first CB1R-selective synthetic 
functional PAM compounds, ORG27569, ORG29647, 
ORG27759 [402] were followed by PSNCBAM-1, which 
works as a NAM of the CB1R both in vitro and in vivo, thus 
mimicking the effects of a silent CB1R antagonist and does 
not affect the constitutive coupling of the hCB1R [403]. Both 
the hCB1R and the hCB2R have a cholesterol-
interaction/recognition amino acid sequence consensus 
(CRAC) in their last 11-amino acid sequence of the 7th 
transmembrane helix (TMH7), however, the lysine 402 in the 
hCB1R is substituted with a glycine in the hCB2R. While 
cholesterol acts as a NAM on the hCB1R, the hCB2R is 
completely insensitive to cholesterol due to the single amino 
acid difference in the CRAC sequence [404]. Apart from 
this, there is at least one more cholesterol binding site in the 
CB1R – denoted as cholesterol consensus motif (CCM), 
which stretches through TMH1-4, and where ORG27569 
competes with cholesterol for allosteric modulation [405]. 
Interestingly though, cholesterol promotes centrifugal CB1R 
trafficking to the lipid rafts of neural processes which are 
rich in endocannabinoid signalosomes, while the treatment 
with ORG27569 works the other way around [405]. These 
also suggest that disturbances in systemic cholesterol 
homeostasis may eventually affect CB1R signaling. 
Interestingly, the cholesterol-derivative endogenous 
hormone, pregnenolone provides negative feedback onto 
CB1R signaling in the brain via negative allosteric 
modulation [406] (see Section 3.3.9). 
In contrast, RTI-371 works as a PAM [407], although it 
was originally meant to be a dopamine transporter (DAT) 
inhibitor (see also Section 3.3.4.1). Lipoxin A4 has been 
identified as an endogenous enhancer of anandamide effects 
at the CB1R [408] 
3.2.3.3. Cannabis Constituents at the CB1R and the CB2R 
Interestingly, certain phytocannabinoids differ in their 
action at the two receptors. The natural stereoisomer of Δ9-
THC is (3R,4R)-(-)-trans-delta-1-tetrahydrocannabinol (in 
early papers it was referred to as Δ1-THC), which is ten-to-
hundred times more potent than the unnatural (3R,4R)-(+)-
Δ1-THC [409]. Δ9-THC in most assays acts as a partial 
agonist at the CB1 and CB2 receptors – i.e., it does not elicit 
the possible maximal effect [388,410], and in some assays 
proves to be more potent at the CB2R than at the CB1R (e.g., 
[411,412]). Importantly, Δ9-THC is more potent at the 
human than the rat CB1R (hence contrasting many other 
cannabimimetics), as concluded from a meta-analysis of 
pharmacological studies [411]. This increased potency 
contributes to the observation that a Δ9-THC dose as low as 
50 µg/kg is enough to elicit subjective responses in humans 
while up to 60-times higher dose is required to obtain 
psychopharmacological responses in the rat [411]. At high 
concentrations, Δ9-THC may paradoxically antagonize the 
CB1R [410]. One major in vivo metabolite of Δ9-THC, 11-
hydroxy-THC is suspected to be a fast-acting major 
psychoactive molecule, in part responsible for the central 
effects of cannabis when ingested orally, but has low plasma 
levels after smoking [188,189]. In vitro, however, 11-
hydroxy-THC proved to be less potent and efficacious than 
Δ9-THC to inhibit Ca2+ uptake in mouse brain synaptosomes 
[413]. 
The non-psychoactive CBN [414] is technically an 
oxidized form of Δ9-THC, and does not bind to either of the 
two receptors [412,415], although there are reports on CBN-
induced minor responses (10% of that of Δ9-THC) at the 
CB1R [267,410]. 
Another major cannabis constituent, Δ9-THCV [416] 
acts as a potent neutral CB1R antagonist and as a partial 
CB2R agonist both in vitro and in vivo [415,417]. Yet, Δ9-
THCV at high doses (≥3 mg/kg) produces in vivo Δ9-THC-
like activity, which is perhaps a consequence of in vivo 
metabolism into 11-hydroxy-THCV [415,417] – a metabolite 
awaiting further characterization. Interestingly, both Δ9-THC 
and Δ9-THCV acted rather like inverse agonists on VGCC 
Ca2+ currents in CB2R-expressing cells [376], suggesting that 
low-efficacy cannabinoid agonists can compete with high-
efficacy (full) agonists for the binding site, thereby reducing 
the overall response. 
(–)-Cannabidiol (CBD), the non-classical non-
psychoactive ingredient of cannabis binds poorly both to the 
CB1R and the CB2R, and exhibits no agonist activity or 
psychoactivity [267]. CBD is not a listed substance, and it is 
believed to have a plethora of beneficial therapeutic effects 
[267]. However, the pharmacological profile of CBD is 
largely unknown at human cannabinoid receptors despite the 
fact that clinical trials have been carried out with this 
molecule [411,418]. As an example, low micromolar CBD 
has been found to induce endothelium-dependent 
vasorelaxation in the human mesenteric arteries partly via 
CB1R activation [419]. Strikingly, in the presence of other 
agonists, CBD can also act as a highly potent antagonist at 
both receptors, and in some assays, CBD exhibited inverse 
agonism [415,420]. CBD content in cannabis also inversely 
correlates with the psychotogenic properties of Δ9-THC 
[175]. Intriguingly, CBD was almost two orders of 
magnitude less potent to displace [3H]CP55940 binding in 
CB1R-rich brain membranes and in hCB2R-transfected CHO 
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cell membranes than to prevent CP55940 from stimulating 
[35S]-GTPγS binding in the same preparations [420]. This 
strongly argues against the idea that CBD surmounts 
agonists at the orthosteric binding pocket; instead, CBD 
seems to modulate CB1/2R function through an allosteric 
binding site. Indeed, a new study claims that CBD is in fact a 
NAM [421]. The trans-isomer of the bicyclic sesquiterpene, 
β-caryophyllene is a CB2R-selective ligand of major 
therapeutic potential found in high concentrations in 
essential hemp oil [422,423]. 
Finally, CBC acts in vivo as a low-potency Δ9-THC-
mimetic [267,424,425], but its pharmacological profile is far 
from understood.  
3.2.3.4. Subtype-preferring Endocannabinoids and Synthetic 
Ligands 
Among the endocannabinoids, 2-arachidonoylglyceryl 
ether (noladin ether) [412,426], N-arachidonoyl dopamine 
(NADA) [427], and oleamide [428] are activators of the 
CB1R but not the CB2R in the nanomolar range, although 
they also have other cognate receptors (see later), thus they 
are not considered "CB1R-selective". 
Docosatetraenylethanolamide (DEA) and homo-γ-
linolenylethanolamide (HEA) are additional, ill-
characterized anandamide-like endocannabinoids produced 
in brain cells, being selective for the CB1R at least over the 
CB2R [429-431]. O-arachidonoylethanolamine 
(virodhamine) is a potent full agonist of the CB2R, but acts 
as a biased ligand (a low-potency partial agonist as well as 
antagonist) at the CB1R [412,432]. 
Additionally, numerous highly selective and potent 
synthetic CB1R and CB2R ligands are also available. For 
example, metabolically stable anandamide analogs, (R)-(+)-
methanandamide [433] and arachidonoyl-2'-
chloroethylamide (ACEA) [434] (Fig. 1) were among the 
first synthetic compounds with considerable selectivity 
toward the CB1R over the CB2R in the nanomolar range, but 
unfortunately, they may exhibit agonist activity at other 
receptors, too. For unknown reasons, there is a paucity of 
commercially available, sufficiently selective and efficacious 
CB1R-selective agonists. As for the CB1R-selective 
antagonists, SR141716A (rimonabant, Acomplia™) and its 
analogs, AM251 [435] and AM281 [436] are the best known 
inverse agonist examples, but SR141716A and AM251 were 
also reported to bind to the GPR18 and the GPR55 (see 
below). Another SR141716A analog, AM6545 is a non-
brain-penetrant silent CB1R antagonist with promising 
therapeutic profile [262], whereas O-2050 and NESS0327 
are brain-penetrant neutral antagonists of the CB1R 
[393,394]. 
As for the CB2R-selective ligands, there are a number 
of structurally different molecules commercially available. 
JWH133 (Fig. 1) is a potent CB2R-preferring Δ8-THC-
derivative [437], although it has considerable affinity in the 
high nanomolar range for the CB1R, too. HU308 is slightly 
less potent than JWH133 but is highly selective for the CB2R 
[438] over the CB1R, while the SR141716A analog 
diarylpyrazole GP1a is a hyperpotent CB2R agonist [439]. 
AM630 (iodopravadoline; [440]), SR144528 [441] and 
JTE907 [442] are the most common antagonists/inverse 
agonists of the CB2R. Interestingly, the so-called "inactive 
enantiomer" of WIN55212-2, i.e., WIN55212-3 is in fact a 
silent CB1R antagonist and a CB2R inverse agonist [443]. 
3.2.4. CB1R and CB2R Accessory Proteins 
The regulation and termination of CB1R signaling is 
controlled by accessory proteins such as GPCR kinases 
(GRKs), β-arrestins, GPCR-associated sorting protein 1 
(GASP1) and cannabinoid receptor interacting protein 
CRIP1a [444]. Agonist-induced GPCR desensitization rather 
than the constitutive internalization starts with the 
phosphorylation by GPCR kinases (GRKs), which is 
followed by β-arrestin binding and the consequent 
prevention of further G protein coupling, as well as GRK- 
and β-arrestin-mediated activation of preferred pathways 
[445,446]. β-arrestin2 (also termed as arrestin3 without β) 
has a major role in the agonist-induced desensitization and 
internalization of the CB1R [376,447,448], which contributes 
to the transient nature of the CB1R activation of downstream 
pathways [449], and probably is also involved in 
cannabinoid tolerance [450-452]. In β-arrestin2 knockout 
mice, the density of β-arrestin1 and CB1Rs remained 
unchanged, but a redistribution of CB1R pools was observed 
to favor the synapses over the somatodendritic 
compartments, and Δ9-THC became less potent in the 
absence of β-arrestin2 [453]. Interestingly, cannabimimetics 
promote desensitization at rates not necessarily proportional 
to their efficacy: noladin ether and WIN55212-2 desensitize 
the CB1R rapidly while Δ9-THC and anandamide do it more 
slowly (~5%/min) [454]. It is believed that β-arrestin1 has 
further roles as it can mediate short term activation of 
ERK1/2, MEK1/2, dual specificity mitogen-activated protein 
kinase kinase 1/2 (MAP2K1/2) and proto-oncogene tyrosine-
protein C-terminal kinase Src (c-Src) [455]. 
In contrast to β-arrestins, chlatrin heavy chain is 
required for both the constitutive and the agonist-induced 
internalization of the CB1R [448]. An additional protein, Src 
homology 3-domain growth factor receptor-bound 2-like 
(endophilin) interacting protein 1 (SGIP1) prevents the 
endocytosis of the activated CB1R and alters its signaling in 
a biased manner [456]. Internalized CB1Rs are not recycled, 
but instead, undergo lysosomal degradation [457]. Some 
suggest that an additional intracellular pool of CB1Rs 
apparently does not participate in the repopulation of the 
plasmalemma [457], and may participate in intracellular 
endocannabinoid signaling including the regulation of 
mitochondrial metabolism [458,459]. The trafficking of 
CB1Rs into the lysosomes involve GASP1-dependent 
sorting, thus viral reduction and genetic ablation of GASP1 
attenuates the downregulation of the CB1R and mitigates 
behavioral tolerance after chronic or long-term treatment 
with WIN55212-2 [460,461]. While this process is probably 
more typical for axons and transfected HeLa or Neuro-2 
cells, somatodendritic CB1Rs may be regulated differently in 
other neurons. Indeed, in cultured hippocampal GABAergic 
neurons, CB1Rs undergo constant endocytosis and recycling, 
in a fashion dependent on eps15, dynamin1, dynamin2, rab5 
and chlatrin [231]. Furthermore, this process can be halted 
by a CB1R inverse agonist, AM281 (analogous to 
SR141716A), leading to the abundance of CB1Rs in 
somatodendritic membranes [231]. This mechanism can 
explain some of the inverse agonism as it increases the 
number of cell-surface CB1Rs, but it is not clear if these 
receptors are readily available to spontaneously couple to 
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second messengers or they are kept in inactive state by the 
inverse agonist. Some new data may suggest that these 
receptors could be functional after all, because a low dose of 
AM281 (0.5 mg/kg) administered for 14 days caused 
conditioned place preference for rats [462]. Finally, the 
adaptor protein AP-3δ has been shown in hippocampal and 
other neurons to assist in the direct transport of CB1Rs into 
late endosomes/lysosomes, where the CB1R – somewhat 
surprisingly – is still active and couples to heterotrimeric G 
proteins [463]. 
CRIP1a (164 amino acids) and CRIP1b (128 amino 
acids) are splice variants of the cannabinoid receptor 
interacting protein gene in primates, while only CRIP1a has 
been detected in lower vertebrates and is highly expressed in 
CB1R-rich areas such as the brain [464]. Both isoforms 
interact with the intracellular C-terminus of the CB1R, and 
apparently the last 9 amino acids of the CB1R are essential 
for this coupling [464]. Only CRIP1a has a palmitoylation 
site that predicts membrane localization for this isoform. 
Indeed, CRIP1a rather than CRIP1b prevented the 
constitutive inhibition of Ca2+ channels in superior cervical 
ganglion neurons, while neither isoform affected 
significantly the binding constant (Kd) of the CB1R [464]. 
Accordingly, a recent study claims that CRIP1a 
overexpression can effectively inhibit both constitutive and 
agonist-induced CB1R activity as well as subchronic agonist 
treatment-induced downregulation but not desensitization of 
the CB1R in HEK293, N18TG2 and hippocampal neuronal 
cultures [465]. These findings were discordant with another 
study which showed that CRIP1a overexpression enhances 
CB1R-mediated G protein activation and the consequent 
inhibition of excitatory currents in the hippocampus [466]. 
The probable explanation to this discrepancy lies in a third 
study which demonstrated that CRIP1a stimulates CB1R 
coupling to some of the G proteins but inhibits it to others: In 
N18TG2 cells, the expression levels of CRIP1a were 
inversely proportional to the extent of CB1R-mediated Gi3 
and Go activation and ERK phosphorylation, and positively 
proportional to Gi1/2 activation [467]. While in this study the 
authors did not find CRIP1a overexpression to affect CB1R 
signaling, they observed that the cannabimimetic CP55940 
showed enhanced efficacy and potency in CRIP1a-deficient 
cells [467]. These studies altogether highlight gaps in our 
understanding of the exact roles of CRIP1a in CB1R 
signaling, which can be a consequence of the overexpression 
protocol which can trigger artificial (contrariwise) responses. 
This hypothesis is bolstered by a study where the authors 
first reproduced previous findings that the cannabimimetic 
WIN55212-2 rather than the CB1R inverse 
agonist/antagonist SR141716A mitigated excitotoxic cell 
death in cultured cortical neurons [468]. CRIP1a 
overexpression above the normal (basal) CRIP1a density did 
not affect glutamate toxicity per se, but strikingly, it reverted 
the role of the agonist and the antagonist, and thus 
SR141716A conferred protection against excitotoxicity, 
rather than WIN55212-2 [468]. The possible role of CRIP1a 
in excitotoxicity has been further supported by the finding 
that the expression of CRIP1a and the CB1R was lower in 
sclerotic hippocampal tissue obtained from epileptic patients 
[469], but whether these were active or passive events in the 
pathogenesis of neurodegeneration is not fully understood. 
The CB2R has been also found to interact with β-
arrestin [470,471]. Notably, the link between β-arrestin2 and 
internalization is not so linear than in the case of the CB1R. 
For instance, it was found in one of the above studies [376] 
that both WIN55212-2 and CP55940 induced β-arrestin2 
recruitment to the membranes of CB2R-transfected HEK293 
cells, but only CP55940 rather than WIN55212-2 or Δ9-THC 
triggered CB2R internalization (resulting in a perinuclear 
accumulation of the CB2R, contrasting the cytoplasmic 
CB1R redistribution), and even more strikingly, WIN55212-
2 and Δ9-THC prevented CP55940 from CB2R 
internalization, acting as antagonists. This is also consistent 
with Δ9-THC being a rather weak CB2R agonist that can 
likely act as an antagonist in the presence of another more 
efficacious agonist [280]. 
3.2.5. GPR18 
The recently "deorphanized" G protein-coupled 
receptor 18 (GPR18 and not GPCR18) was first reported in 
1997 as a protein highly expressed in spleen and testis [472], 
and is currently emerging as a possible candidate of the 
endocannabinoid receptor family [473]. This receptor has 
been identified with the elusive abnormal-cannabidiol (abn-
CBD) receptor of the past [474,475], although it is feasible 
that some of the reported observations with the atypical 
cannabinoid, abn-CBD were in fact mediated by the GPR55 
(see Section 3.2.6). Endogenous agonists for GPR18 are N-
arachidonoylglycine (NAGly) [473,476-479] and the 
nonclassical eicosanoid, resolvin 2D, which is a COX-2 
product involved in the resolution of acute inflammation 
[480]. Notably, NAGly has been proposed to be the 
endogenous agonist for additional GPCRs, namely the 
GPR82 and the GPR141, respectively [481]. 
Δ9-THC, as well as the atypical cannabinoids, abn-CBD 
and O-1602 are also potent full agonists at the GPR18, 
together with the endocannabinoid, anandamide and its 
metabolically resistant analog, ACPA [473,474,478,482-
485]. Notably, another study questioned whether the above 
ligands truly serve as agonists for GPR18 [486]. 
WIN552122, CP55940, JWH133 and JWH015 do not 
activate the GPR18 [478]. AM251, SR141716A and CBD 
are non-selective antagonists (as having affinity to other 
cannabinoid receptors, see above), while the atypical 
cannabinoid, O-1918 is apparently a selective GPR18 
antagonist [474,475,478,485,487]. 
GPR18 signalizes through pertussis toxin-sensitive G 
proteins, PI3K, p42/44 mitogen-activated protein kinase and 
Akt [487]. Among the tested ligands, only Δ9-THC was 
capable of inducing β-arrestin recruitment in CHO cells 
transfected with GPR18. 
3.2.6. GPR55 
The "deorphanized" G protein-coupled receptor 55 
(GPR55) is the fourth relevant metabotropic receptor that 
interacts with cannabis constituents as well as synthetic and 
endogenous cannabinoids. Its discovery was reported in 
1999 [488], and it was initially classified as an orphan 
GPCR, because its endogenous ligands – lysophospholipids 
– were discovered only a few years later. This 7 
transmembrane-domain receptor has 319 amino acids in 
humans and 327 in mice, and its gene is probably exclusive 
to mammals [489]. GPR55 exhibits low sequence homology 
to CB1Rs and CB2Rs (13-15%) [489,490]. GPR55 can 
couple to Gα13 [412,491], Gα12, or Gαq [492], resulting in the 
elevation of [Ca2+]i or in the activation of ERK, p38 MAPK, 
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PLC, Ras homolog gene family member A (RhoA), and 
Rho-associated protein kinase (ROCK) [490-495]. 
L-α-lysophosphatidylinositol (LPI), 2-arachidonoyl-sn-
glycero-3-phosphoinositol (2-AGPI) and lysophosphatidyl-
β-D-glucoside (LysoPtdGlc) have been identified as the most 
potent and efficacious endogenous activators of the GPR55 
[496-498]. True endocannabinoids including 2-AG, 
anandamide, noladin ether as well as additional 
"endocannabinoid-like" molecules, virodhamine, 
palmitoylethanolamide and oleoylethanolamide are also 
potent activators of the GPR55, although differences are 
reported throughout different experimental approaches 
[412,489,490,499-502]. In fact, the pharmacology of the 
GPR55 is the most complex and the least understood among 
the cannabinoid receptors, because the same ligands can 
behave as an agonist, antagonist or a neutral ligand in 
different assays or even in the same assay, depending on the 
presence or absence of an endogenous agonist 
[489,503,504]. It is believed that the GPR55 possesses an 
allosteric modulator site where certain exogenous ligands 
either have no effect on their own or seemingly activate the 
GPR55 assuming that it is unoccupied by endogenous 
ligands, but in the presence of endogenous GPR55 activator 
lipids, these exogenous ligands become antagonists 
[412,492-494,503-507]. Collating data from the above 
studies, we can draw a general pharmacological profile of 
the GPR55, keeping in mind that not all agonists would 
behave consistently in all the assays. (1) Phytocannabinoids 
Δ9-THC, Δ9-THCV and CBDA per se act as weak (partial) 
agonists at the GPR55, but they inhibit LPI-induced GPR55 
activation, together with CBD and CBDV [508] and CBGV. 
(2) Synthetic analogs and derivatives of phytocannabinoids, 
that is, the classical cannabimimetic HU210, the non-
classical cannabimimetic CP55940, and the atypical 
cannabinoids, abn-CBD and O-1602 exhibit (partial) 
agonism of varying potencies, while the CB2R agonist 
analogs, HU438 and HU914 antagonize LPI-induced 
ERK1/2 phosphorylation at the GPR55. (3) Among the 
CB2R-preferring agonists, the naphthoylindole-type JWH015 
can activate the GPR55 while the classical-type JWH133 
behaves as an inverse agonist (i.e., it inhibits both basal and 
LPI-induced GPR55 activity). (4) The hydrolysis-resistant 
anandamide analog R-methanandamide also activates the 
GPR55. (5) Finally, the CB1R-preferring inverse agonists, 
the 1,5-diarylpyrazole compounds AM251 and SR141716A 
in most cases act as low-potency agonists or allosteric 
activators, but again, they antagonize LPI. The term "low-
potency" stands for EC50 and IC50 values in the micromolar 
range. Cannabinoids with such low potency are of minor 
pharmacological importance, because in the low micromolar 
range, the number of their novel binding sites and off-target 
effects increase drastically [381,509], while their solubility 
in assay media and body fluids becomes an issue. 
Nevertheless, the considerably overlapping pharmacological 
profile of the four above cannabinoid receptors, i.e., CB1R, 
CB2R, GPR18 and GPR55 prompts caution when 
interpreting observations. The use of GPR55-selective 
antagonists such as CID16020046 [510] and ML193 [511] 
and the GPR18-selective antagonist, O-1918 (see Section 
3.2.5) certainly can facilitate the identification of the two 
novel deorphanized receptors in bioassays. 
Altogether, the inconvenient question whether the 
GPR18 and the GPR55 are bona fide members of the 
endocannabinoid system challenges the classical view of 
receptor pharmacology, and soon a reclassification of 
signaling systems based on domain-specific signalosomes 
will be inevitable. 
3.2.7. Transient Receptor Potential Channels 
The transient (light-induced) receptor potential (TRP) 
channel superfamily accommodates 27 polymodal sensor 
cation channels divided among 6 groups in humans [512]. 
Among these, 4 families have members with which 
cannabinoids and cannabis constituents interact 
[380,509,512]. As they are involved in nociception, 
analgesia and immune modulation, cannabis constituents are 
well-positioned to modulate pain sensation and inflammation 
through these channels. 
3.2.7.1. TRP Vanilloid Family 
The TRP vanilloid family (TRPV) has 6 members, 
among which the TRPV1R, the TRPV2R and the TRPV4R 
are closely related channels [512]. The TRPV1R is a 
principal noxious stimulus receptor of the body, as it is 
activated by heat, protons, phytotoxins such as capsaicin, 
piperine, curcumin and gingerol, and animal venoms [512-
514]. TRPV1R is also activated by many lipids [515] 
including endocannabinoids, anandamide [516], NADA 
[517] and 2-AG [518]. Albeit the lack of 2-AG agonism or 
the intracellular ligand binding site were widely accepted 
dogmas for quite a while, now it is clear that the binding site 
of the TRPV1R faces the extracellular side [519,520]. 
Furthermore, it appears that the TRPV1R is sufficient to 
serve as an endocannabinoid membrane transporter, that is, 
the pore of the TRPV1R permits the passage of anandamide 
through the cell membrane [521]. 
Among the cannabis constituents (in rank order of 
efficacy) CBGA, CBGV, Δ9-THCV, CBD, and CBG 
provoked sound Ca2+ entry in HEK293 cells transfected with 
the human TRPV1R with EC50 values below 5 µM, while Δ9-
THC, Δ9-THCA, CBN and CBC failed to elicit [Ca2+]i 
elevation at reasonable concentrations [190,191,522]. An 
obvious enigma is the apparent lack of CBD pungency, and 
the answer probably lies in differential responses by the 
TRPV1R. In fact, capsaicin evokes small inward currents at 
the human TPRV1R but with high potency in comparison 
with piperine from the black pepper, which produces large 
currents but at low potency [523]. In the rat eye-wipe assay, 
NADA and capsaicin provoked irritation while anandamide 
and ACEA failed to do so, even though they also activate 
TRPV1R current. It is probable that the cation current evoked 
by the non-pungent agonists is short-lived due to rapid 
desensitization; hence it probably does not trigger 
depolarization that could excite the sensory afferents. Indeed, 
CBD has been shown to desensitize the TRPV1R to the 
action of capsaicin [190]. Others even found a lack of 
agonist activity for CBD at the rat TRPV1R [524]. 
Furthermore, CBD has been claimed to be an inhibitor of the 
elusive anandamide or endocannabinoid membrane 
transporter (EMT) [190], and EMT activity can be attributed 
at least in part to TRPV1R-dependent mechanisms [521]. 
Synthetic cannabinoid ligands, such as HU210 and JWH015 
were also reported to act as low potency partial agonists at 
the TRPV1R. Altogether, it is easy to agree on the inclusion 
of the TRPV1R in the cannabinoid receptor family. 
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The TRPV1R has been consistently shown to 
participate in synaptic plasticity (notably, long-term 
depression or LTD) in the brain of adolescent and young 
adult laboratory rodents [299,525]. Surprisingly, 
SR141716A but not AM251 was shown to block TRPV1R in 
the low micromolar range [525], indicating that some forms 
of LTD, previously thought to be CB1R-dependent, might 
have been in fact TRPV1R-dependent [525]. Additionally, 
SR141716A was shown to enhance neurogenesis via the 
TRPV1R [526] (see also Section 3.3.7). Though the 
inactivation of the TRPV1R has anxiolytic therapeutic 
potential [527], the presynaptic neuromodulator role of the 
TRPV1R remains elusive in the adult brain of laboratory 
rodents [512,528]. Some studies prompt the hypothesis that 
TRPV1Rs are post-synaptic and probably intracellular. For 
instance, indirect activation of these putative post-synaptic 
intracellular TRPV1Rs by increasing intracellular 
anandamide levels impairs DAGLα-mediated mobilization 
of 2-AG both in the striatum [529] (Fig. 8) and in the 
hippocampus [530]. 
The TRPV2R is activated by temperatures above 53 ºC, 
and is also involved in pathological conditions and pain 
sensation [512]. One publication reported that several 
cannabinoids activate the TRPV2R with high efficacy albeit 
low micromolar potency [524]. In order of efficacy, TRPV2R 
is activated by CBD, Δ9-THC, CBN, nabilone, 11-hydroxy-
THC, CP55940, and to a lesser extent, by 2-AG, while 
anandamide had no effect [524]. A later work reported that 
additional cannabis constituents activated the rat TRPV2R 
with the following rank order of efficacy: CBGV ≈ Δ9-
THCV ≈ CBG > Δ9-THCA > Δ9-THC ≈ CBDV ≥ CBD ≈ 
CBN. The potency of these compounds ranged between 650 
nM (Δ9-THC) and 19 µM (CBN) [191]. 
3.2.7.2. Other TRPs from the Ankyrin, Canonical and 
Melastatine Families 
The TRPA1R is a sole member of its TRP ankyrin 
family [512]. TRPA1R is a nonspecific chemosensor 
activated by a wide variety of irritants including allyl 
isothiocyanate, the pungent substance of mustard, horse 
radish and wasabi as well as cold (<17ºC) [512,531,532]. 
The first studies detected that cannabinoids including 
WIN55212-2, CP55940, CBD and Δ9-THC activate the 
TRPA1R with efficacies comparable or exceeding that of 
allyl isothiocyanate [524,531]. Later studies established the 
following rank order of efficacies: Δ9-THCV (243% of the 
effect of 100 µM allyl isothiocyanate) > THCV acid 
(THCVA) > CBGA > CBGV > CBD > Δ9-THC ≈ CBC ≈ 
CBDA > CBN [191,533]. The most potent among them was 
CBC (EC50 < 100 nM), CBD (110 nM), Δ9-THC (230 nM) 
and most of the remaining cannabinoids also had potencies 
in the high nanomolar-low micromolar range [191,533]. 
The canonical TRP channel family (TRPC) can be 
regarded as the ionotropic counterpart of the above detailed 
phospholipid receptor GPRs, because they are activated by 
various lipids including DAG, phosphatidylinositols, or 
lysophospholipids, as well as light mechanical stimuli [512]. 
The gene of the TRPC1R was the first mammalian TRP gene 
to be discovered two decades ago, but the role of this Ca2+ 
channel still remains elusive [512]. It is widely expressed 
throughout the mammalian body, and probably forms 
heteromeric complexes with other TRP members [512]. 
Therefore, the physiopharmacology of the TRPC1R remains 
ill-defined, which is further complicated by the lack of overt 
phenotype in the TRPC1R -/- mice. Of course, cannabis has 
to poke its nose into the TRPC1R channel, too: it was 
reported that low micromolar Δ9-THC, CBN, HU210 but not 
CBD or CP55940 induce sustained Ca2+ rise in immune cells 
[534,535]. The concentration-response curve of Δ9-THC was 
inverse U-shaped. Unfortunately, it is not clear whether the 
underlying TRPC1R phenotype was a homodimer (as some 
believe that this would not be functional [512]) or a 
heterodimer with other TRP channels, and thus, which of the 
existing isoforms were responsible for the underlying effects. 
Interestingly, low micromolar SR141716A and SR144528 
both acted as antagonists at the TRPC1R even in splenocytes 
from CB1R -/- and CB2R -/- mice, indicating that these 
antagonists possess numerous additional targets besides the 
CB1R or the CB2R. 
The melastatin TRP family (TRPM) inherited its 
denomination by the melanoma suppressor TRP gene. 
TRPM8 is also a cold-sensitive channel activated by low 
temperature (<22ºC) and by "refreshing" agents such as 
eucalyptol, menthol and icilin [512,532]. Interestingly, 
TRPV1R activators act as antagonists at the TRPM8 channel: 
capsaicin, resiniferatoxin, NADA and anandamide all inhibit 
icilin- and menthol-evoked responses [533,536]. A 
subsequent study characterized the IC50 values for cannabis 
constituents (IC50, 60 nM – 4.8 µM), and in fact major and 
minor cannabinoids all abolished responses to icilin with the 
following rank of potencies: CBD > CBG > Δ9-THCA > Δ9-
THC > CBN > Δ9-THCV > CBDV > CBGA > THCVA > 
CBGV > CBDA [191]. 
3.2.8. Additional Cannabinoid Receptor Candidates 
The following receptors are considered to have minor 
or no significance in mediating the effects of cannabis 
constituents. There are two additional metabotropic receptors 
related with the endocannabinoid system, GPR35 [537,538] 
and GPR119 [380,539,540], which are activated by 
numerous endogenous lipids including anandamide, but to 
our knowledge, there is no evidence for their direct 
interaction with Cannabis constituents. The endogenous 
agonists of GPR35 (a receptor expressed in the brain) are 
kynurenic acid (KynA), together with 2-
oleoyllysophosphatidic acid and chemokine CXCL17 [490]. 
GPR119 is activated by oleoyllysophosphatidylcholines and 
the GPR55 agonist, oleoylethanolamide [538]. 
3.3. The Biomedical Significance of Cannabinoids 
This part of our review briefly outlines the distribution 
and the functions of cannabinoid receptors. In conjunction 
with this, we evaluate the therapeutic potential of cannabis 
constituents as well as the health consequences of cannabis 
abuse. Below, we lay emphasis on the (patho)physiology of 
the brain as this organ is the fundamental target of cannabis. 
3.3.1. The Cellular and Tissue Distribution of Cannabinoid 
Receptors 
The CB1R has high expression (mRNA levels) and high 
density (protein levels) in the brain, while at lower levels, it 
is also expressed in adrenal gland, heart, lung, prostate, 
uterus, ovary, testes, bone marrow, thymus and tonsils [338]. 
Although there is a paucity of large-scale studies with 
modern techniques on CB1R distribution in non-neuronal 
tissues, we can conclude from the literature that CB1Rs are 
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much more widely distributed – albeit at low density – 
among cells and tissues than thought before, and often co-
exist with other cannabinoid receptors (see Section 3.3.5.1). 
Even though it is tempting to speculate that the amplitude of 
CB1R-mediated effects are in close correlation with the local 
density of the CB1R protein, and therefore CB1Rs have little 
to do with peripheral tissues, this is far from the truth. The 
outcome of CB1R activation is more likely dependent on the 
efficacy of coupling with the signal amplification by the 
second messenger systems. An elegant example for this has 
been presented in hippocampal GABAergic neurons where 
CB1Rs inhibited axon potential-evoked Ca2+ transients in a 
fashion independent from their density at individual axon 
boutons [541]. 
In the brain, CB1R expression and protein densities are 
highest in the cerebellar molecular layer, substantia nigra 
pars reticulata (containing the CB1R-laden terminals of the 
striatonigral pathway), globus pallidus externa and interna, 
inner granule cell layer of the olfactory bulb, anterior 
olfactory nucleus, layers II–III, Va and VI of the cerebral 
cortex (in humans, the highest levels were found in the 
cingulate gyrus, frontal, secondary somatosensory and motor 
cortices), hippocampus, as well as in the dorsolateral 
striatum, while moderate levels of CB1R expression are 
found in the hypothalamus and ventral striatum/nucleus 
accumbens, and finally, low CB1R levels can be found in the 
brainstem with a lack of CB1Rs in the respiratory control 
centers [286,335,396,410,542-550]. These explain why 
cannabis has mild effects on cardiovascular and respiratory 
functions [551]. Fig. 9 illustrates the distribution of CB1R 
immunoreactivity in a mediansagittal slice of the adult rat 
brain and in coronal slices of the adult mouse brain. 
The CB2R was originally identified as a protein with no 
expression in the brain and high density in the immune cells 
and tissues [276]. As discussed later, an emerging body of 
evidence supports now physiological and pathological roles 
for neuronal CB2Rs in the brain. For instance, a recent paper 
clearly argues for that cerebral CB2R proteins are mostly 
neuronal in the healthy brain, while inducible CB2Rs become 
predominant in glia or microglia under disease conditions 
[555]. In line with this evidence, an ultrasensitive and 
specific in situ hybridization method called the RNAscope 
revealed the CB2R mRNA predominantly in excitatory and 
inhibitory neurons throughout the hippocampus with rare 
expression in microglia [556]. Although the vast majority of 
presynaptic cannabinoid receptors in the brain can be 
identified with the CB1R, there is also pharmacological 
evidence for presynaptic inhibitory CB2Rs in GABAergic 
terminals of the hippocampus [557] and in its relative 
vicinity, in the medial entorhinal area [558]. There are also 
intracellular CB2Rs in layer II/III pyramidal cells of the 
medial prefrontal cortex where their activation results in 
IP3R-dependent opening of Ca2+-activated Cl− channels, and 
a consequent inhibition of neuronal firing [559,560]. CB2Rs 
are also expressed in hippocampal principal neurons, where 
they modulate the sodium/bicarbonate co-transporter, 
thereby causing a hyperpolarization of the neuron. This 
robustly alters the input/output function of CA3 pyramidal 
cells, and modulates γ oscillations in vivo [561]. Apparently, 
functional CB2Rs are also present in hippocampal and 
cortical astrocytes, and CB2R activation both in these 
neurons and astrocytes increases glucose uptake, which may 
be a self-regulatory process to provide energy supply to the 
circuitry under load [562]. Other instances of neuronal 
CB2Rs will be discussed later. 
GPR18 is present in cells and tissues related with the 
immune system including the spleen, thymus, small 
intestine, leukocytes, lymph nodes, as well as in testis and in 
gametes. The brain, heart, lung, liver, kidney, pancreas, 
colon, skeletal muscle and ovary are apparently devoid of 
significant GPR18 expression [483,563]. 
The GPR55 is expressed in the following tissues of 
laboratory rodents and humans: white adipose tissue, certain 
regions of the central nervous system including the frontal 
cortex, striatum and spinal cord, adrenal tissue; small 
intestine, osteoblasts and osteoclasts, vasculature and 
immune cells [488,490,498,504,564-569]. The GPR55 is 
now in the spotlight of research because it is involved in 
some specific health conditions including cancer cell 
proliferation, osteoporosis, obesity, inflammation and 
neuropathic pain, and neuromodulation – coinciding with its 
general expression patterns [490,498,504,538,567-570]. 
Functional presynaptic GPR55 has been also shown in the 
CA3-CA1 synapses where it transiently potentiates evoked 
glutamate release from Schäffer collaterals. 
For curiosity, we investigated whether [3H]SR141716A 
(tritiated rimonabant) binding was subject to displacement 
by GPR18 and GPR55 ligands in the rat, wild-type (WT) and 
CB1R -/- mice. AM251 (1 µM) readily displaced 40% of 
total [3H]SR141716A (1 nM) binding from total brain 
membranes of rats and WT mice, which was similar in 
amplitude to the consequence of the genetic deletion of the 
CB1R (Fig. 10C3). The silent CB1R antagonist, O-2050 (1 
µM), the synthetic cannabimimetic, O-2545 (1 µM) and the 
CB1R/TRPV1R hybrid agonist, NADA (1 µM) did not fully 
displace [3H]SR141716A from the rat membranes (Fig. 
10C3). Surpisingly, the CB1R inverse agonist, LY320135 
did not displace [3H]SR141716A binding at all, suggesting 
that it is rather a NAM than an orthostheric blocker on the rat 
CB1R, since LY320135 already acted as CB1R antagonist in 
the rat brain in two of our studies [396,571]. Similarly to 
AM251, O-2050 fully displaced [3H]SR141716A binding 
from the CB1Rs in the mouse brain membranes, and to a 
smaller extent, O-2545 and WIN55212-2 together with 
LY320135 all displaced CB1R binding in the WT mice. 
None of the above ligands affected significantly the non-
CB1R dependent residual [3H]SR141716A binding, because 
they did not affect [3H]SR141716A binding in the CB1R -/- 
mice [572] (Fig. 10C3). N-oleoyldopamine (OLDA) is 
another endogenous TRPV1R agonist, analogous to NADA 
but it does not bind to the CB1R [512]. Since we mentioned 
above that SR141716A binds to the TRPV1R [525,526], we 
now tested if OLDA displaced [3H]SR141716A binding in 
rat brain membranes, but unlike NADA, OLDA did not 
affect [3H]SR141716A binding. Finally, the GPR18/GPR55 
agonist, O-1602 (10 µM) also did not displace 
[3H]SR141716A at all in none of these animals, suggesting 
that either [3H]SR141716A has much lower affinity to 
TRPV1R, GPR18 and GPR55 than to the CB1R and hence at 
1 nM, [3H]SR141716A only binds to the CB1R, or that the 
three additional targets have negligible density compared to 
the CB1R or both (Fig. 10C3). To our knowledge, this is the 
first such large-scale analysis of [3H]SR141716A binding in 
the rodent brain. 
3.3.2. The Role of CB1Rs in Neurophysiology 
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Δ9-THC exerts its rich physiologic, psychotropic and 
psychotogenic actions via the modulation of fast synaptic 
transmission in the brain, acting at CB1Rs which can be 
present both pre- and post-synaptically in the synapse. Fast 
synaptic transmission encompasses signaling with glutamate 
and GABA which activate their fast ionotropic receptors. 
Later we will discuss several other neuron types that also 
express CB1Rs, and thus contribute to the psychoactivity of 
marijuana. As a short note, here we mention that astrocytes 
are also equipped with CB1Rs. CB1Rs in astrocytes mediate 
a plethora of surprising functions, including the regulation of 
glucose metabolism [458], the impairment of working 
memory [574], heterosynaptic modulation of synaptic 
transmission in the hippocampus [575], or the modulation of 
leptin signaling in the brain [576]. 
3.3.2.1. Presynaptic Plasticity 
Without entering into much detail, at least the half of 
GABAergic and glutamatergic cells in the brain is endowed 
with CB1Rs, which are predominantly localized to axonal 
terminals, hence those receptors are presynaptic 
[286,390,547,549,552-554,577-580] (Figs. 6 and 8). 
Presynaptic CB1Rs have a major role in various forms of 
synaptic plasticity in the brain, as reviewed extensively 
elsewhere [286,299,581,582]. We here briefly overview a 
few of these mechanisms. One major function of presynaptic 
CB1Rs in glutamatergic nerve terminals is to relay the 
"message received" confirmation after a successful synaptic 
event. Namely, glutamate depolarizes the post-synaptic 
dendrites to cause Ca2+-entry and may also activate 
metabotropic glutamate receptors (mGluR1/5), both of which 
alone or convergently can stimulate DAGLα and the 
consequent release of 2-AG (Fig. 6). 2-AG then traverses 
back in the synaptic cleft, and activates presynaptic CB1Rs, 
still well within a second, counting from the beginning of 
glutamate release [317,552,583,584]. This short-term CB1R 
activation will induce the translocation of the βγ subunit of 
the respective G protein in the membrane to inhibit voltage-
gated Ca2+ channels (VGCCs) and to potentiate GIRKs; both 
leading to the hypopolarization of the nerve terminal and the 
transient impediment of further glutamate release [585,586] 
(Fig. 6). It is possible that the CB1R has to form heteromeric 
complexes with GIRKs [368] and N-type VGCCs [541] to 
effectively modulate their activity. This mechanism 
guarantees an optimal strength of synaptic communication: it 
allows the stimulation of the post-synaptic neuron 
sufficiently to trigger depolarization, but prevents 
overstimulation by excitotoxic amounts of glutamate. The 
activation of CB1Rs in GABAergic nerve terminals requires 
other mechanisms including heterosynaptic activity, 
metabotropic glutamate or muscarinic receptor activation, or 
probably lateral endocannabinoid diffusion, because GABA 
does not produce post-synaptic responses that could mobilize 
endocannabinoids [286,552,587-589] (Fig. 8). 
These trans-synaptic feed-back mechanisms are termed 
as "retrograde endocannabinoid signaling" [590-592]. 
Depolarization can trigger trans-synaptic endocannabinoid 
signaling via post-synaptic Ca2+-entry, which can affect both 
GABAergic and glutamatergic nerve terminals, hence these 
phenomena are called depolarization-induced suppression of 
inhibition or excitation (DSI/DSE) (Figs. 6 and 8). If trans-
synaptic endocannabinoid mobilization is activated by 
metabotropic receptor activation, the process is denoted as 
metabotropic stimulation-induced suppression of 
inhibition/excitation (MSI/MSE) (Figs. 6 and 8). A special 
case is the combination of the two: Ca2+-assisted ER (Ca2+-
ER/RER) when PLCβ serves as a coincidence detector to 
collate subtreshold Ca2+ entry and metabotropic receptor 
activation, none of which would be sufficient alone, to 
readily trigger 2-AG release [298,593,594]. 
In contrast to the short forms of CB1R-dependent 
plasticity that normalize within seconds, lasting activation of 
the CB1R on the minute scale (either via long trains of 
depolarization or external application of agonists) causes 
long-term depression (CB1R-LTD) of inhibitory and 
excitatory transmission. Importantly, CB1R-LTD requires 
additional presynaptic stimuli to take place, including 
intracellular Ca2+ concentration rise, or receptor stimulation 
[299,582,586]. Only the induction but not the maintenance 
of the CB1R-LTD requires the CB1R, and once LTD is 
induced, it involves the following steps: the Gαi subunit 
detaches from the CB1R, and inhibits adenylyl cyclase, 
leading to the decrease in protein kinase A (PKA) activity. In 
the absence of CB1R activation, PKA constantly 
phosphorylates Rab3-interacting molecule-1α and -2α 
(RIM1/2α), thus maintaining the integrity of the synaptic 
scaffold. An additional stimulus besides CB1R activation 
induces [Ca2+]i rise that activates calcineurin, which in turn 
dephosphorylates RIM1/2α in the absence of PKA activity, 
and consequently destabilizes the release machinery for long 
minutes or hours [299,582,588,595,596] (Fig. 6). If we take 
marijuana ingestion as an example, it will also cause lasting 
stimulation of the CB1Rs in the brain. However, it is not 
entirely clear to us whether lasting presence of Δ9-THC 
around its receptors is enough to cause LTD in the brain, or 
the CB1Rs would rather trigger βγ subunit-mediated short-
term plasticity. It is sure though that cannabis decreases 
transmitter release probability at central synapses; just the 
exact mechanisms have not yet been fully detailed. Of 
course, not only 2-AG but other endocannabinoids, e.g., 
anandamide and NADA are also fully capable of inhibiting 
depolarization-induced Ca2+ entry in the presynaptic 
terminals, which we demonstrate for this review in striatal 
nerve terminals (Fig. 10B1-B5). 
3.3.2.2. Spike-Timing-Dependent Plasticity 
Spike-Timing-Dependent Plasticity (STDP) is a major 
synaptic learning rule that integrates the recent pre- and post-
synaptic activities on the millisecond scale and adjusts 
synaptic strength accordingly [597]. STDP is probably a 
basic mechanism that tailors brain physiology. New exciting 
physiopharmacological studies combined with mathematical 
modeling unveiled the crucial role of the CB1R at 
corticostrial STDP [598,599]. First, the authors showed that 
the number and the order of presynaptic and post-synaptic 
stimulation pairs (within 30 msec interval) can profoundly 
affect the outcome of synaptic plasticity. 75-100 post-pre 
pairings induced NMDAR-dependent long-term potentiation 
(NMDAR-LTP), which was mimicked with 2-AG puffs 
[598]. This was later shown to be Ca2+/calmodulin-
dependent protein kinase II (CaMKII)-dependent (the 
amount of activated CaMKII progressively accumulates with 
the number of pairings) [599]. 
Surprisingly, a low number, i.e., 5-10 post-pre pairings 
also induced LTP at 1 Hz, which was dependent on mGlur5, 
muscarinic M1 receptor (M1Rs), D2R, TRPV1R, Gq/11, PLCβ, 
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DAGLα, 2-AG release and CB1R activation (CB1R-LTP). It 
can be induced with few pairings in both striatopallidal and 
striatonigral medium spiny neurons (MSNs). GABAA 
receptors set the polarity: picrotoxin reverses the post-pre 
into pre-post requirements. At higher frequencies, symmetric 
Hebbian plasticity was observed, because post-pre pairing 
also caused LTP with mixed CB1R-NMDAR-dependent 
phenotype [598]. 
Finally, the authors found that 50-100 pre-post pairings 
induced CB1R-dependent LTD, but below 50 pre-post pairs, 
no LTD was observed. To reconcile the complex results, the 
authors used mathematical models which closely described 
the phenomena: Prolonged release of moderate to high levels 
of 2-AG leads to CB1R-LTD via calcineurin inhibition, while 
brief releases of high 2-AG concentration yield LTP via 
CB1Rs coupling to PKA activation [599]. Therefore, 
intermediate levels of CB1R activation trigger CB1R-LTD 
through a combination of PKA inhibition and calcineurin 
activity, whereas high levels of CB1R activation lead to 
CB1R-LTP through the reverse combination: PKA activation 
combined with calcineurin inhibition. For the rest of the non-
CB1R-dependent conditions see [599]. 
3.3.2.3. Post-Synaptic Plasticity 
There are CB1Rs also in somatodendritic (i.e., post-
synaptic) compartments with the ability of controlling 
synaptic plasticity, as reported in cortical pyramidal cells 
[600] and GABAergic interneurons [601]. The activation of 
these post-synaptic CB1Rs causes slow self-inhibition, which 
is another form of synaptic plasticity probably relevant for 
the understanding of the effects of cannabis. We also found 
CB1Rs post-synaptically in the dorsal striatum [390] as well 
as in the rodent and human cerebral cortex and hippocampus 
(Köfalvi, unpublished data). In the hippocampus, a new 
publication showed that CB1Rs in the dendrites of pyramidal 
cells close to the stratum radiatum in the dorsal hippocampus 
of mice control hyperpolarisation-activated, cyclic 
nucleotide-gated (HCN) channels [602]. HCN channels are 
cation channels that are activated by hyperpolarisation at 
negative voltages around -50 mV [603]. The cyclic 
nucleotides cAMP and cyclic guanosine monophosphate 
(cGMP) directly enhance channel activity, underlying 
pacemaker currents found in many excitable cells including 
neurons [603]. HCN channels modulate dendritic integration 
of excitatory inputs, learning and memory [604,605]. Maroso 
and colleagues [602] found that the activation of local 
dendritic CB1Rs substantially increased the depolarizing sag 
response, a measure of HCN activity under somatic whole-
cell current clamp mode. The authors elegantly unvelied the 
steps leading to HCN current modulation, which started with 
2-AG activation of the CB1R, leading to the stimulation of 
mitogen-activated protein kinases (MAPKs) of the JNK 
family, which in turn can boost cGMP levels through 
increased activation of nitric oxide-mediated activation of 
guanylyl cyclase. As mentioned above, the increase in cGMP 
levels consequently triggers a depolarizing shift in the 
activation curve of the HCN1 channel. To our knowledge, 
this study is the first presenting clear evidence of post-
synaptically located functional CB1Rs in the hippocampus. 
Furthermore, the authors revealed that the activation of this 
novel CB1R-HCN1 axis can block the induction of long-term 
potentiation (LTP), evoked by theta-burst stimulation of 
either the Schaffer-collaterals or the temporoammonic 
pathway. Consequently, CB1R activation via HCN1 channel 
modulation can also impair spatial memory consolidation 
[602]. 
3.3.3. The Therapeutic Potential of Cannabinoids 
The therapeutic potential of cannabis and cannabinoids 
has been recently assessed by a meta-analysis of randomized 
clinical trials on the following health conditions: nausea and 
vomiting due to chemotherapy, appetite stimulation in 
HIV/AIDS, chronic pain, spasticity due to multiple sclerosis 
or paraplegia, depression, anxiety disorder, sleep disorder, 
psychosis, intraocular pressure in glaucoma, or Tourette 
syndrome [606]. The authors also reviewed case series and 
other studies based on eligibility. The evaluated 
cannabinoids were synthetic forms of Δ9-THC or CBD 
alone, Δ9-THC combined with CBD (Nabiximols, 
Sativex®), or the two synthetic Δ9-THC-analogs, 
levonantradol and nabilone per se. The authors [606] 
concluded that there was moderate-quality evidence to 
support the use in chronic neuropathic or cancer pain 
(smoked Δ9-THC and nabiximols) and spasticity due to 
multiple sclerosis (nabiximols, nabilone, Δ9-THC/CBD 
capsules and dronabinol). For the rest of the conditions, they 
found limited statistical support for therapeutic potential; 
however, phytocannabinoids were associated with an 
increased risk of adverse effects [606]. The negative overall 
result of the metaanalysis is probably due to inadequate 
design of the trials rather than a lack of therapeutic potential 
for phytocannabinoids [607]. Indeed, there is an increasing 
need to support research on cannabis and phytocannabinoids 
because the legalization of cannabis and medical marijuana 
worldwide meets controversial reception by the societies, 
researchers and health care professionals [607]. For instance, 
acclaimed Canadian researchers point out the discrepant 
policy of Canada which supports cannabis use for medical 
purposes but has little interest in financing cannabis research 
[608]. They emphasize that the state of Colorado, US, 
harnesses private support from the medical marijuana 
industry to support cannabis research. This is in fact 
homologous to those private funds from the tobacco and 
coffee industries that support research on nicotine and 
caffeine. 
Phytocannabinoids of the cannabis plant have been 
proven therapeutic potential in a number of human disorders, 
and these molecules also serve as useful templates for 
organic chemists to design novel medicines [21,609]. Below 
we review the physiopharmacology of the endocannabinoid 
system and the therapeutic potential of cannabis in selected 
health conditions. Unfortunately, due to space constraints, 
we can only refer to other excellent reviews and original 
works for additional (patho)physiological cases, including 
but not limited to analgesia, inflammation and pain [610-
612], immunomodulation and beyond [613-615]; 
neuroinflammation and neurodegeneration [23,616-618], 
stroke and subacute brain trauma [619-621], multiple 
sclerosis and spasticity [622-624], normal and pathological 
brain aging [618,625], suicide [626,627], liver diseases and 
hepatic encephalopathy [628-630], food intake and eating 
disorders [631-634], systemic energy balance and metabolic 
disorders [260-262,490,635-637], mitochondrial function 
[458,638-641], cancer and cancer care [642-646]; 
osteoarthritis [647,648]; bone remodelling, bone metabolism 
and osteoporosis [490,566,649-652], asthma, bronchospasm, 
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respiratory tract changes [249,653], glaucoma [654,655], 
bladder dysfunction [656], preimplantation embryo 
development and miscarriage [657,658]. 
3.3.3.1. Cannabidiol – a New Adjunctive Therapy for 
Epileptic Seizures? 
The therapeutic role of cannabinoids in epilepsy and 
excitotoxicity deserves an additional paragraph [22,659-
664]. As a result of the three-decade knowledge that CBD 
lowers seizures for epilepsy, clinical trials with CBD are 
underway with the objective of marketing this useful 
molecule as an antiepileptic medicine [21]. Similarly, a 
recent pediatric clinical trial with medical cannabis oil of 
high (20:1) CBD:Δ9-THC ratio significantly reduced the 
severity and incidence of intractable epilepsy in the majority 
of the 74 children and adolescents [23]. GW Pharmaceuticals 
has been conducting four Phase III pivotal clinical trials in 
the US with Epidiolex® (a liquid formulation of pure plant-
derived CBD), as an adjunctive therapy for the treatment of 
seizures associated with rare and catastrophic forms of 
childhood-onset epilepsy, namely Dravet syndrome, Lennox-
Gastaut syndrome and tuberous sclerosis complex. On 
March 14, 2016, GWPharma announced positive results 
from the first of these pivotal trials in Dravet syndrome. This 
trial enrolled 61 Epidiolex®- and 59 placebo-treated children 
(mean age: 10 years), who have been already on average on 
their 5th type of antiepileptic medication and still had 13 
convulsive seizures per month (median baseline frequency). 
Epidiolex® (20 mg/kg/day) caused a significant 39% median 
reduction (P<0.01) in monthly convulsive seizures, which 
was 3-times greater than the placebo effect [665]. 
3.3.4. Modulation of Neuromodulation 
Cannabinoids not only affect the activity of the 
principal (glutamatergic) cells and the GABAergic inhibitory 
neurons, but are also capable of modulating the release of 
other neuromodulators. This interaction is bidirectional, 
because endocannabinoid release can be triggered by the 
stimulation of neuromodulator receptors (Figs. 6 and 8). 
Finally, cannabinoid receptors can form heterodimers with 
receptors of other neuromodulator systems (Fig. 6). Such 
complex interaction with other neuromodulators at different 
levels provides the basis for the fine-tuning of synaptic 
transmission and synaptic plasticity, and lie behind learning 
and memory, emotions, stress coping, mood, motivation, 
reward, and cognition among others [666,667]. The delicate 
spatiotemporal regulation of this system allows an 
exceptional flexibility in the control of brain functions. 
Chronic intake of exogenous cannabinoids in the form of 
either agonists such as Δ9-THC or inverse agonists such as 
SR141716A (rimonabant, Acomplia™) takes away this 
flexibility. Rigid neuromodulation cannot correctly regulate 
neural plasticity, and the patient may drift into 
neuropsychiatric conditions. These include the typical 
chronic mental consequences of regular cannabis intake 
[668-670], tolerance such as hyperemesis [671] and cannabis 
withdrawal symptoms [672], as well as Acomplia™-induced 
depression and suicide [263,673]. 
3.3.4.1. The Interaction of Cannabis with Dopamine in the 
Reward Areas 
Drug-induced increases in midbrain dopaminergic 
activity or striatal/accumbal dopamine levels or both predict 
an abuse potential for the substance [674-676]. 
Cannabimimetics including Δ9-THC increase midbrain 
dopaminergic activity or extracellular dopamine levels in the 
striatum or both of laboratory animals [677-686]. Inhaled 
cannabis also increases the displacement of the D2/D3 
receptor tracer [11C]raclopride in the ventral striatum and the 
precommissural dorsal putamen of human individuals [687], 
i.e., in the reward areas associated with the subjective "high" 
and the abuse liability of cannabis. The underlying 
mechanism for cannabinoid-stimulated dopamine increase is 
thought to be indirect: midbrain dopaminergic cell clusters 
are under tonic inhibition by the dense GABAergic 
innervations arising from the tail of the ventral tegmental 
area (VTA)/rostromedial tegmental nucleus and from other 
areas. The activation of presynaptic CB1Rs disinhibits these 
GABAergic synapses, thus resulting in the increase of the 
firing activity of the dopaminergic target cells [688-690]. 
In contrast, there is a high probability that CB1Rs do 
not exert a major role (if any) in the presynaptic modulation 
of dopamine release in the basal ganglia, albeit this question 
is not satisfactorily settled. Some found a virtual absence of 
CB1R mRNA [691] and CB1R protein [552] in the 
dopaminergic nerve terminals of the striatum. However, 
other studies did find sparsely distributed CB1R mRNA in 
dopaminergic cells [335] and CB1R protein in dopamine-
transporter-positive nerve terminals at low levels [390]. We 
speculate that CB1R mRNA is likely present in many 
mammalian cells which have mitochondria 
[458,459,639,640], because the cell nucleus provides the 
mRNA for the trafficking of the CB1R to the outer leaflet of 
the mitochondrion. Therefore, the presence of CB1R mRNA 
and protein is insufficient evidence for a direct 
neuromodulator role of the CB1R in a given cell. Moreover, 
albeit cannabimimetics fail to directly modulate single pulse 
stimulation-evoked release of dopamine in striatal and 
accumbal slices [692-694], they can do so on the release of 
dopamine evoked by a train of pulses in striatal slices [695], 
possibly by disinhibiting D2 autoreceptor-mediated 
presynaptic inhibition of dopamine release [694], or by 
modulating local GABAergic signaling in the striatum [693] 
and the nucleus accumbens [696]. Stunningly, some of the 
above studies reported that cannabimimetics inhibited the in 
vitro release of dopamine [693-695], contrasting other in 
vitro studies that found no effect [390] or even, detected 
stimulation [696]. 
In fact, the vital roles of cannabinoids in dopaminergic 
modulation, and the decisive role of dopamine in 
reinforcement learning and motivation for incentive stimuli 
underlines the central role of the endocannabinoid system in 
reward and addiction [697-699] (see also Section 3.3.5.5). 
This statement is strongly corroborated by the following 
observations: CB1R activation is a prerequisite for the 
excitation of mesoaccumbal dopaminergic pathway by 
nicotine, ethanol and cocaine [685]; mice mutant for major 
genes of the endocannabinoid system exhibit impaired 
addictive behavior [700,701]; cannabimimetics reinstate 
extinguished drug-seeking behavior after a prolonged 
withdrawal [702-704]; and thus CB1R antagonists show great 
promise in controlling addiction [705-707]. However, the 
feasibility of addiction therapies based on CB1R blockers is 
tapered by the significant side effects caused by inverse 
agonism [263,673]. The workaround solution could be the 
use of silent CB1R antagonists [232,395], but the allosteric 
modulation of the CB1R also holds promise [406,708]. 
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Recently, CB2R ligands have attracted increased interest for 
the treatment of drug dependence [344,345,709]. Indeed, 
CB2Rs are present in both the nucleus accumbens [710] and 
midbrain dopaminergic cells, and JWH133 efficiently 
decreased cocaine self-administration in rats and mice 
[344,345]. Last but not least, there is one question left to be 
answered: Is cannabis is a gateway drug, that is, can 
cannabis use increase the probability of transition to 
"heavier" drugs? Even though many healthcare professionals 
and researchers would respond with yes to this relevant 
question, to give a statistically sound answer is almost 
impossible [711-713]. A recent review proposes a dual 
hypothesis for the likely association of earlier experience 
with marijuana with following later use of heavier drugs: (1) 
based on animal models, it is possible that early marijuana 
use causes dopaminergic dysfunction in the reward area 
which increases the likeliness of moving towards heavy 
drugs, or (2) increased individual susceptibility to addiction 
first manifests in the abuse of the easily accessible 
marijuana, and later of the harder substances [177]. In fact, 
decreased striatal dopamine release has been found in 
cannabis dependent patients as compared with controls 
[714]. 
Below we will discuss an additional level of interaction 
between the two neuromodulator systems, namely that D2R 
activation increases endocannabinoid tone in the brain 
[715,716]. Yet another unexpected form of cannabinoid-
dopamine interaction is worth mentioning: in the low 
micromolar range, cannabinoid receptor agonists and 
antagonists including CBD can inhibit the dopamine 
transporter (DAT) of the rat and the mouse, independently 
from cannabinoid receptors [717-719]. This cross-sensitivity 
between DAT and cannabinoids is bidirectional, because 
many DAT inhibitors including cocaine is a PAM at the 
CB1R [407]. This means that cocaine, besides directly 
increasing accumbal dopamine levels, also stimulates CB1R 
signaling, reinforcing its actual addictive nature (see also 
Section 3.2.3.1 and [406]). 
3.3.4.2. Cannabinoid Interaction with Acetylcholine 
Cholinergic signaling has robust roles in cognition, 
metabolism, immunity, and is implicated in the etiology of 
neuropsychiatric disorders such as Alzheimer's disease and 
addiction [720]. Data suggest diverse cholinergic responses 
to cannabinoids varying among brain regions, species and 
doses. In vitro, WIN55212-2 strongly and potently inhibited 
the evoked release of acetylcholine in the hippocampus and 
the neocortex [721-724] – but not the striatum or the nucleus 
accumbens of rats and mice [695,721,723]. For the sake of 
this review, we now also tested WIN55212-2 on the 
electrically evoked release of acetylcholine from superfused 
striatal slices of the rat, and we can confirm the lack of 
cannabinoid effect on striatal acetylcholine release (Fig. 
10A1-A2). In human neocortical slices, WIN55212-2 
produced a biphasic concentration-response curve on the 
electrically evoked release of acetylcholine, and under some 
stimulation paradigms, SR141716A stimulated thereof, 
indicating the existence of endogenous control by 
endocannabinoids on acetylcholine release [724]. 
In vivo, WIN55212-2, CP55940 and Δ9-THC all 
reduced acetylcholine levels in microdialysates from the 
hippocampus and the medial prefrontal cortex of freely 
moving rats, while SR141716A increased acetylcholine 
efflux [725,726]. Systemically administered WIN55212-2 at 
a low dose (0.5 mg/kg) stimulated hippocampal 
acetylcholine efflux via the disinhibition of the septum – the 
origin of the majority of hippocampal cholinergic nerve 
terminals, whereas at 5 mg/kg dose, it inhibited acetylcholine 
release via intrahippocampal CB1Rs [727]. Soon a follow-up 
study demonstrated that both systemic and local 
intrahippocampal infusions of the CB1R-preferring 
antagonists, SR141716A and AM251 readily and dose-
dependently increased hippocampal acetylcholine release 
[580]. This study also identified dopamine-mediated and 
direct actions of CB1Rs in hippocampal acetylcholine 
release, and reported high percentages of CB1R-positive 
cholinergic and dopaminergic nerve terminals in the rat 
hippocampus. This is in agreement with a previous 
pioneering paper reporting that one third of septal 
cholinergic neurons that project to the hippocampus are 
positive for both CB1 and GABAA receptors [728]. 
Endocannabinoid signaling also has crucial 
neurodevelopmental role in the fetal pathfinder cholinergic 
afferents [729]. Outside the hippocampus, however, the 
presence of CB1R immunoreactivity in cholinergic cell 
bodies and nerve terminals remain controversial in the adult 
brain [730,731], and for instance the large aspiny cholinergic 
or somatostatin-positive striatal interneurons are devoid of 
the receptor [732], in line with the findings of lack of CB1R 
effects on striatal acetylcholine release. These findings 
implicate predominantly polysynaptic rather than 
presynaptic roles for CB1Rs in controlling cortical 
acetylcholine release.  
Though intrastriatal CB1Rs do not appear to modulate 
striatal acetylcholine levels, an interaction does happen in an 
inverse fashion: the M1R was shown to elicit 2-AG release in 
the dendrites of MSNs, which caused retrograde activation 
of presynaptic CB1R in GABAergic synapses, thereby 
heterosynaptically disinhibiting MSN activity [733]. In fact, 
the basal ganglia are not the only place where this occurs: it 
seems to be the rule rather than the exception that 
acetylcholine, by activating M1 or M3 muscarinic receptors, 
mobilizes 2-AG, by involving PLCβ and DAGLα, and 
consequently inhibits GABA release in the hippocampus and 
the cerebral cortex [734]. This process is a typical example 
for MSI (see also Section 3.3.2.1), and it is likely that many 
effects of muscarinic drugs could be blocked by a CB1R 
antagonist. 
The first footnote to the above studies is that AM251 
and SR141716A could have elicited their stimulatory effects 
on acetylcholine and monoamines via GPR18 inhibition or 
GPR55 activation, too (see Sections 3.2.5-6). Nevertheless, 
WIN55212-2 causes an opposite effect in the above assays 
without being a ligand either of the GPR18 or of the GPR55. 
Hence, we stick to the simplest explanation, that is, the 
effects of cannabinoids on forebrain acetylcholine and 
monoamine levels are mainly mediated by CB1Rs.  
The second footnote implicates unorthodox interaction 
between two signaling systems. Many cannabinoids can 
directly interact with ligand- and voltage gated channels 
including the α7 nicotinic acetylcholine receptor (α7 
nAChR), the 5-HT3R serotonin receptor, voltage-gated Ca2+, 
Na+ and K+ channels and the NMDA receptor, respectively 
[369,381,509,735,736]. Cannabis constituents are not 
thought to have major off-target effects on the above 
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channels at reasonable concentrations except CBD which 
exhibits a moderate antagonist activity at the human α7 
nAChRs [737]. Remarkably, an elegant study showed that 
the behavioral consequences of Δ9-THC in squirrel monkeys 
and rats, including dependence and Δ9-THC-triggered 
dopamine release in the reward center are counteracted by a 
kynurenine 3-monooxygenase inhibitor [738]. The authors 
identify the α7 nAChR as the target of KynA. Hence, CBD 
may be able to counteract some Δ9-THC effects at the α7 
nAChR regarding the importance of the α7 nAChR in 
marijuana addiction [738]. CBD has important antipsychotic 
potential [217], but some of the symptoms of schizophrenia, 
namely, deficits in cognition, sensorimotor gating and 
voluntary smooth pursuit eye movement deficit are reliant 
upon impaired α7 nAChR signaling [739-742]. While α7 
nAChR activation would likely help to alleviate these 
negative symptoms of schizophrenia [217], it is worth to 
mention that α7 nAChR activation in neurons also stimulates 
anandamide formation [743]. An increase in anandamide 
levels is thought to worsen the positive symptoms of 
schizophrenia [217]. It is therefore an open question whether 
the antipsychotic efficacy of CBD is in part reliant on α7 
nAChR blockade and consequent decrease in anandamide 
production, or the other way around, if CBD actually 
worsens some negative symptoms of schizophrenia by 
blocking α7 nAChRs. 
3.3.4.3. Cannabinoid Interaction with Serotonin and 
Noradrenaline 
The apparent discrepancy between cortical and 
subcortical cannabinoid modulations also exists for 
monoamines: systemic SR141716A administration facilitates 
the release of serotonin, dopamine and noradrenaline in the 
prefrontal cortex [744,745] whereas in the nucleus 
accumbens, only serotonin is stimulated by CB1R blockade 
[744,746]. This assumes that functional cannabinoid 
receptors are present in cortical and hippocampal 
monoaminergic nerve terminals. Indeed, CB1Rs are present 
in the raphe neurons that give rise to forebrain serotonin 
innervation [747] as well as in frontocortical serotonergic 
nerve terminals [396]. CB1Rs are also present in 
noradrenergic varicose terminals of the frontal cortex 
[748,749]. The source of the endocannabinoid 2-AG to 
activate monoaminergic fibres in the frontal cortex is likely 
the cortical neurons [750], thus retrograde endocannabinoid 
control is also relevant for monoamines. 
CB1R activation inhibits the electrically and chemically 
evoked release of serotonin and noradrenaline in the cerebral 
cortex including the frontal cortex and the hippocampus 
[396,722,751,752]. The stimulated release of serotonin in 
CB1R -/- frontocortical nerve terminals is greater compared 
to WT nerve terminals [396]. In mice, Δ9-THC (2.5 mg/kg) 
as well as CBC and CBD, but not Δ8-THC, CBG or CBN, 
acutely elicited antidepressive behavior in the forced swim 
test or the tail suspension test or both [753]. However, 
chronic cannabis intake is associated with an increased risk 
for depression – an affective disorder thought to involve 
monoaminergic dysregulation [668,669]. For instance, in 
adult rats, chronic (12-day) treatment with HU210 caused an 
imbalance in 5-HT1AR vs. 5-HT2AR activity [754]. Also in 
adult rats, chronic (8-day) treatment with Δ9-THC reduced 
frontocortical 5-hydroxyindolacetic acid vs. serotonin levels, 
indicating decreased serotonergic activity [755]. 
Interestingly, the increase in serotonin 5-HT2A receptor (5-
HT2AR) sensitivity in the prefrontal cortex seen by the 
previous study [754] is apparently CB2R-dependent: 
repeated administration of CP55940 increases CB2R-
mediated arrestin3 recruitment and GRK5 activation, and 
consequently augments 5-HT2AR density, conferring 
susceptibility to anxiety and psychosis in rats [756,757]. 
Besides regulating mood, sociability and anxiety in rodents 
[758-761], prefrontocortical CB1Rs can also promote active 
stress-coping behavior in rats via serotonergic mechanisms 
[762]. 
Acute Δ9-THC is anxiolytic and antidepressant via 
CB1R- and serotonin 5-HT1AR dependent mechanisms 
[758,759]. That is why it came as a surprise that the non-
cannabimimetic CBDA and Δ9-THCV also enhance 5-
HT1AR activation in the nanomolar range, probably acting 
directly as 5-HT1AR agonists, hence showing therapeutic 
potential in the treatment of nausea and schizophrenia 
[763,764]. Chronologically speaking, CBD was reported first 
to activate the rat, shrew and human 5-HT1AR thus exhibiting 
antiemetic, antidepressive and anxiolytic profile, but its 
useful concentration ranges and doses were rather high to be 
therapeutically relevant [765-767]. CBD therefore has the 
capacity to counteract catalepsy induced by different 
treatments, including the activation of CB1R or the inhibition 
of NO synthase, the 5-HT1AR or the D2R, which was 
demonstrated in a mouse study [768]. CBD via 5-HT1AR 
activation has been also shown to mitigate neuropathic pain 
elicited by the anticancer agent, paclitaxel [769]. 
Additionally in rodents, CBD acting via 5-HT1AR confers 
anxiolysis [766], antidepressant effects [770], and 
neuroprotection in ischemic injury [771-773] and in hepatic 
encephalopathy [628]. 
Another very remarkable property of cannabis is its 
antiemetic profile [774]. Therefore, the legality of medical 
cannabis has been granted in some countries against 
chemotherapy-induced nausea and vomiting [775], but 
skepticism among physicians and the lack of thorough 
scientific studies do not support the use of cannabis and 
synthetic cannabinoids as first-line treatment [776]. 
Cannabinoids can alleviate nausea and vomiting in many 
circumstances, involving both central and peripheral 
mechanisms, as well as CB1 and CB2 receptors, but most 
importantly, by engaging serotonergic signaling [777,778]. 
This scenario can be expanded with the direct inhibition of 
the 5-HT3 receptor by cannabinoids [381,509] and the 
activation of 5-HT1AR by CBD. The antiemetic property of 
cannabis has become a dogmatic knowledge. Until recently, 
the general public was unaware of that chronic cannabis 
consumption can cause a rebound effect, i.e., cyclic vomiting 
syndrome or hyperemesis without apparent cause and 
deleterious consequences [671,779,780]. The patients often 
have difficulties with admitting their severe cannabis 
dependence, and they use compulsive hot bathing to control 
nausea [779,781]. 
Below we will discuss the significance of cannabinoid 
receptor complexing in a diverse array of patho(physical) 
processes. Here we start out with the CB1R/5-HT2AR 
heterodimer. The earliest observation in vitro in rat cortical 
and cerebellar membranes demonstrated that HU210 and 
oleamide stimulated [3H]ketanserin binding to the high-
affinity binding site via CB1R activation [782]. Reciprocally, 
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serotonin modulated SR141716A and WIN55212-2 binding 
but not CP55940 binding to CB1Rs in rat cerebellar 
membranes [783]. Many years later a novel study proved the 
existence of the CB1R/5-HT2AR heterodimer [784]. The 
antagonists of each receptor can cause cross-inhibition to 
prevent the effect of the agonist of the partner receptor, while 
the co-activation of both receptors can trigger effects ranging 
from synergism on the inhibition of stimulated cAMP levels 
to cross-antagonism on arrestin3 recruitment. The genetic 
deletion of 5-HT2AR did not affect Δ9-THC-induced 
hypolocomotion, decrease in body temperature and 
anxiogenesis at the dose of 3 mg/kg. Remarkably though, 5-
HT2AR deletion prevented the amnesic effect of 3 mg/kg 
dose of Δ9-THC in mice, and impaired the Δ9-THC- (0.3 
mg/kg) induced anxiolysis and increase in social interactions 
[784]. 
Besides dopamine acting at D2Rs and acetylcholine at 
M1/3Rs, other neuromodulators such as noradrenaline and 
serotonin, too, can use endocannabinoids to execute 
neuromodulation. Recently, it was found that cocaine blocks 
noradrenaline reuptake in the VTA of rats, and in turn, the 
excess extracellular noradrenaline activates post-synaptic 
Gq/11-coupled α1 adrenoceptors, thereby mobilizing 2-AG, 
which disinhibits GABAergic afferents onto the same 
dopaminergic cells [785]. Another study found in rats that α1 
receptor activation in the dorsal raphe (the origin of 
ascending serotonergic fibres) triggers endocannabinoid-
dependent LTD at glutamatergic afferents, and that chronic 
stress impairs this mechanism [786]. As for serotonergic 
MSI, 5-HT2R activation inhibits glutamatergic afferents in 
the inferior olive via similar retrograde endocannabinoid 
mechanism [787]. 
CBG potently stimulates [35S]-GTPγS binding to mouse 
brain membranes already at a concentration as low as 1 nM, 
but this stimulation is reversed into strong inhibition above 
the concentration of 1 µM [788]. Further analysis revealed 
that CBG is an ultrapotent α2 adrenoceptor agonist (EC50, 
200 pM) and a potent 5-HT1AR antagonist (IC50, 52 nM), as 
well as a low potency CB1R antagonist [788]. This is 
interesting in that sense that in the frontal cortex, presynaptic 
CB1R activation inhibits noradrenaline release from 
afferents, and noradrenaline α2R activation desensitizes this 
action of the CB1R (presumably via heterodimer formation 
or via second messenger systems) [749]. Strikingly, this is 
mirrored at the post-synaptic level in layer V/VI pyramidal 
cells, where both acute and chronic treatment with 
WIN55212-2 impairs the inhibitory action of α2R activation 
[789]. This leads us to speculate that the effect of cannabis 
consumption on executive functions, mood and anxiety may 
depend on its Δ9-THC/CBG ratio. 
3.3.4.4. Footnote: Biphasic Cannabinoid Effects 
The above reported biphasic effects for cannabinoids 
are not uncommon. At low doses, cannabimimetics stimulate 
the central responses, while at doses ~10 times higher, 
inhibition rather than stimulation is observed. Additional 
reports include the effects of Δ9-THC on hippocampal 2-
deoxyglucose use [790] and on the modulation of 
electrically-evoked cortical potentials [791]. Biphasic 
responses are general consequences of actions at cannabinoid 
receptors of different sensitivities that can even form 
heterodimers with each other (see Section 3.3.5.1), biased 
agonism (see Section 3.2.3.1), and direct local vs. indirect 
polysynaptic mechanisms. 
The simplest example of polysynaptic events is the 
concurrent modulation of excitatory glutamatergic and 
inhibitory GABAergic neurotransmissions. The global 
(external) activation of cerebral CB1Rs thus causes both the 
inhibition of excitation and inhibition in the same time. This 
can lead to opposing effects in the behavior, as observed in 
"knockout" mice with selective deletion of CB1R in cortical 
glutamatergic or GABAergic neurons [661], as compared to 
their wild-type littermates in a predominant C57BL/6N 
background. In these mice, it was observed that the deletion 
of CB1Rs in cortical glutamatergic neurons increases passive 
coping (freezing time) in fear-conditioning protocol using 
foot-shocks, while the deletion of CB1Rs in GABAergic 
terminals increases active coping behavior (escape attempts 
and risk assessment) when facing aversive stimuli [792]. 
Additionally, accumbal CB1Rs cause hypophagia through 
inhibition of GABAergic transmission, while the activation 
of those cerebral CB1Rs that modulate excitatory 
transmission increases food intake [631]. 
CB1R-mediated bidirectional actions are apparent at the 
level of the circuitry, too: CB1R activation in the basal 
ganglia direct pathway induces thalamocortical 
hypersynchrony, whereas the activation of CB1Rs expressed 
in cortical glutamatergic neurons decreases cortical 
synchrony and thalamocortical hypersynchrony [793]. 
Additionally, the activation of CB1Rs in cortical 
glutamatergic neurons decreases the activity of the cortical 
networks; however, CB1R blockade stimulates network 
activity when basal network activity is low, whereas the 
opposite is detected when its initial level is high [794]. 
An elegant paper recently tackled the neurochemical 
phenotype of CB1Rs in GABA- vs. glutamatergic terminals, 
and the authors found that there are more than twice as much 
CB1Rs in GABAergic than in glutamatergic cells in the 
hippocampus, albeit the efficacy of CB1Rs to couple with G 
proteins is much greater in pyramidal cells (aka in the 
hippocampus of mice lacking interneuronal CB1Rs) [795]. 
This is somewhat in accordance with the observations of one 
of the authors of this review that the EC50 of the synthetic 
cannabinoid, WIN55212-2 to inhibit the KCl-evoked release 
of glutamate is ~7 nM in isolated striatal nerve terminals, 
while this value is ~70 nM for the evoked release of GABA 
(Köfalvi, unpublished). This would suggest that 
glutamatergic nerve terminals are more sensitive to 
cannabinoid agonists, but this assumption is contrasted in a 
more complex system, in striatal slices where others found 
that striatal GABAergic neurotransmission is much more 
sensitive to endocannabinoids and WIN55212-2 than 
glutamatergic neurotransmission, hence, low-frequency (1 
Hz) stimulation elicits preferentially LTD [796]. One 
possible explanation for this discrepancy is that striatal A2A 
adenosine receptors may impede CB1R function (see Section 
3.3.5.3) in the presence of adenosine in a striatal slice or in 
vivo, while in superfused nerve terminals, ambient adenosine 
levels around the receptors are negligible.  
3.3.5. Cannabinoid Receptor Heteromers 
A receptor is the smallest functional unit capable of 
transducing a chemical signal [797]. One receptor can be 
composed of several equal or different nonfunctional 
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subunits, which make a receptor either homomeric or 
heteromeric [797]. These functional receptors can further 
assemble into receptor heteromers with physiopharmacology 
considerably different from that of the individual 
components [797]. For instance, metabotropic receptors 
typically signalize in heteromers formed with other 
metabotropic and ionotropic receptors, including but not 
limited to receptors for acetylcholine, adenosine, dopamine, 
glutamate and serotonin [798-800]. Receptor heteromer 
mosaics can be assembled from two or more different 
receptors [797,800,801], with striking consequences to the 
outcome of their signaling [802-804]. Such example is the 
A2AR-D2R-CB1R heterotrimer, which assembles via 
triangular electrostatic interactions among the intracellular 
domains of individual receptors [805]. These domains are 
rich in arginine as well as phosphorylatable serine and 
threonine residues [805]. Endogenous ligands can activate 
intracellular signaling on the basis of "first come, first 
served", because the binding of an orthosteric agonist to its 
cognate receptor often render the partner receptor inactive 
[806]. This cross-desensitization has been described not only 
for agonists but also, for antagonists, and such is the case for 
the dopamine D2 (D2R) and adenosine A2A receptors (A2ARs) 
[806]. Heteromerization thus provides the cells with the 
capacity of cross-correlation analysis – the power of local 
computational units – to prioritize modulator signals. 
3.3.5.1. Heteromerization within the Cannabinoid Receptor 
Family 
Endocannabinoid receptors are also prone to assemble 
with each other, often generating functional diversity. The 
most trivial example is the CB1R-CB1R homodimer – the 
way CB1Rs are expected to exist in the cell membrane 
[807,808]. The CB1R-CB2R heterodimer has been also 
described in both expression systems and in pinealocytes and 
in situ, in the nucleus accumbens [710]. The CB1R-CB2R 
heterodimer shows negative allosteric interaction, because an 
inverse agonist of one receptor (AM251 or AM630) was 
capable of antagonizing the selective agonist of the other 
receptor, while the simultaneous use of two selective 
agonists, JWH133 and ACEA resulted in a much smaller 
effect amplitude (on Akt phosphorylation) than the 
individual effect amplitudes of each drug alone [710]. 
Additionally, there is a decrease in the density of the CB1R, 
the CB2R and their heterodimer in the pallidothalamic 
pathway in experimental Parkinsonism, while L-DOPA 
treatment disrupts this heterodimer [809]. 
The CB2R-GPR55 heterodimer has been recently 
reported by two groups, both in HEK293 [810,811] and 
human glioma and breast cancer cell lines [811]. Again, the 
action of the GPR55 agonist LPI was inhibited by both 
AM630 and HU308, i.e., the CB2R agonist and antagonist, 
respectively, and vice versa, the effect of HU308 was 
inhibited by LPI and the GPR55 antagonist, HBA [811]. The 
excellent twist of this latter study was testing Δ9-THC at a 
wide concentration-range: Δ9-THC at low concentrations 
first activated the CB2R, and thus inhibited forskolin-induced 
cAMP accumulation and stimulated ERK1/2 
phosphorylation. At higher concentrations, Δ9-THC begun to 
activate the GRP55, too, thus started to inhibit its own effect 
at the CB2R [811]. These data highlight that the 
concentration-response curve of anti-prolific Δ9-THC action 
is U-shaped: too high or too low concentrations are both 
ineffective. 
Last but not least, the CB1R also forms dynamic protein 
complexes with the GPR55, for instance, in the vascular 
endothelium [500]. Here the authors tested the dual agonist, 
anandamide, which also showed cross-inhibition, but this 
was dependent of external Ca2+-induced recruitment of 
adapter proteins. Namely, integrin clustering prevented 
anandamide from inhibiting GPR55-mediated 
intraendothelial Ca2+ rises via CB1R activation [500]. CB1R-
GPR55 heteromer is also present in the rat and monkey 
striatum, and it exhibits cross-antagonism on ERK1/2 
phosphorylation and stimulation of nuclear factor of 
activated T-cells (NFAT) [812]. It is of course difficult to 
predict how cannabis constituents would affect this highly 
context-dependent heterodimer, because if Δ9-THC activates 
both receptors it would produce cross-antagonism on their 
common second messengers. The concentration of ligands is 
a crucial factor, because one of the two receptors often has 
greater affinity toward a common non-selective ligand of 
both receptors. Besides, the simultaneous presence of other 
ligands such as CBD and Δ9-THCV can greatly affect the 
signaling outcome of a CB1R-GPR55 heterodimer. In the 
following paragraphs, we will discuss selected cases of 
CB1R-GPCR heterodimers. Note that other heterodimers also 
exists: the CB1R has been described in functional 
heteromeric complexes with other receptors such as the 
angiotensin AT1 receptor [813], as well as the orexin OX1 
receptor [814-816]. However, due to space limitations, these 
interesting receptor interactions will not be discussed. 
In fact, these negative crosstalks among the 
cannabinoid receptor heteromers, irrespective of the use of 
agonists or antagonists, are in full agreement with data 
reported for the A2AR-D2R heterodimer [806]. It seems 
plausible that when a ligand binds to its cognate receptor and 
induces a conformational change impacting the conformation 
of the partner receptor(s), it is largely irrelevant if the ligand 
in question was an agonist or an inverse agonist, because 
either way the ligand affects conformation. Nevertheless, it 
would be interesting to test how a true silent agonist would 
affect the partner receptor in the heteromer. 
3.3.5.2. The CB1R-D2R Heterodimer 
While the above examples covered the so far known 
CB2R and GPR55 heterodimers, the CB1R has been shown 
in much more functional complexes formed with a diverse 
array of receptors. Perhaps the first such identified 
heterodimer was with the D2R [817-820]. The interaction is 
directly physical (electrostatic) between the C-terminus and 
the third intracellular loop of the CB1R and the third 
intracellular loop of the D2R [805,820]. Although both 
receptors alone in homodimer signalize with Gi/o proteins, 
their concurrent activation results in a coupling to Gs and the 
stimulation of cAMP accumulation [817-819]. It is believed 
that concurrent stimulation of the two receptors would 
induce heterodimer formation [819]. Ultrastructural evidence 
documents that the two receptors have partially overlapping 
subcellular distributions in both dendritic and axonal profiles 
in the nucleus accumbens [821]. As we discussed above, 
D2R-like receptor activation in the striatum triggers post-
synaptic anandamide formation and release [715] (Fig. 8). 
Thus, it is possible that anandamide, produced upon D2R 
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activation can exert a feedback on its release. This is hinted 
by the study discussed above [694]. 
3.3.5.3. The A2R-CB1R Heterodimer Filtering the 
Corticostriatal Inputs 
The striatum is also a venue for the highly studied 
A2AR-CB1R heterodimer [822-824]. Strong evidence 
supports that A2AR activation dampens presynaptic CB1R 
signaling at rat corticostriatal nerve terminals [553,571,825]. 
Still there is more to it: pre- and post-synaptic location of 
CB1 and A2A receptors, their regulation by D2Rs and 
mGluR5s, their converging intracellular signaling, and the 
control of endocannabinoid release by these receptors all 
make it difficult to disentangle the therapeutic value of the 
A2AR-CB1R heterodimer in the (palliative) treatments of 
Parkinson's disease and marijuana addiction (Fig. 8). 
Here, we briefly overview the spatiotemporal and 
molecular orchestration of A2AR-CB1R interaction at the 
corticostriatal synapse, which also serves to highlight the 
complexity of endocannabinoid function in the regulation of 
network activity. Presynaptically, half of the corticostriatal 
nerve terminals is equipped with CB1Rs, and the half of 
these CB1R+ terminals is also positive for A2AR [553] – the 
adenosine receptor subtype activated by phasic adenosine 
peaks originated from the extracellular catabolism of ATP 
co-released with glutamate from excitatory nerve terminals 
[826]. Presynaptic CB1Rs also inhibit ATP release from 
depolarized striatal nerve terminals [553], suggesting that 
CB1Rs could control the generation of synaptic adenosine, 
too. In fact, corticostriatal A2ARs form mutually inhibitory 
heterodimers with adenosine A1 receptors [827]. The A1 
subtype is the receptor activated by ambient (low) synaptic 
levels of adenosine, keeping a brake on glutamatergic noise. 
Hence, presynaptically, we deal with at least an A1R-A2AR-
CB1R heterotrimer. Post-synaptically in the MSNs, A2ARs 
are present predominantly in the indirect pathway that 
projects to the globus pallidus [828]. Post-synaptic A2ARs 
are highly coexpressed with both D2Rs [828] and mGluR5, 
which co-localize with DAGLα and microtubule-associated 
protein 2 (MAP2) in the perisynaptic border of dendritic 
spines of the MSNs [552] (Fig. 8). As briefly mentioned in 
Section 3.2.1.1, the activation of Gq/11 protein-coupled 
metabotropic receptors such as the mGluR5 stimulates 
DAGLα-mediated 2-AG release (Fig. 6). mGluR5 is typically 
activated by glutamate spill-over as a result of high-
frequency corticostriatal discharge [829], which leads to 2-
AG release in the synapse [552,830]. D2Rs have been also 
reported in MSN dendritic spines to prolong mGluR5-
induced transient 2-AG release [716] (Fig. 8). Post-synaptic 
A2ARs are negatively coupled to both mGluR5 and D2Rs, 
thus forming dynamic trimeric complexes [801,823]. A2AR 
activation by phasic adenosine levels inhibits post-synaptic 
metabotropic receptor-induced endocannabinoid formation 
[823,831,832]. Thus, if certain corticostriatal terminals reach 
sufficient firing frequency (or "saliency" – see e.g., [833]), 
the consequent retrograde endocannabinoid signaling will no 
longer affect glutamate release via presynaptic CB1Rs as 
simultaneously high adenosine levels will allow the A2AR to 
overrule the A1R-mediated [826,827] and the CB1R-
mediated inhibition of corticostriatal glutamate release 
[553,571]. This rescues the most salient nerve terminals. 
Then what is the fuss about these interactions of many pre- 
and post-synaptic receptors? Our model predicts that 
neuromodulators, adenosine, dopamine and 
endocannabinoids may interact with surrounding synapses, 
too, within a confined space to cause heterosynaptic 
plasticity. Additionally, corticostriatal terminals which do 
not generate enough adenosine may be silenced, thus 
enhancing the saliency of the passing information. When this 
delicate system permanently loses one of its components the 
consequences are motor diseases or addiction, as the 
following two examples demonstrate. 
Nevertheless, CB1Rs are also present in the MSN of 
both the direct and the indirect pathway, and in the latter, 
A2ARs may form heterodimers with CB1Rs [822,834]. Post-
synaptic A2ARs, however, were shown to enhance the action 
of CB1Rs at the corticostriatal terminal, because the selective 
genetic eliminiation of A2ARs from the MSN impaired the 
action of WIN55212 on the field potential and the paired-
pulse facilitation [835]. The same group later elegantly 
showed how intricate this dichotomy is between pre- and 
post-synaptic A2ARs: in rats overexpressing A2ARs in cortical 
but not striatal neurons (i.e., are expected to abundantly 
express presynaptic A2ARs at corticostriatal terminals), CB1R 
function became impaired both in vivo and in vitro [836]. 
Certainly, there is more effort required to disentangle the 
interaction among pre- and posst-synaptic A2ARs and CB1Rs 
in the regulation of striatal information flow [834]. 
3.3.5.4. CB1R and A2AR Ligands as Palliative Therapy in 
Parkinson's Disease? 
The above-mentioned fine-tuned system can be thrown 
out of balance by the lack of dopamine in Parkinson's disease 
(PD) which precludes proper synaptic plasiticity at 
corticostriatal synapses, leading to dyskinesias 
[831,837,838]. There has been an increasing interest in the 
therapeutic use of cannabis in basal ganglia disorders to 
provide symptom relief or to slow the progression of the 
disease or both [839,840]. PD patients report beneficial 
effects of cannabis use on their symptoms [841,842]. 
Accordingly, the Δ9-THC analog, nabilone was found to 
decrease and delay the development of levodopa-induced 
dyskinesia in both non-human primates [843] and in human 
patients in a randomized, double-blind, placebo-controlled, 
crossover trial [844]. In contrast, some admit that the picture 
could be more nuanced [845]: the administration of 
phytocannabinoid agonists did not ameliorate dyskinesia and 
Parkinsonism syndromes in a randomized, double-blind, 
placebo-controlled crossover trial [846]. However, we 
believe that controlling the increased adenosine levels in the 
PD-affected striatum may result in better outcomes. Indeed, 
A2AR antagonists mirror the motor effects of D2R agonists, 
and the overactivation of striatal A2ARs in PD contributes to 
motor symptoms [847]. The idea of using A2AR antagonists 
(e.g., istradefylline) to delay the onset and mitigate the 
severity of L-DOPA-induced dyskinesia has been toyed for 
decades [847]. Thus, we foresee that a clinical trial 
addressing the beneficial effects of cannabimimetics under 
istradefylline adjunct therapy could provide a more 
consistent and probably more successful outcome. Also, the 
outcomes of clinical trials should be controlled for coffee 
consumption of the patients as caffeine is a general 
adenosine receptor antagonist [847]. 
In fact, the self-report studies admittedly carry some 
bias because those who regularly use cannabis to treat PD 
symptoms also get psychological relief from the anxiolytic 
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and antidepressant effects of cannabis [310,848], besides, 
many patients refuse to respond queries [842]. As discussed 
above, long-term Δ9-THC-treatment or cannabis intake 
triggers CB1R desensitization and down-regulation in the 
brain [229,451,772]. Nevertheless, CB1Rs in the basal 
ganglia are quite resistant to chronic cannabis intake as 
shown in 30 male participants with the help of positron 
emission tomography (PET) using an inverse agonist 
radioligand of the CB1R, [18F]FMPEP-d2 [849]. This may 
contribute to the lack of tolerance to the euphoric effects of 
cannabis [216]. We also explained earlier that Δ9-THC is a 
weak agonist and its prolonged presence at low levels around 
central receptors may cause CB1R antagonism. In line with 
these, animal studies evidence that CB1R blockade could 
surpass the efficacy of cannabimimetics to control motor 
symptoms in PD [837,840,850]. As a matter of fact, the only 
test carried out in human PD patients [851] did not find 
improvement with the use of SR141716A (rimonabant). The 
patients of this study were well-responders to classic 
dopamine-replacement therapies, thus it would be interesting 
to involve poorer responders as well. Also, the use of a 
relatively low SR141716A dose could balance between 
decreased somatodendritic CB1R internalization versus 
CB1R blockade (see Section 3.2.4). Besides, it would be 
helpful to evaluate neutral antagonists such as NESS0327 on 
dyskinesias in animal models and in human patients. Last but 
not least, L-DOPA treatment in itself is a confounding factor 
that disrupts both CB1R-CB2R and A2AR-D2R-CB1R 
heteromers in the basal ganglia in experimental 
Parkinsonism [812,852]. In conclusion, one cannot directly 
extrapolate from physiological cannabis actions in the 
healthy basal ganglia to the potential of cannabis-based 
medicine in PD. 
3.3.5.5. The A2AR-CB1R Heterodimer and Δ9-THC-addiction 
Squirrel monkeys self-administrate Δ9-THC, 
anandamide and R-methanandamide intravenously [853], 
which subserves a sufficiently good research model to study 
human cannabis addiction. In fact, the subsequent two 
studies from the same research group nicely demonstrated 
that the blockade of presynaptic A2ARs counteract while the 
blockade of post-synaptic A2ARs potentiate the intravenous 
self-administration of Δ9-THC and anandamide, but leaving 
cocaine self-administration or food intake unaffected 
[854,855]. The distinction between the pre- and post-
synaptic A2ARs is made possible by their different 
pharmacological profile [856]. These data cannot be 
conveniently explained by invoking only one responsible 
brain area. On the contrary, the complexity of these data 
testifies that Δ9-THC addiction is a result of multilevel 
interaction between the cerebral cortex and the basal ganglia, 
and may involve the concomitant modulation of GABA, 
glutamate and dopamine. Hence, further studies are required 
to map the therapeutic potential of different A2AR ligands as 
either an adjunct therapy together with cannabinoids in PD 
or as a monotherapy in cannabis addiction. 
Interestingly, adenosine and adenosinergic compounds 
also act as antagonists at the TRPV1R [857], which is 
another example for the antagonistic relationship between 
the endocannabinoid and adenosinergic systems. 
3.3.5.6. CB1R Heteromers with Opioid Receptors 
The endogenous opioid signaling constitutes the other 
major neuromodulator system involved in drug addiction 
[858]. Interestingly, there is a strong correlation between the 
opiatergic and endocannabinoid systems [859-862]. For 
instance, opioids and cannabimimetics exhibit similar 
pharmacological effects, including analgesia, hypotension, 
hypothermia, motor impairment and sedation [863-865]. 
Moreover, Δ9-THC-induced dopamine release in the shell of 
the rat nucleus accumbens is counteracted by the µ1 opioid 
receptor antagonist, naloxazine [681]. Some of these 
interactions are thus a likely result of physical complexing 
between opioid and CB1 receptors. 
The first reported such heteromer was the µ opioid 
receptor (µOPR)-CB1R complex, at which the agonists 
WIN55212-2 or HU210 co-applied with morphin or 
DAMGO (a µOPR-selective peptide) showed mutual cross-
antagonism on [35S]-GTPγS and the activation of the Gαi–
Rap–Src–Signal transducer and activator of transcription 3 
(Stat3) pathway that leads to neuritogenesis [866]. In another 
study, the coexpression of the CB1R was enough to decrease 
DAMGO-evoked signaling at the µOPR, and this was 
prevented by the inverse agonist SR141716A but not by the 
neutral antagonist, O-2050 [867]. The recently described δ 
opioid receptor (δOPR)-CB1R heterodimer is abundant in 
mouse cortical neurons, and in the absence of δOPR, basal 
CB1R coupling is enhanced, and the potency of HU210 to 
stimulate [35S]-GTPγS binding increases from ultrapotent 
(EC50, 190 pM) to hyperpotent (50 pM), together with its 
potency by +10% [803]. In Neuro2A neuroblastoma cell line 
where endogenous CB1R is normally trafficked to 
endosomes, δOPR expression brought the CB1R to the cell 
surface, though diminished by 3-fold the potency of HU210 
to stimulate intracellular pathways. Stimulation of 
intracellular CB1Rs by HU210 increased apoptosis in 
Neuro2A cell line, while δOPR expression increased cell 
viability threefold. In contrast, in cortical neurons of wild-
type (WT) mice, CB1R blockade by AM251 triggered an 
80% cell death which was absent in cortical neurons of 
δOPR -/- mice [803]. Altogether, this study highlights the 
importance of δOPR in the CB1R control of cell fate, with 
consequences to neurodegenerative disorders and brain 
cancer. More, CB1Rs can also reciprocally control the 
function of δOPRs: in peripheral nerve-lesioned rats, 
changes in the neocortical density and signaling of both 
receptors were observed, and a non-signaling concentration 
of HU210 (1 pM) strongly increased the efficacy of δOPR 
signaling [868], suggesting that this strategy can be helpful 
as a palliative treatment in neuropathic pain. Last but not 
least, pharmacological data prompt the existence of an 
intestinal κ-opioid receptor(κOPR)-CB1R-CB2R 
heterotrimer, which is activated by the diterpene salvinorin 
A from Salvia divinorum, resulting in decreases in colonic 
motility and in neurogenic ion transport [869]. 
Nonetheless, those who engage in the study of 
cannabinoid-opioid interactions should be advised that 
SR141716A and AM251 are potent antagonists/inverse 
agonists of the µOPR [389,870,871], the δOPR [872] and the 
κOPR [873]. Unfortunately, these two early CB1R-preferring 
inverse agonists proved to be really "dirty drugs" in the last 
two decades and they should be replaced with more selective 
and silent antagonists, such as NESS0327. 
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3.3.5.7. Additional CB1R Heterodimers and Cell Fate – 
Receptor Tyrosine Kinases 
The CB1R has been found to control the signaling of a 
diverse array of growth hormone receptors including 
receptor tyrosine kinases (RTKs) for insulin and insulin-like 
growth hormone, epidermal growth factor (EGFR); platelet-
derived growth factor; fibroblast growth factor (FGFR), 
brain-derived neurotrophic factor (TrkB) and vascular 
endothelial growth factor in different cellular models such as 
CHO cells, murine N18TG2 neuronal cells; pancreatic β 
cells, in glioblastoma and lung cancer cells, and neurons of 
the immature brain [351,874-878]. At the current level of 
evidence, CB1Rs most probably control RTKs via adapter 
proteins or converging intracellular signaling. Nevertheless, 
it has been shown that CB1Rs form heteromeric complexes 
in the presence of agonists with the TrkB [879] and the 
insulin receptor [878,880]. Whether these complexes involve 
"bridges" of intracellular or intramembranal proteins or the 
two receptors are directly connected to each other, is unclear. 
Accordingly, cannabimimetics including Δ9-THC have 
the capability of accelerating cancer growth via the 
transactivation of EGFR [874] or compromising pancreatic β 
cell viability via the inhibition of insulin signaling [878]. 
Chronic activation of central CB1Rs also disrupts 
neuritogenesis, growth cone steering, synaptogenesis, and 
the migration and network integration of neurons, by 
perturbing signaling at FGFR and TrkB among other RTKs 
[361,875,876,879,881,882]. These led to the recognition that 
the developing brain is very sensitive to the deleterious 
effects of cannabimimetics, from the in utero life until the 
end of adolescence [883-889]. Prenatal cannabis exposure 
can also lead to epileptic phenotype of the offspring due to 
impaired connectomes and excitability in the developing 
brain [882,890,891]. 
As a footnote, interactions between trophic factors and 
the endocannabinoid systems also occur beyond the RTK-
CB1R heterodimers: CB1R activation stimulates insulin 
release in pancreatic β-cells [892] while insulin triggers 2-
AG release onto accumbal glutamatergic terminals, with a 
consequent LTD on these excitatory afferents [893]. A CB1R 
antibody has been shown by us to immunoprecipitate the 
insulin receptor β chain in accumbal homogenates of the rat, 
and CB1R activation impaired the insulin-stimulated glucose 
uptake in rat accumbal slices [880] (see also Section 3.3.9). 
3.3.5.8. The CB2R-CXCR4 Chemokine Receptor Heterodimer 
in Tumor Progression 
A fresh sudy reported that CXCR4 can form an induced 
heterodimer with CB2R in human breast and prostate cancer 
cells, and simultaneous activation of CB2Rs and CXCR4 
receptors resulted in reduced CXCR4-mediated expression 
of phosphorylated ERK1/2, and ultimately, reduced cancer 
cell functions [894]. 
3.3.6. Is Cannabis a Friend or a Foe of the Adult Brain? 
Cannabinoids and their receptors confer 
neuroprotection [895,896], but only when brain cells are 
challenged with noxious stimuli [897] such as ischemia and 
infarct [771-773,898,899], disruptors of ion gradients [900], 
reactive oxygen species (ROS) [640] or toxic proteins like β-
amyloid [901], as evidenced from animal experiments. 
Cannabinoid neuroprotection involves both receptor-
independent chemical and receptor-mediated mechanisms. 
The simplest direct action is the neutralization of harmful 
ROS molecules, because Δ9-THC and congeners – even 
some of those which lack known activity at any receptors – 
can scavenge ROS [772,902,903]. Receptor-dependent 
mechanisms encompass a CB1R-mediated inhibition of 
excitotoxicity [664,903], as well as the anti-
neuroinflammatory roles of the CB2R [904,905], taken that 
neuroinflammation entails progressive neurodegeneration 
and impaired brain glucose metabolism. 
Nevertheless, several lines of evidence demonstrate that 
cannabis is toxic to the healthy brain [906]. Long-term 
administration of Δ9-THC (5-times/week for 8 months) 
decreased neuronal density and increased astrogliosis in the 
hippocampi of laboratory rodents, and also augmented the 
levels of corticosteroids which are known to be neurotoxic 
on the long run ([907]; see also Section 3.3.9). In man, 
regular cannabis use decreases the grey matter volume in 
those brain regions which are associated with memory, 
cognition, and motivational, emotional as well as affective 
processing, including but not limited to the hippocampus, 
amygdala and several areas of the cerebral cortex [908-910]. 
These changes positively correlate with the frequency of 
cannabis use and negatively with CBD content. Strikingly, 
two of these studies found increased cerebellar grey matter 
volume in regular cannabis users [909,910], but the 
significance of this finding is unclear. Finally, cortisol levels 
are also augmented upon acute cannabis use both in healthy 
controls and frequent users [216]. These indicate that either 
neuronal viability or neurogenesis or both may be affected 
by cannabis. First, we discuss the possibility of 
neurotoxicity. 
High Δ9-THC concentrations (5 µM) induce the activation of 
JNK, p53, then Bax (Bcl-2-associated X protein), caspase-3 
and Bcl (B-cell lymphoma oncogene), which pathway causes 
DNA fragmentation and apoptosis in cultured cortical 
neurons [911,912]. In hippocampal culture, even a short, 15-
min exposure to 3.5 µM Δ9-THC was found to induce ~70% 
cell death within a day, but 0.5 µM Δ9-THC also caused 
~40% cell death within 6 days [913]. The authors concluded 
that CB1Rs stimulate the mobilization and the subsequent 
COX-2-dependent metabolism of arachidonic acid, resulting 
in the production of ROS and other toxic metabolites, which 
cause DNA fragmentation and neuronal shrinkage. Many 
years later, a study elaborated on these observations: the 
authors found that a single Δ9-THC injection (5 mg/kg) 
transiently increased COX-2 (rather than COX-1) expression 
in the mouse hippocampus, and repeated 7-day 
intraperitoneal injection increased COX-2 levels 
permanently in wild-type but not CB1R -/- mice [914]. This 
came as surprise to the authors because 2-AG inhibits COX-
2 expression in the hippocampus via CB1R activation, and 
Gαi1 stimulation [914,915]. In contrast, as it turned out, Δ9-
THC rather stimulated COX-2 expression via a βγ, Akt, 
ERK, p38 MAPK, and NF-κB cascade, thus blaming biased 
agonism for the untoward effects of Δ9-THC. Next, the 
authors showed that 7-day Δ9-THC-injection hampered the 
integrity (decreased spine density) and plasticity of synapses 
in the hippocampus of these mice, with a consequent 
impairment in spatial and fear memories [914]. Genetic or 
pharmacological ablation of COX-2 prevented all these 
negative effects of Δ9-THC. Strikingly, COX-2 manipulation 
did not jeopardize the neuroprotective effects of Δ9-THC in 
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an animal model of β-amyloidosis. The authors also 
discovered that Δ9-THC reduces β-amyloid levels via the 
upregulation of the endopeptidase neprilysin, which is a 
novel model of receptor-mediated neuroprotection [914]. 
Albeit in these above assays, Δ9-THC was tested for 
toxicity at relatively high doses and concentrations, there is 
uncertainty about the peak levels of Δ9-THC around its 
receptors in the brain during cannabis consumption. Our 
educated guess is that on an average occasion, a smoked full 
joint should equal a dosage of a 100-500 µg/kg net Δ9-THC 
intake. Taken the upper end and dividing it with a low 
estimate of 50 kg of soft tissue, we obtain a dose of 10 µg 
Δ9-THC/kg, roughly equivalent with the concentration of 
~30 nM/L aqueous solution (regardless of hepatic 
metabolism and excretion). This is a crude and simplistic 
estimation of peak Δ9-THC levels calculated with 
homogenous drug distribution, although we expect the brain 
to sequester Δ9-THC from the plasma, hence cerebral Δ9-
THC levels might be always greater than those in the plasma 
(see also Section 3.1.2.1). Altogether, in an infrequent 
marijuana smoker's brain, we do not expect peak levels of 
Δ9-THC to be greater than 1 µmol/kg wet tissue, not even 
under heavy cannabis intoxication, albeit the new trend of 
"dabbing" cannabis wax may transiently result in way 
greater peak doses than these estimates. Dabbing apparently 
poses a huge risk of emergent psychosis [185], which is the 
topic of Section 3.3.8. Nevertheless, our assumptions on the 
Δ9-THC doses in the brain are of course very limited because 
a large part of the brain volume is not a dilute aqueous 
solution but a dense lipophilic mass, rendering the theories 
of receptor pharmacology completely useless. Another 
confounding factor is the higher affinity of the human CB1R 
to Δ9-THC, as compared to the rodent CB1R [411], 
suggesting that lower Δ9-THC doses are sufficient to cause 
neurotoxicity. 
As a result of biased agonism, cannabinoids at very low 
concentrations may stimulate cAMP production [370] (see 
Section 3.2.3.1), which in turn can entail excitotoxicity. 
Thus, the next study looked at the leftmost end of the Δ9-
THC dose-response curve, and the striking findings were 
certainly a game-changer [916]. The extreme low dose of 1 
µg/kg Δ9-THC caused an effect opposite to what intoxicating 
(psychoactive) doses of Δ9-THC would trigger in drug-naïve 
mice, i.e., it increased body temperature, potentiated 
responses to noxious stimuli and increased locomotor 
activity [916]. Hence, this is another good evidence for 
contrasting biphasic cannabinoid actions at different doses 
(see Section 3.3.4.4). Three weeks after the single Δ9-THC- 
(or vehicle-) injection, the mice were trained and tested for 
their escape latencies in the Morris water maze test, and the 
Δ9-THC-injected mice still underperformed the vehicle-
injected control mice. The authors speculated that extreme 
low doses of Δ9-THC cause lasting neurotoxicity, but 
paradoxically, the much higher recreational doses of Δ9-THC 
achieved on occasions of cannabis ingestion probably protect 
the brain from the toxic effects [916]. We hypothesize that 
Δ9-THC may accumulate in non-psychoactive (neurotoxic) 
quantities in individuals under exposure to cannabis smoke. 
For this reason, it is imperative to carry out human studies to 
screen passive cannabis smokers for their plasma Δ9-THC 
levels and their neurocognitive performance. 
3.3.7. Clearing the Smoke on Neurogenesis 
Adult neurogenesis and gliogenesis provide the adult 
brain with constant supply of new cells that migrate toward 
and integrate themselves in the circuitry where they are 
needed. This process has major implications in learning and 
forgetting, mood disorders and stroke repair [917-919]. 
Adult neuronal stem cells also contain CB1Rs [920-923], and 
cannabimimetics in most cases stimulate the proliferation of 
neural progenitors in the neurogenic niches 
[918,920,922,924]. Quite remarkably, the CB1R -/- mice 
exhibit a ~30-50% reduction in new bromodeoxyuridine-
(BrdU)-labeled cells [526,921]. Since CB1R activation 
readily stimulates astrogliogenesis beyond neurogenesis 
[921], this reduction in bromodeoxyuridine-labeling in the 
CB1R -/- mice was also accompanied with a relative increase 
in neurogenesis over astrogliogenesis in the CB1R-deficient 
mice [921]. 
Of course, there is no cannabinoid receptor 
involvement without contrasting data. Other studies in fact 
found that CB1R activation decreases neurogenesis and 
progenitor cell differentiation [925,926]. In concert with this, 
6 weeks of orally fed Δ9-THC have been found to decrease 
neurogenesis, while CBD slightly increased proliferation, 
and even more, it strongly stimulated the survival of 
neuroblasts. However, this latter case could be attributed to 
CB1R desensitization and elimination upon prolonged 
activation. Besides, in one of the former studies, only 
anandamide was tested as agonist, hence the involvement of 
other receptors beyond the CB1R is also possible [925]. 
Indeed, CB2Rs also stimulate neurogenesis and migration of 
neuroblasts from the subventricular zone (SVZ) to the 
olfactory bulb, in positive correlation with the age of the 
mice, i.e., the older the animal the greater the stimulation of 
neurogenesis and migration by CB2Rs, although the 
migration was rather inhibited in young mice [927]. This 
property of the CB2R becomes very useful in the treatment 
of human immunodeficiency virus- (HIV-) induced 
neurodegeneration, because CB2R activation rescues neural 
progenitors from HIV-1 glycoprotein Gp120-induced 
apoptosis, and restores their proliferation [928]. 
3.3.8. Cannabis and Psychosis 
The role of impaired endocannabinoid signaling in the 
etiology of schizophrenia has been widely recognized 
[217,697,929]. The association between psychosis and 
cannabis use is also clear and unequivocally accepted [930-
932]. However, many confounding factors – age of initiation 
of marijuana consumption, dose and type(s) of marijuana 
consumed including its Δ9-THC/CBD ratio, genetic 
predisposition, social factors, and abuse of other drugs – all 
make it very difficult to correctly estimate the weight of 
marijuana abuse in the onset of psychosis and schizophrenia. 
First of all, cannabis use is associated with delusional-
like experiences [933]. Even the late-onset cannabis use (i.e., 
in the range of 21-50 years of age) is associated with 
elevated risk of psychosis, but clearly, if cannabis 
dependence took place between the age of 12 and 16 years, 
the chance for delusional-like experiences was almost 
tenfold greater than in the non-user population [933]. 
Cannabis user schizophrenia patients experience the 
onset of the disease earlier with more positive and less 
negative symptoms, which is often combined with violent 
behavior and cannabis dependence [934-936]. Schizophrenia 
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patients also found cannabis more rewarding than control 
subjects [936]. It is also observable that schizophrenia 
patients prefer cannabis of high Δ9-THC/CBD ratio, such as 
"skunk" which practically lacks CBD. Cannabis use not only 
speeds up the development of psychotic disorders, but also 
worsens the course of the illness, causing more frequent 
hospital visits, and poorer psychosocial functioning [937-
939]. 
There are more schizophrenics among cannabis users 
than in the general population and more cannabis users 
become schizophrenic in a given time-frame than non-users 
[670,930,940]. However, the causality between cannabis use 
and schizophrenia has not been settled. Some discrepancies 
could not be simply ignored, such that the increased 
frequency of cannabis use in the general population is not 
generally associated with greater incidence of schizophrenia 
population-wide [932,941]. The resolution of these 
discrepancies is that cannabis precipitates, accelerates the 
onset and worsens psychosis in susceptible individuals with 
genetic predisposition, but not in the rest of the population 
[941]. In other words, genetic traits that render the individual 
susceptible to schizophrenia (or its prodrome neurochemical 
status) increase the odds for cannabis use [942]. In concert 
with these, the Diagnostic and Statistical Manual (5th ed.) 
[943] already lists CUD as a moderately hereditary 
psychiatric condition [182,672]. It seems therefore 
convenient to conclude that cannabis abuse just accelerates 
the onset and worsens the course of psychosis in susceptible 
young people, but alarming reports suggest that the case is 
more complex than that. For instance, south London has 
startlingly high incidence of new schizophrenia cases, a rate 
that doubled since 1965, and this is likely due to the 
appearance of highly potent cannabis breeding lines such as 
"skunk" [944,945]. In fact, a recent study directly blames 
"skunk"-like cannabis for at least 1/4 of the schizophrenia 
cases in south London [945], and "high-potency" marijuana 
has been aggressively and steadily gaining popularity in the 
last decades [885]. 
These latter studies leave open the possibility that the 
low-potency (classical) cannabis preparations would only 
facilitate the onset of schizophrenia in the presence of 
genetic and other environmental liabilities; however, 
cannabis of high Δ9-THC/CBD ratio itself may provoke 
schizophrenia in the absence of other major risk factors. A 
meta-analysis of previous studies has clearly concluded the 
strong association between CUD and psychosis, and was 
able to set temporal priority for cannabis use – especially 
during adolescence – as a causal factor for schizophreniform 
disorders [930]. 
Likely, the general belief that cannabis is not overtly 
dangerous lies in the partial agonist properties of Δ9-THC 
and its co-occurrence with other molecules (CBD, Δ9-
THCV) that can dampen the effects of this psychoactive 
compound [946]. A confounding factor often ignored in 
animal studies is the use of the full agonist WIN55212-2 in 
regimens sufficient to produce clear-cut evidence of 
causality between CB1R activation and schizophrenia 
symptoms [178,947]. In these animal models, exposure to 
WIN55212-2 during their adolescence but not later, causes 
persistent psychobiological changes in the adult animals. 
These animals do not have genetic liability to schizophrenia 
but still, they exhibit some characteristics of the human 
psychosis patients if they are treated with WIN55212-2 
during the critical neurodevelopmental window of 
adolescence [178]. Synthetic cannabinoids (e.g., "spice" 
preparations) are also more potent and efficacious than Δ9-
THC (more "WIN55212-2-like"), often full agonists at the 
CB1R [946,948], and therefore they can frequently cause 
life-threatening or fatal accidents [257,885,946,948-950]. 
The incisive term "spiceophrenia" has also been coined 
based on a systematic review of 41 spice-related 
psychopathology studies [951]. This is a clear indication for 
the increased health risks associated with full agonist 
cannabimimetics. The forthcoming years will tell if the 
growing popularity of potent cannabis variations and 
synthetic full agonists indeed increases the overall incidence 
of schizophrenia in the general population, or irrespective of 
their potency and efficacy, all CB1R agonist are alike in that 
sense that they carry the risk of untoward health effects for 
those with pre-existing risk factors. 
But even if only a fraction of the users were susceptible 
to cannabis-induced psychosis, the rest of the adolescent 
users will also have to face negative neurodevelopmental and 
psychobiological consequences [672,952-955]. Hourslong 
CB1R activation by acute cannabis intake overwhelms the 
delicate neuromodulator interactions and overrides the 
regulation of lower and higher order brain functions. This 
provokes a wide variety of recreational cannabis effects 
which we discussed above. Chronic exposure to 
cannabinoids may even offset the threshold sensitivity for 
feed-back and feed-forward cross-regulations among 
neuromodulators, often culminating in neuropsychiatric 
illnesses in the vulnerable. These adverse effects on mental 
health which are not necessarily dependent on neural 
development encompass impairment in emotional 
processing, associative learning, cognition, memory 
performance [697,954,955-958], substance use disorders 
[698,701,959], mood disorders, anxiety, impaired sociability, 
and pathological neuroendocrine response to stress 
[761,954,960-965]. 
3.3.9. Δ9-THC and Steroid Hormones 
Steroid hormones interact with the endocannabinoid 
system, which has significant therapeutic potential. One 
important feature of glucocorticoid receptors (GcRs) is that 
they co-localize with DAGLα in post-synaptic neural 
compartments apposing CB1R-positive nerve terminals in the 
brain [397]. GcR activation in the prefrontal cortex triggers 
endocannabinoid release [966], which in turn downregulates 
the hypothalamo-pituitary-adrenal (HPA) axis to decrease 
circulating corticosteroid levels [967,968], facilitate the 
extinction and impair the retrieval of aversive memories 
[965,967,969-971]. A similar phenomenon was suspected 
based on a pharmacological approach in the rat nucleus 
accumbens: dexamethasone via GcR activation stimulated 2-
AG production, and consequently, activated CB1Rs in 
heteromeric complexes with insulin receptors, thus impairing 
insulin-stimulated accumbal glucose uptake [880]. Such 
mechanism could explain how chronic stress, Cushing-
syndrome or chronic glucocorticoid treatment could impair 
the regulation of food intake or even, cerebral insulin 
sensitivity. 
Albeit acute mild stress is beneficial and increases the 
fitness of the individual, acute extreme stress may 
persistently imprint painful (aversive) memories in the brain, 
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leading to post-traumatic stress disorder (PTSD), which is a 
debilitating psychiatric condition lacking efficient 
therapeutic strategies [972]. It develops after an extremely 
stressful event, and the symptoms that can be divided into 
four clusters are eventually associated with the difficulties of 
forgetting those painful and shocking memories [972]. In 
animal models, the activation of amygdalar CB1Rs facilitates 
while their blockade dampens the retrieval of aversive 
memories [969]. In contrast, medial habenular CB1Rs are 
critical for the expression of aversive memories [973]. There 
is a growing body of evidence for the favorable effects of 
cannabis on various symptoms of PTSD, including stress, 
insomnia and nightmares [974,975]. Although the long-term 
use of cannabis to treat PTSD is cautioned by its abuse 
potential and the above-mentioned deleterious effects on 
brain functioning – including susceptibility to psychosis and 
depression –, the promising small-scale studies and self-
reports from PTSD patients prompt large-scale randomized 
clinical trials under controlled conditions. Besides acute 
extreme stress, chronic mild stress (as well as subclinical 
Cushing syndrome and long-term corticosterioid treatments) 
can also negatively affect the brain, in part because of 
chronic CB1R overactivation that hampers synapses, 
neuroenergetics and neurogenesis [976]. 
A recent interesting paper revealed that Δ9-THC and 
other cannabimimetics (WIN55212-2, HU210) stimulate a 
massive increase in the synthesis of pregnenolone, the 
inactive precursor of all steroid hormones, in the brain [406]. 
The authors also found that the CB1R PAM cocaine (see 
Sections 3.3.4.1 and 3.3.4.3) also stimulates pregnenolone 
synthesis, albeit with lower efficacy. Pregnenolone in turn 
acts as a NAM, thus dampening CB1R-dependent effects in 
the brain, such as Δ9-THC-induced food intake, memory 
impairment, decrease in synaptic transmission, and increased 
accumbal dopamine release (see Sections 3.3.4.1 and 
3.3.5.5) [406]. This well-positions pregnenolone in the list of 
potential CB1R-inhibitor medicines without deleterious side 
effects. Other CB1R-targeting strategies that involve 
glucocorticoid-induced illnesses are metabolic syndrome 
[977] and osteoporosis [652] among others. 
3.3.10. Other Atypical Targets 
The previously detailed off-target actions at opioid 
receptors are not exceptional: phytocannabinoids, 
endocannabinoids and other synthetic cannabinoid ligands 
are notorious for producing diverse off-target effects in the 
micromolar range [381,390,391,509,719,978-983] with 
unclear (patho)physiological significance. These must be 
taken into consideration, and whenever possible, 
cannabinoids should be used at the concentration not greater 
than 1 µM in vitro. Nevertheless, studies directed to 
understand the molecular and physicochemical properties of 
off-target cannabinoid effects can help to design much more 
potent and selective ligands of testable therapeutic potential.  
Several studies have documented therapeutic potential 
for phytocannabinoids in models where cannabinoid 
receptors were chemically or genetically ablated. Many 
times a compound's useful in vitro concentration range is too 
high, which anticipates that the therapeutic and the toxic in 
vivo doses would be too close to each other. For instance, (1) 
Δ9-THC competitively inhibits acetylcholinesterase by 
binding to its peripheral anionic binding site with the Ki of 
10.2 µM, thereby preventing the enzyme from serving as a 
chaperon in the formation of β-amyloid fibrils [984]. (2) 
Micromolar Δ9-THC and other cannabinoids were found to 
inhibit monoamine oxidases A and B, which may contribute 
to the antidepressant effects of cannabis [985]. (3) 
Micromolar concentrations of CBD and CBN, as well as 
WIN55212-2 (and its cannabinoid receptor inactive 
enantiomer, WIN55212-3) were found to inhibit a Ca2+-
ionophore-induced interleukin-2 production in mouse 
splenocytes, even in the presence of the CB2R 
antagonist/inverse agonist SR144528 [441] and the CB1R 
antagonist/inverse agonist/GPR55 and GPR18 ligand 
SR141716A, and actually both SR141716A and SR144528 
acted also as agonists [986]. (4) Micromolar concentrations 
of the non-psychoactive phytocannabinoids, CBC, CBD, 
CBDA, and CBG showed antitumoral and anticancer effects 
both in vivo and in vitro [522]. At those concentrations, 
phytocannabinoids were shown to interact with multiple 
targets of the endocannabinoid system, and their beneficial 
effects were not dependent on solely one protein [522]. 
3.3.11. The Anti-inflammatory Effects of Ajulemic Acid 
More than 2 decades ago, the quest for Δ9-THC-like 
medicines which retain therapeutic usefulness without 
psychotropic activity has led to the discovery of a synthetic 
THC-COOH derivative called ajulemic acid (AJA) [987]. 
AJA has prolonged anti-inflammatory and analgesic action, 
which was virtually unrelated to CB1 or CB2 receptors. AJA 
in the low micromolar range can activate the peroxisome 
proliferator-activated receptor γ (PPARγ), being selective 
over the PPARα and PPARδ [988]. The PPARγ is a 
significant member of the nuclear receptor superfamily 
[989,990]. Intriguingly, 2-AG, noladin ether and NAGly (if 
not their COX-2 metabolites) are also activators of PPARγ 
[990,991]. Based on the potent actions of AJA, it came as no 
surprise that Δ9-THC and CBD also proved to be PPARγ 
activators: CBD and Δ9-THC induced slow vasorelaxation in 
rat aortae and 3T3-L1 fibroblast differentiation into 
adipocytes in a PPARγ antagonist- (GW9662) sensitive 
manner, which could be mimicked with the PPARγ agonist, 
rosiglitazone [992,993]. Δ9-THC and rosiglitazone (but 
surprisingly, not CBD or nabilone) protected a human 
neuroblastoma cell line via PPARγ activation from 
Parkinson's disease-relevant toxins (1-methyl-4-
phenylpyridinium - MPP+, paraquat and lactacystin) [994]. 
In the first clinical trial on patients with chronic neuropathic 
pain with or without allodynia and hyperalgesia, daily doses 
of 40 and 80 mg AJA (also known as CT-3) proved more 
efficacious than placebo to reduce pain, without major 
adverse effects including psychoactivity [995,996]. The 
unexpected twists were those reports that found AJA to be 
more potent at the CB1R and the CB2R than at the PPARγ, 
and to produce some psychoactivity at the useful analgesic 
dose [380,997-999]. It turns out that the contrasting findings 
were likely due to the impurity of the earlier AJA 
preparations, and that AJA is in fact a potent and selective 
CB2R agonist in the low nanomolar range [1000]. In fact, the 
highly purified AJA preparation is now termed as JBT101 
which has 12-fold CB2R-selectivity over the CB1R, while the 
original preparation is termed as HU239 which has 5-fold 
CB1R-selectivity over the CB2R [1000]. JBT101 is a safe 
medicine with minor metabolism in the body [1001] and 
under the name Resunab™ (Corbus Pharmaceuticals) is 
currently being evaluated against inflammation and fibrosis 
in three phase II clinical trials. 
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4. CONCLUSIONS 
Our aim was to provide the reader with up-to-date 
information about the botany, psychobiology and therapeutic 
potential of cannabis. We advocate that the decision on 
cannabis legalization should not be the privilege of 
politicians, because researchers, health care professionals 
and social workers ought also to be involved in the 
discussion. It is not appropriate to promote the legalization 
of recreational cannabis based on its therapeutic potential. 
We presented numerous lines of evidence for the medical 
potential of cannabis constituents in a wide variety of 
diseases. Many clinical trials are already underway to market 
CBD and other inoffensive constituents to alleviate 
symptoms and mitigate the outcome of illnesses. This proves 
the concept that the cannabis plant is a true "treasure trove" 
[1002]. Yet, we should make it clear that whenever it seems 
meaningful to target the endocannabinoid system in a 
particular disease, it does not necessarily mean that cannabis 
would also serve as a remedy. On the contrary: first, because 
several health conditions require the inhibition rather than 
the activation of cannabinoid receptors, and second, cannabis 
is a double-edged sword and can do just as much harm as 
good. In our apposite example, cannabis is somewhat 
analogous to the way the mafia works: once you get involved 
you have hard time to turn your back on it. It will protect 
your cells in hour of need, but it will also take its protection 
racket from the healthy cells. Unfortunately, it does not 
always depend on the discretion and the good sense of 
cannabis users whether they open the treasure trove or 
instead, Pandora's box. 
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ABBREVIATIONS 
-/-, KO = "knockout" mouse lacking a specific protein 
(receptor) 
2-AG = sn-2-arachidonoylglycerol 
2-AGPI = 2-arachidonoyl-sn-glycero-3-phosphoinositol 
5-HT1A/2A/3R = serotonin 5-HT1A/2A/3 receptor 
α2R = α2 adrenoceptor 
A1/2AR(s) = adenosine A1/2A receptor(s) 
ABDH4/6/12 = α,β domain serine hydrolase 4 or 6 or 12 
abn-CBD = abnormal cannabidiol 
ACEA = arachidonoyl-2'-chloroethylamide 
ACh = acetylcholine 
ACPA = arachidonoylcyclopropylamide 
ADTR = agonist-directed trafficking of response 
AJA = ajulemic acid (CT-3) 
Akt = protein kinase B 
Bax = Bcl-2-associated X protein 
Bcl = B-cell lymphoma oncogene 
BrdU = bromodeoxyuridine 
[Ca2+]i = intracellular Ca2+ concentration 
Ca2+-ER/RER = Ca2+/receptor dependent endocannabinoid 
release 
CaMKII = Ca2+/calmodulin-dependent protein kinase II 
cAMP = 3',5'-cyclic adenosine monophosphate 
CB1R(s) and CB2R(s) = cannabinoid CB1 and CB2 
receptor(s) 
CBC = cannabichromene 
CBCA = cannabichromenic acid 
CBCV = cannabichromevarin 
CBD = (–)-cannabidiol 
CBDA = cannabidiolic acid 
CBDV = cannabidivarin 
CBG = cannabigerol 
CBGA = cannabigerolic acid 
CBGV = cannabigerovarin 
CBN = cannabinol 
cGMP = cyclic guanosine monophosphate 
CHO = Chinese hamster ovary 
COX-2 = cyclooxygenase-2 
CRIP1a/b = CB1R interacting protein 1a or 1b 
CUD = cannabis use disorder 
δOpR = δ opioid receptor 
Δ8-THC = Δ8-tetrahydrocannabinol 
Δ9-THC = Δ9-tetrahydrocannabinol 
Δ9-THCA = Δ9-THC acid 
Δ9-THCV = Δ9-tetrahydrocannabivarin 
DA = divarinic acid 
D1/2R(s) = dopamine D1/2 receptor(s) 
DAG = sn-2-diacylglycerol 
DAGLα/β = sn-2-DAG lipase α or β 
DAT = dopamine transporter 
DEA = docosatetraenylethanolamide 
DLE = delusional-like experiences 
DSI/DSE = depolarization-induced suppression of 
inhibition/excitation 
EGFR = epidermal growth factor receptor 
EMT = putative endocannabinoid membrane transporter 
ERK1/2 = extracellular regulated kinase 1/2 
FAAH-1/2 = fatty acid aminohydrolase-1 or 2 
FGFR = fibroblast growth factor receptor 
FLAT = FAAH-like anandamide transporter 
GABA = γ-aminobutyric acid 
GASP1 = GPCR-associated sorting protein 1 
GIRKs = inwardly rectifying K+ channels 
GOT = geranylpyrophosphate:olivetolate geranyltransferase 
GPCR(s) = G protein-coupled receptor(s) 
GPP = geranyl pyrophosphate/geranyl diphosphate 
GPR18 = GPR55, G protein-coupled receptor 18 or 55 
GRKs = GPCR kinases 
[35S]-GTPγS = [35S]-guanosine 5'-O-[gamma-
thio]triphosphate  
HEA = homo-γ-linolenylethanolamide 
HCN = cyclic nucleotide-gated (HCN) channels 
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HEK293 = human embryonic kidney cell line 293 
JNKs = c-Jun N-terminal kinases 
κOpR = κ opioid receptor 
KynA = kynurenic acid 
LPI = L-α-lysophosphatidylinositol 
LTP, LTD = long-term potentiation, long-term depression 
LysoPtdGlc = lysophosphatidyl-β-D-glucoside 
µOpR = µ opioid receptor 
M1/3R(s) = muscarinic acetylcholine M1 or M3 receptor(s) 
MAGL = monoacylglycerol lipase 
MAPKs = mitogen-activated protein kinases 
mGluR5(s) = metabotropic glutamate receptor(s) 5 
MPP+ = 1-methyl-4-phenylpyridinium 
MSI/MSE = metabotropic stimulation-induced suppression 
of inhibition/excitation 
MSN(s) = medium spiny neuron(s) 
nAChR(s) = nicotinic acetylcholine receptor(s) 
NADA = N-arachidonoyl dopamine 
NAGly = N-arachidonoylglycine 
NAM = negative allosteric modulator 
NAPE = N-arachidonoyl-phosphatidylethanolamine 
NFAT = nuclear factor of activated T-cells 
NMR = nuclear magnetic resonance spectroscopy 
OA = olivetolic acid 
OAC = OA cyclase 
OLDA = N-oleoyldopamine 
p38 (MAPK) = p38 mitogen-activated protein kinases 
PAM = positive allosteric modulator 
PD = Parkinson's disease 
PI3K = phosphoinositide 3-kinase 
PIP2 = phosphatidylinositol 4,5-bisphosphate 
PKA = protein kinase A 
PLCβ = phospholipase Cβ 
PPARα/δ/ γ = peroxisome proliferator-activated receptor α 
or δ or γ 
PTSD = post-traumatic stress disorder 
RhoA = Ras homolog gene family member A 
RIM1/2α = Rab3-interacting molecule-1α or -2α 
ROCK = Rho-associated protein kinase 
ROS = reactive oxygen species 
RTK(s) = receptor tyrosine kinase(s) 
Src = proto-oncogene tyrosine-protein kinase Src 
STAT3 = signal transducer and activator of transcription 3 
STDP = spike-timing-dependent plasticity 
TKS = tetraketide synthase 
TrkB = tropomyosin receptor kinase B (brain-derived 
neurotrophic factor receptor) 
TRP = transient receptor potential 
TRPA1R = TRP ankyrin family type 1 receptor 
TRPC1R = TRP canonical family type 1 receptor 
TRPM8 = TRP melastatin (melanoma suppressor) family 
type 8 receptor 
TRPV1/2/4R = TRP vanilloid family type 1 or 2 or 4 ion 
channels  
VGCCs = voltage-gated Ca2+ channels 
VTA = ventral tegmental area 
WT = wild-type 
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Fig. (1). Chemical structure of important cannabinoid receptor agonists. 1st column: Major phytocannabinoids of the Cannabis 
plant, Δ9-THC and CBD. 2nd column: The most investigated two endocannabinoids, 2-AG and anandamide. 3rd column: The 
most efficacious non-selective, synthetic aminoalkylindole WIN55212-2, and the potent non-classical Δ9-THC-analog 
CP55940. 4th column: The CB1R-selective, metabolically-resistant synthetic anandamide-analog (eicosanoide) ACEA, and the 
CB2R-selective classical synthetic cannabinoid and Δ9-THC-analog, JWH133. 
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Fig. (2). Outline of the biosynthesis of the major phytocannabinoids. For abbreviations please see the text or the List of 
Abbreviations. Gray text and dotted gray arrows indicate other metabolic pathways which provide the precursors for 
cannabinoid biosynthesis. The reactions are catalyzed by the following enzymes: 1. TKS/PKS, 2. OAC, 3. GOT, 4. CBCA 
synthase, 5. THCA synthase, 6. CBDA synthase.  
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Fig. (3). Capitate-stalked secretory glands of Cannabis. A) Scanning electron micrographs of three capitate-stalked secretory 
glands on the abaxial epidermis of a perigonal bract (the bract surrounding the pistil) in a drug-type Cannabis sativa strain. 
Several claw-like unicellular cystolith hairs can be observed in the background. Bar: 100 µm. Micrograph courtesy to E. Small 
and T. Antle (Agriculture and Agri-Food Canada, Ottawa). B) Structure of a captitate-stalked secretory gland in cross section. 
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Fig. (4). Transmission electron micrographs showing plastids and the secretory process in Cannabis sativa disc cells from 
conventionally (chemically fixed) samples (reproduced with permission from [147]). A) Plastid with constriction (long arrow) 
and two distended regions, the upper containing a paracrystalline reticulate body, the lower containing a thylakoid (short 
arrow). B) Plastid section containing a reticulate body with different lattice orientations that fills the entire circular plastid 
section. Another plastid section within the same cell (lower part of the figure) has differently stained membranes of the 
reticulate body and the stroma. C) Plastid with reticulate body and voluminous inclusions (containing the secreted material) 
along the envelope surface (arrowhead). D) Plasma membrane (long arrow) showing inclusion (plastid-derived secreted 
material) positioned in periplasmic space, delimited by a surface (short arrow) and being in contact with the plasma membrane 
(arrowhead). Bar: 0.2 µm (A, B, C) and 0.1 µm (D). Unlisted abbreviations: I, inclusion (secreted material); P, plastid; R, 
reticulate body, W, cell wall. 
 




Fig. (5). Overview of the endocannabinoid system. The central oval encompasses the most basic elements of the 
endocannabinoid system in the narrow sense, i.e., (1) the CB1 and CB2 cannabinoid receptors, as well as their specific adaptor 
proteins such as the CRIP1a. Additional receptors may be associated with the endocannabinoid system in the broad sense, such 
as (2) the GPR18, the GPR55 and the TRPV1R. Although these latter three receptors can be activated by lipids which do not 
bind to the CB1R and the CB2R, other lipid-derivatives such as (3) anandamide and 2-AG are agonists of the endocannabinoid 
receptors of both the narrow and the broad sense, thus they are called endocannabinoids. The endocannabinoid system also 
creates intersections with sets of enzymes such as (4) ABDH6/12, COX-2, DAGLα, FAAH, MAGL, PLD, which are key 
components of endocannabinoid signaling but are not exclusive to the endocannabinoid system. Many phytocannabinoids 
including (5) Δ9-THC and CBD interact with the endocannabinoid system of both the narrow and the broad sense, but the 
majority of phytocannabinoids (CBN, CBCV, CBGV and so on) do not have submicromolar affinity toward these receptors. 
They are still called phytocannabinoids because of the plant that produces them and their structural resemblance to Δ9-THC, but 
not because of their action. Finally, the class of synthetic cannabinoids is fully encircled by the endocannabinoid system of both 
the narrow and the broad sense, because these ligands are designed on purpose to interact only with cannabinoid receptors. 
Among them, (6) WIN55212-2 is known to interact only with the CB1R and the CB2R, at least in the nanomolar range. 
However, many synthetic cannabinoids are potent ligands for the endocannabinoid receptors of both sensu stricto et lato. In 
fact, some of them are often incorrectly called “selective” to one receptor. This list includes but is not limited to (7) ACEA, 
ACPA, AM251, CP55940, HU210, HU308, JWH133, and SR141716A. Finally, (8) CID16020046, iodoresiniferatoxin, 
ML193, O-1602 and O-1918 among many others are ligands for many receptors of the endocannabinoid system of the broad 
sense, except for the CB1R and the CB2R. For details, see text. For the abbreviations, please consult the List of Abbreviations. 
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Fig. (6). Schematic illustration of endocannabinoid signaling in a glutamatergic synapse. Note that DAG, DAGLα, ABDH6 and 
ABDH12 as well as MAGL are key components of 2-AG signaling, which is believed to be the major form of retrograde 
endocannabinoid signaling. NAPE and PLD are also displayed in this figure, both of which are necessary for anandamide 
signaling, but it is possible that anandamide exerts its effect locally where it is produced, i.e., presynaptically, or in an 
anterograde fashion such as classical neurotransmitters. NmR stands for a general neuromodulator receptor which can be many 
of those receptors detailed in the text, including but not limited to M1R, D2R, 5-HT2AR, A2AR, insulin receptor, or 
glucocorticoid receptor. Unlisted abbreviations: AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; 
NMDAR, N-methyl-D-aspartic acid receptor. 
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Fig. (7). Major signaling routes of the CB1R via Gi/o proteins. Note that for sake of simplicity, the CB1R here is represented as a 
monomer; however, it is thought to exist in the membrane as a homodimer which can even be a part of a heteromultimeric 
assembly. Abbreviations: AC, adenylyl cyclase; Akt, protein kinase B; Ask1, apoptosis signal-regulating kinase 1; BAD, Bcl-2-
associated death promoter; c-Raf-1, proto-oncogene serine/threonine-protein kinase, also known as mitogen-activated protein 
kinase (MAPK) kinase kinase (MAP3K); CAPPs, ceramide-activated protein phosphatases; CREs, cAMP response elements; 
DAG, 1,2-diacylglycerol; ERK1/2, extracellular regulated kinase 1/2; Gαi/o, Gβγ, dissociated inhibitory alpha subunit binding 
GTP, and the beta-gamma complex of the activated heterotrimeric inhibitori (i/o) G protein; GAP, GTPase-activating protein; 
GIRK, G-protein-gated inwardly rectifying K+ channel; GSK3, glycogen synthase kinase-3; IP3, inositol-1,4,5-trisphosphate; 
JNK, c-Jun N-terminal kinase; MEK, ERK kinase; mTOR, mammalian target of rapamycin; p38 mitogen-activated protein 
kinases; PI3K1B, class 1B phosphoinositide 3-kinase; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C; 
Rap-1, Ras-proximate-1; S1P, sphingosine 1-phosphate; SMase, sphingomyelinase; Src, proto-oncogene tyrosine-protein C-
terminal kinase; Stat3, signal transducer and activator of transcription 3; VGCCs, voltage-dependent Ca2+ channels. 
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Fig. (8). Simplified scheme of modulation of synaptic transmission and neuromodulation in the dorsolateral striatum. For sake 
of simplicity, we omitted a few typical features of the striatum that were not essential for the understanding of the figure, 
including but not limited to adenosinergic signaling, the origin of anandamide, thalamostriatal afferents, or the distinction 
between direct and indirect pathways nor astrocytes. For the the abbreviations, see or the List of Abbreviations. + in a circle: 
stimulatory receptor; - in a circle: inhibitory receptor. 
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Fig. (9). Fluorescence microscopy images showing the distribution of CB1R immunoreactivity in the 40 µm-thick 
mediansagittal brain slice of an adult rat (A), and in 30 µm-thick coronal slices of the brain of an adult C57bl/6 mouse, cut at 
the level of the striatum (B) and the hippocampus (C). Confocal microscopy images at 63× magnification representing (A1) a 
dense and artistic meshwork of CB1R-positive fibres in the entopeduncular nucleus of the rat, and (C1) CB1R-positive 
interneurons as well as granule cells in the mouse dentate gyrus. Unlisted abbreviations: CA1, CA3, cornu Ammonis 1 and 3 
subfields of the hippocampus; CbeC, cerebellar cortex; CgC, cingulate cortex; L. II, III, Va, VI: different layers of the cerebral 
cortex; DG, dentate gyrus of the hippocampus; DlS, dorsolateral striatum; DmS, dorsomedial striatum; GPi and GPe, globus 
pallidus interna and externa; MoC, motor cortex; nAcc, nucleus accumbens; PiC, piriform cortex; PfC, prefrontal cortex; s. gl., 
stratum granulare; s. ml., stratum moleculare; SN, substantia nigra; s. pyr., stratum pyramidale; SeC, sensory cortex; ViC, 
visual cortex. Immunostaining was carried out with a guinea pig anti-CB1R antibody [552], at 1:200 dilution, and with an anti-
guinea-pig dylight 594 secondary antibody. For additional details and CB1R KO controls, see [458,553]. For additional details 
on hippocampal CB1R distribution, see [458,554]. These previously unpublished immunostainings were kindly provided by Dr. 
Samira G. Ferreira, Center for Neuroscience and Cell Biology of Coimbra, University of Coimbra, Portugal. All studies were 
conducted according to the principles and procedures outlined in the EU directive (2010/63/EU) for the care and use of 
laboratory animals, according to the guidelines of "3Rs" (replacement, reduction, refinement) in the guidelines of EU 
(86/609/EEC) and FELASA, and were approved by the local Animal Care Committee of the university (license number 
025781) and the Portuguese Ministry of Agriculture. Particular care was taken to minimize both animal suffering and the 
animal number used in each study. The same applies for the experiments shown in Fig. (10). 
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Fig. (10). Previously unpublished neurochemical data supporting the dominance of the CB1R in the central effects of 
cannabimimetics. Panel A1 is a diagram showing the time-course of [3H]acetylcholine release values (mean ± S.E.M. of 4-6 
rats) in the presence of hemicholinium-3 (10 µM) in rat striatal slices. As indicated by S1 and S2, the resting efflux was 
stimulated twice with electrical pulses, too (40 V, 2 Hz, 360 × 1 ms shocks). WIN55212-2 (1 and 10 µM) as well as 
SR141716A (1 µM) were given 10 min before S2, and their mean effect amplitudes (± S.E.M) are displayed in panel A2. 
Experiments were carried out by A.K. For further details, see the methods for similar experiments in [390,554]. 
Panel B1 shows the mean (n=8 rats) effect of anandamide (3 µM) treatment on 20 mM K+-evoked Ca2+ entry in striatal nerve 
terminals. Treatment with anandamide or its vehicle, EtOH started at 0 second. Panels B2, B4 and B5 show that the hybrid 
CB1R/CB2R/GPR18/GPR55/TRPV1R agonist, anandamide and the hybrid CB1R/TRPV1R agonist, NADA, but not the selective 
TRPV1R agonist, OLDA or the NADA/OLDA analog, palmytoyldopamine (PALDA) inhibit the depolarization-induced Ca2+ 
entry in a concentration-dependent fashion. The effect of anandamide is not due to a putative rapid metabolism, as its 
metabolically stable analog, R-methanandamide (B3) is also capable of mimicking the effect of anandamide. For further detalis, 
see [391,573]. Experiments were performed by Dr. Samira G. Ferreira, Center for Neuroscience and Cell Biology of Coimbra, 
University of Coimbra, Portugal. 
Panel C1 displays a [3H]SR141716A (3H-rimonabant) binding isotherm in total brain homogenates of 3-5 rats. Panel C2 calls 
the attention to our discovery that the presence of already as low as 0.1% ethanol (EtOH) greatly increases non-specific 
[3H]SR141716A binding on the costs of specific [3H]SR141716A binding, decreasing the latter value. Therefore, DMSO is 
always recommended to dissolve any ligands to be tested in CB1R binding assays. Bovine serum albumin decreases non-
specific binding by harvesting [3H]SR141716A from the assay medium, hence falsifying the radioligand concentration (not 
shown). Panel C3 shows that AM251 (1 µM) is the best choice to measure specific [3H]SR141716A binding at CB1Rs in the 
brain, and that at the used concentration of 1 nM, [3H]SR141716A binding was exclusively CB1R-dependent, showing no 
evidence for the involvement of other receptors including GPR18, GPR55 or TRPV1R in the total binding of [3H]SR141716A. 
Experiments were carried out by A.K. For additional details, see [396,553]. 
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